

# SANTOSH

Deemed to be University



**3.2.1 Total Grants for research projects / clinical trials sponsored by non-government sources such as industry, corporate houses, international bodies, endowments, professional associations, endowment-Chairs etc., in the Institution during the last five years**

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Date: 14/07/2021

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni



**Sharad Ranjan**  
(Authorized Signatory)



Date: 21/01/2022

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 8,30,000 towards following projects by your faculty

S.No	Name of the Project	Name of the Principal Investigator	Funds provided (INR in Lakhs)
1	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora	1.30
2	A prospective study to investigate the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh	1.50
3	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma	2.50
4	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma	1.30
5	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan	0.90
6	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni	0.80

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Sharad Ranjan**  
(Authorized Signatory)

CC to:

1. Dr Latika Arora
2. Dr Gauresh Singh
3. Dr Suveer Sharma
4. Dr Preeti Sharma
5. Dr Harshbardhan
6. Ms Namrata Soni



सत्यमेव जयते  
भारत सरकार



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रमांक / Enrollment No.: 0013/01001/05060


To  
शरद रंजन  
Sharad Ranjan  
C/O Vinod Kumar,  
C-71, East End Appartments,  
Mayur Vihar Phase-1 Extension,  
VTC: Mayur Vihar,  
PO: Vasundhra Enclave,  
Sub District: Preet Vihar, District: East Delhi,  
State: Delhi,  
PIN Code: 110096,  
Mobile: 9205374121

02/05/2012

1625066



MF016250669F1



आपका आधार क्रमांक / Your Aadhaar No. :

**3627 1192 9378**

मेरा आधार, मेरी पहचान



भारत सरकार  
Government of India



शरद रंजन  
Sharad Ranjan  
जन्म तिथि / DOB : 21/12/1979  
पुरुष / Male

**3627 1192 9378**

मेरा आधार मेरी पहचान

02/05/2012

आयकर विभाग

INCOME TAX DEPARTMENT

SHARAD RANJAN

VINOD KUMAR

21/12/1979

Permanent Account Number

AKFPR1636J

Signature



भारत सरकार

GOVT. OF INDIA



## Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal

7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal



आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005



To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Date: 14/07/2021

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni

**Sharad Ranjan**  
 (Authorized Signatory)

Date: 21/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 8,30,000 towards following projects by your faculty

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>	<b>Funds provided (INR in Lakhs)</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora	1.30
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh	1.50
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma	2.50
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma	1.30
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan	0.90
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni	0.80

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Sharad Ranjan**  
(Authorized Signatory)

CC to:

1. Dr Latika Arora
2. Dr Gauresh Singh
3. Dr Suveer Sharma
4. Dr Preeti Sharma
5. Dr Harshbardhan
6. Ms Namrata Soni



सत्यमेव जयते  
भारत सरकार



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रमांक / Enrollment No.: 0013/01001/05060

To

शरद रंजन

Sharad Ranjan

02/05/2012

C/O Vinod Kumar,

C-71, East End Appartments,

Mayur Vihar Phase-1 Extension,

VTC: Mayur Vihar,

PO: Vasundhra Enclave,

Sub District: Preet Vihar, District: East Delhi,

State: Delhi,


PIN Code: 110096,

Mobile: 9205374121

1625066



MF016250669F1



आपका आधार क्रमांक / Your Aadhaar No. :

**3627 1192 9378**

मेरा आधार, मेरी पहचान



भारत सरकार

Government of India



शरद रंजन

Sharad Ranjan

जन्म तिथि / DOB : 21/12/1979

पुरुष / Male

02/05/2012

**3627 1192 9378**

मेरा आधार मेरी पहचान

आयकर विभाग

INCOME TAX DEPARTMENT

SHARAD RANJAN

VINOD KUMAR

21/12/1979

Permanent Account Number

AKFPR1636J

Signature



भारत सरकार

GOVT. OF INDIA



## Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding



Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal

7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal



  
**Kadambri Educational and Charitable Trust**  
**(Authorized Signatory)**



# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 11 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 23,10,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav	0.80	12 months	Faculty of Medicine
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur	1.20	12 months	Faculty of Medicine
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhnupal	1.10	12 months	Faculty of Medicine
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal	0.70	12 months	Faculty of Medicine

5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra	1.00	24 months	Faculty of Medicine
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal	0.60	6 Months	Faculty of Medicine
7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara	0.60	6 Months	Faculty of Medicine
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal	1.20	24 months	Faculty of Dentistry
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma	0.60	12 months	Faculty of Dentistry
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh	3.60	24 months	Faculty of Medicine
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh	1.10	12 months	Faculty of Dentistry
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat	0.80	12 months	Faculty of Medicine
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal	0.80	12 months	Faculty of Medicine
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat	0.60	6 Months	Faculty of Medicine
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla	1.20	18 months	Faculty of Medicine
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal	1.40	18 months	Faculty of Medicine

17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand	0.90	18 months	Faculty of Medicine
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi	0.80	18 months	Faculty of Medicine
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh	0.60	6 Months	Faculty of Medicine
20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir	0.50	6 Months	Faculty of Dentistry
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal	1.60	18 months	Faculty of Medicine
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal	1.40	18 months	Faculty of Medicine



Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004  
Permanent Account Number

AAATK8461D

08012005

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Date: 14/07/2021

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni

**Sharad Ranjan**  
 (Authorized Signatory)

Date: 21/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 8,30,000 towards following projects by your faculty

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>	<b>Funds provided (INR in Lakhs)</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora	1.30
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh	1.50
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma	2.50
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma	1.30
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan	0.90
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni	0.80

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Sharad Ranjan**  
(Authorized Signatory)

CC to:

1. Dr Latika Arora
2. Dr Gauresh Singh
3. Dr Suveer Sharma
4. Dr Preeti Sharma
5. Dr Harshbardhan
6. Ms Namrata Soni





सत्यमेव जयते  
भारत सरकार



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रमांक / Enrollment No.: 0013/01001/05060

To

शरद रंजन

Sharad Ranjan

02/05/2012

C/O Vinod Kumar,

C-71, East End Appartments,

Mayur Vihar Phase-1 Extension,

VTC: Mayur Vihar,

PO: Vasundhra Enclave,

Sub District: Preet Vihar, District: East Delhi,

State: Delhi,


PIN Code: 110096,

Mobile: 9205374121

1625066



MF016250669F1



आपका आधार क्रमांक / Your Aadhaar No. :

**3627 1192 9378**

मेरा आधार, मेरी पहचान



भारत सरकार

Government of India



शरद रंजन

Sharad Ranjan

जन्म तिथि / DOB : 21/12/1979

पुरुष / Male

02/05/2012

**3627 1192 9378**

मेरा आधार मेरी पहचान

आयकर विभाग

INCOME TAX DEPARTMENT

SHARAD RANJAN

VINOD KUMAR

21/12/1979

Permanent Account Number

AKFPR1636J

Signature



भारत सरकार

GOVT. OF INDIA



## Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding



Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal

7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal



  
**Kadambri Educational and Charitable Trust**  
**(Authorized Signatory)**

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 11 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 23,10,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav	0.80	12 months	Faculty of Medicine
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur	1.20	12 months	Faculty of Medicine
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhnupal	1.10	12 months	Faculty of Medicine
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal	0.70	12 months	Faculty of Medicine

5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra	1.00	24 months	Faculty of Medicine
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal	0.60	6 Months	Faculty of Medicine
7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara	0.60	6 Months	Faculty of Medicine
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal	1.20	24 months	Faculty of Dentistry
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma	0.60	12 months	Faculty of Dentistry
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh	3.60	24 months	Faculty of Medicine
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh	1.10	12 months	Faculty of Dentistry
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat	0.80	12 months	Faculty of Medicine
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal	0.80	12 months	Faculty of Medicine
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat	0.60	6 Months	Faculty of Medicine
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla	1.20	18 months	Faculty of Medicine
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal	1.40	18 months	Faculty of Medicine

17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand	0.90	18 months	Faculty of Medicine
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi	0.80	18 months	Faculty of Medicine
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh	0.60	6 Months	Faculty of Medicine
20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir	0.50	6 Months	Faculty of Dentistry
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal	1.60	18 months	Faculty of Medicine
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal	1.40	18 months	Faculty of Medicine





Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Date: 14/07/2021

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni

**Sharad Ranjan**  
 (Authorized Signatory)

Date: 21/01/2022

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 8,30,000 towards following projects by your faculty

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>	<b>Funds provided (INR in Lakhs)</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora	1.30
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh	1.50
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma	2.50
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma	1.30
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan	0.90
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni	0.80

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Sharad Ranjan**  
(Authorized Signatory)

CC to:

1. Dr Latika Arora
2. Dr Gauresh Singh
3. Dr Suveer Sharma
4. Dr Preeti Sharma
5. Dr Harshbardhan
6. Ms Namrata Soni



सत्यमेव जयते  
भारत सरकार



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रमांक / Enrollment No.: 0013/01001/05060

To

शरद रंजन

Sharad Ranjan

02/05/2012

C/O Vinod Kumar,

C-71, East End Appartments,

Mayur Vihar Phase-1 Extension,

VTC: Mayur Vihar,

PO: Vasundhra Enclave,

Sub District: Preet Vihar, District: East Delhi,

1625066


State: Delhi,

PIN Code: 110096,

Mobile: 9205374121



MF016250669F1



आपका आधार क्रमांक / Your Aadhaar No. :

**3627 1192 9378**

मेरा आधार, मेरी पहचान



भारत सरकार

Government of India



शरद रंजन

Sharad Ranjan

जन्म तिथि / DOB : 21/12/1979

पुरुष / Male

02/05/2012

**3627 1192 9378**

मेरा आधार मेरी पहचान

आयकर विभाग

INCOME TAX DEPARTMENT

SHARAD RANJAN

VINOD KUMAR

21/12/1979

Permanent Account Number

AKFPR1636J

Signature



भारत सरकार

GOVT. OF INDIA





# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,



We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

<b>S.No.</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal



7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal



  
**Kadambri Educational and Charitable Trust**  
**(Authorized Signatory)**

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 11 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 23,10,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav	0.80	12 months	Faculty of Medicine
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur	1.20	12 months	Faculty of Medicine
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhnpal	1.10	12 months	Faculty of Medicine
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal	0.70	12 months	Faculty of Medicine

5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra	1.00	24 months	Faculty of Medicine
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal	0.60	6 Months	Faculty of Medicine
7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara	0.60	6 Months	Faculty of Medicine
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal	1.20	24 months	Faculty of Dentistry
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma	0.60	12 months	Faculty of Dentistry
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh	3.60	24 months	Faculty of Medicine
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh	1.10	12 months	Faculty of Dentistry
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat	0.80	12 months	Faculty of Medicine
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal	0.80	12 months	Faculty of Medicine
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat	0.60	6 Months	Faculty of Medicine
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla	1.20	18 months	Faculty of Medicine
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal	1.40	18 months	Faculty of Medicine

17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand	0.90	18 months	Faculty of Medicine
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi	0.80	18 months	Faculty of Medicine
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh	0.60	6 Months	Faculty of Medicine
20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir	0.50	6 Months	Faculty of Dentistry
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal	1.60	18 months	Faculty of Medicine
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal	1.40	18 months	Faculty of Medicine



Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Date: 14/07/2021

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni

**Sharad Ranjan**  
(Authorized Signatory)



Date: 21/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 8,30,000 towards following projects by your faculty

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>	<b>Funds provided (INR in Lakhs)</b>
<b>1</b>	Morphometric study of Intratemporal course of facial nerve in relation to pneumatization of temporal bone	Dr Latika Arora	1.30
<b>2</b>	A prospective study to investigate the the utility of anthropometric airway parameters as predictors of difficult airway in neonates	Dr Gauresh Singh	1.50
<b>3</b>	An observational study to assess different airway assessment methods in predicting difficult laryngoscopy	Dr Suveer Sharma	2.50
<b>4</b>	A pilot study to compare Triglyceride glucose (TyG) index with HbA1C as a marker of prediabetes and also with HOMA-IR (Homeostatic model assessment for assessing insulin resistance) as a marker of insulin resistance.	Dr Preeti Sharma	1.30
<b>5</b>	A cross sectional study to assess Acute ECG changes during smoking and tobacco chewing	Dr Harshbardhan	0.90
<b>6</b>	Knowledge, attitude, and practices of tobacco vendors toward selling tobacco products to young children and adolescents in Ghaziabad	Ms Namrata Soni	0.80

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Sharad Ranjan**  
(Authorized Signatory)

CC to:

1. Dr Latika Arora
2. Dr Gauresh Singh
3. Dr Suveer Sharma
4. Dr Preeti Sharma
5. Dr Harshbardhan
6. Ms Namrata Soni



सत्यमेव जयते  
भारत सरकार



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रमांक / Enrollment No.: 0013/01001/05060


To  
शरद रंजन  
Sharad Ranjan  
C/O Vinod Kumar,  
C-71, East End Appartments,  
Mayur Vihar Phase-1 Extension,  
VTC: Mayur Vihar,  
PO: Vasundhra Enclave,  
Sub District: Preet Vihar, District: East Delhi,  
State: Delhi,  
PIN Code: 110096,  
Mobile: 9205374121

02/05/2012

1625066



MF016250669F1



आपका आधार क्रमांक / Your Aadhaar No. :

**3627 1192 9378**

मेरा आधार, मेरी पहचान



भारत सरकार  
Government of India



शरद रंजन  
Sharad Ranjan  
जन्म तिथि / DOB : 21/12/1979  
पुरुष / Male

**3627 1192 9378**

मेरा आधार मेरी पहचान

02/05/2012

आयकर विभाग

INCOME TAX DEPARTMENT

SHARAD RANJAN

VINOD KUMAR

21/12/1979

Permanent Account Number

AKFPR1636J

Signature



भारत सरकार

GOVT. OF INDIA



# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding



Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

<b>S.No.</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal

7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal

**Kadambri Educational and Charitable Trust**  
 (Authorized Signatory)

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 11 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 23,10,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav	0.80	12 months	Faculty of Medicine
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur	1.20	12 months	Faculty of Medicine
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhnpal	1.10	12 months	Faculty of Medicine
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal	0.70	12 months	Faculty of Medicine



5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra	1.00	24 months	Faculty of Medicine
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal	0.60	6 Months	Faculty of Medicine
7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara	0.60	6 Months	Faculty of Medicine
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal	1.20	24 months	Faculty of Dentistry
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma	0.60	12 months	Faculty of Dentistry
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh	3.60	24 months	Faculty of Medicine
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh	1.10	12 months	Faculty of Dentistry
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat	0.80	12 months	Faculty of Medicine
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal	0.80	12 months	Faculty of Medicine
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat	0.60	6 Months	Faculty of Medicine
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla	1.20	18 months	Faculty of Medicine
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal	1.40	18 months	Faculty of Medicine

17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand	0.90	18 months	Faculty of Medicine
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi	0.80	18 months	Faculty of Medicine
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh	0.60	6 Months	Faculty of Medicine
20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir	0.50	6 Months	Faculty of Dentistry
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal	1.60	18 months	Faculty of Medicine
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal	1.40	18 months	Faculty of Medicine



Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005

Date: 28/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No.</b>	<b>Title</b>	<b>Name of Principal investigator</b>
1	A Study on Profile of Poisoning Cases in a Tertiary Care Hospital in Ghaziabad	Dr Shilpa Singh
2	Uncoupling proteins in various gene-environment interaction associated with heavy metal exposure and type 2 Diabetes Mellitus in North Indian Population	Dr Juhi Aggarwal, Dr Jyoti Batra

**Rajeev Khanna**  
**(Authorized Signatory)**



Date: 13/01/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 60,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1	A Study on Profile of Poisoning Cases in a Tertiary Care Hospital in Ghaziabad	Dr Shilpa Singh	0.30	6 Months
2	Uncoupling proteins in various gene-environment interaction associated with heavy metal exposure and type 2 Diabetes Mellitus in North Indian Population	Dr Juhi Aggarwal, Dr Jyoti Batra	0.30	3 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.


Thank you and regards.

**Rajeev Khanna**  
**(Authorized Signatory)**

CC to:

1. Dr Shilpa Singh
2. Dr Juhi Aggarwal, Dr Jyoti Batra

प्रायः अकाउंट नम्बर /PERMANENT ACCOUNT NUMBER  
AEFPK6006D




नाम /NAME  
RAJEEV KHANNA

पिता का नाम /FATHER'S NAME  
RANBIR KHANNA

जन्म तिथि /DATE OF BIRTH  
20-09-1961

हस्ताक्षर /SIGNATURE



अधिकार अधिकारी, मेरठ  
COMMISSIONER OF INCOME-TAX, MEERUT



भारतीय विशिष्ट पहचान प्राधिकरण

भारत सरकार

Unique Identification Authority of India


Government of India

नामांकन क्रम / Enrollment No.: 2020/75007/00131

To  
राजीव खन्ना  
Rajeev Khanna  
S/O: Ranbir Khanna  
B-9 Shivaji colony cantt board Fiat  
rajman bazar  
Bela  
laikurti Bazar  
Mawana Meerut  
Uttar Pradesh 250001  
9471422664

19/10/2014

186494859



ML864948593FT



आपका आधार क्रमांक / Your Aadhaar No. :

**5599 9190 4205**

आधार - आम आदमी का अधिकार



भारत सरकार

Government of India



राजीव खन्ना  
Rajeev Khanna  
जन्म तिथि / DOB : 20/09/1961  
पुरुष / Male



**5599 9190 4205**

आधार - आम आदमी का अधिकार



# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding



Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

<b>S.No.</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal

7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal



  
**Kadambri Educational and Charitable Trust**  
**(Authorized Signatory)**

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 11 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 23,10,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav	0.80	12 months	Faculty of Medicine
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur	1.20	12 months	Faculty of Medicine
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhnpal	1.10	12 months	Faculty of Medicine
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal	0.70	12 months	Faculty of Medicine

5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra	1.00	24 months	Faculty of Medicine
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal	0.60	6 Months	Faculty of Medicine
7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara	0.60	6 Months	Faculty of Medicine
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal	1.20	24 months	Faculty of Dentistry
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma	0.60	12 months	Faculty of Dentistry
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh	3.60	24 months	Faculty of Medicine
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh	1.10	12 months	Faculty of Dentistry
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat	0.80	12 months	Faculty of Medicine
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal	0.80	12 months	Faculty of Medicine
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat	0.60	6 Months	Faculty of Medicine
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla	1.20	18 months	Faculty of Medicine
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal	1.40	18 months	Faculty of Medicine

17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand	0.90	18 months	Faculty of Medicine
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi	0.80	18 months	Faculty of Medicine
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh	0.60	6 Months	Faculty of Medicine
20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir	0.50	6 Months	Faculty of Dentistry
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal	1.60	18 months	Faculty of Medicine
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal	1.40	18 months	Faculty of Medicine



Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005



Date: 11/06/2021

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	A single blind split mouth study to assess the effect of photobiomodulation on pain during the initial phase of orthodontic treatment	Dr Abhishek Nagpal
2	A study on effect of Omega-3 fatty acids supplements for dry eye syndrome	Dr Sarita Agrawal

*Deepak Goyal*

**Deepak Goyal**  
(Authorized Signatory)

Date: 07/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 1,50,000 towards following projects by your faculty

<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>	<b>Department of Principal Investigator/ Co Investigator</b>	<b>Funds provided (INR in Lakhs)</b>	<b>Duration of the project</b>
A single blind split mouth study to assess the effect of photobiomodulation on pain during the initial phase of orthodontic treatment	Dr Abhishek Nagpal	Faculty of Dentistry	1.10	18 months
A study on effect of Omega-3 fatty acids supplements for dry eye syndrome	Dr Sarita Agrawal	Faculty of Medicine	0.40	18 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.

*Deepak Goyal*

**Deepak Goyal**  
(Authorized Signatory)

CC to:  
Dr Abhishek Nagpal  
Dr Sarita Agrawal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA



स्थायी लेखा संख्या कार्ड  
Permanent Account Number Card  
ATPPG3250J



नाम / Name  
DEEPAK GOYAL

पिता का नाम / Father's Name  
DALEEP GOYAL

जन्म की तारीख /  
Date of Birth  
10/12/1986

*Deepak Goyal*  
हस्ताक्षर / Signature

03012021





# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding



Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

<b>S.No.</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal

7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal



  
**Kadambri Educational and Charitable Trust**  
**(Authorized Signatory)**

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 11 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 23,10,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav	0.80	12 months	Faculty of Medicine
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur	1.20	12 months	Faculty of Medicine
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhnpal	1.10	12 months	Faculty of Medicine
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal	0.70	12 months	Faculty of Medicine



5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra	1.00	24 months	Faculty of Medicine
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal	0.60	6 Months	Faculty of Medicine
7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara	0.60	6 Months	Faculty of Medicine
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal	1.20	24 months	Faculty of Dentistry
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma	0.60	12 months	Faculty of Dentistry
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh	3.60	24 months	Faculty of Medicine
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh	1.10	12 months	Faculty of Dentistry
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat	0.80	12 months	Faculty of Medicine
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal	0.80	12 months	Faculty of Medicine
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat	0.60	6 Months	Faculty of Medicine
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla	1.20	18 months	Faculty of Medicine
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal	1.40	18 months	Faculty of Medicine

17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand	0.90	18 months	Faculty of Medicine
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi	0.80	18 months	Faculty of Medicine
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh	0.60	6 Months	Faculty of Medicine
20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir	0.50	6 Months	Faculty of Dentistry
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal	1.60	18 months	Faculty of Medicine
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal	1.40	18 months	Faculty of Medicine



Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005

Date: 14/07/2021


To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

SNo.	Name of the Project	Name of the Principal Investigator
1	Cognitive Impairment among the Elderly Population of Ghaziabad and its Association with Smoking, Alcohol Intake and Impairments in Vision, Hearing and Activities of Daily Living	Dr Anupama Singh
2	A cross-sectional observational study to evaluate Internalized Stigma and Psychiatric Morbidity among Patients with Psoriasis	Dr Ravindra Kumar Bansal
3	A retrospective study to assess direct bilirubin levels and skeletal muscle weakness in patients with heart failure as prognostic markers for liver failure	Dr Mayurika Tyagi
4	Prevalence and correlates of bullying perpetration and victimization among school going adolescents in Ghaziabad	Dr Rani Srivastava
5	Effect of Social Networking Sites on the Quality of Life of College Students in Urban Ghaziabad	Mr Anoop Peter

  
**Ankit Goyal**  
 (Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding


Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 3,90,000 towards following projects by your faculty

SNo.	Name of the Project	Name of the Principal Investigator	Funds provided (INR in Lakhs)	Duration of the project
1	Cognitive Impairment among the Elderly Population of Ghaziabad and its Association with Smoking, Alcohol Intake and Impairments in Vision, Hearing and Activities of Daily Living	Dr Anupama Singh	0.4	24 months
2	A cross-sectional observational study to evaluate Internalized Stigma and Psychiatric Morbidity among Patients with Psoriasis	Dr Ravindra Kumar Bansal	0.4	24 months
3	A retrospective study to assess direct bilirubin levels and skeletal muscle weakness in patients with heart failure as prognostic markers for liver failure	Dr Mayurika Tyagi	1.1	18 months
4	Prevalence and correlates of bullying perpetration and victimization among school going adolescents in Ghaziabad	Dr Rani Srivastava	1.7	18 months
5	Effect of Social Networking Sites on the Quality of Life of College Students in Urban Ghaziabad	Mr Anoop Peter	0.3	18 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Ankit Goyal**  
(Authorized Signatory)

CC to:

1. Dr Anupama Singh
2. Dr Ravindra Kumar Bansal
3. Dr Mayurika Tyagi
4. Dr Rani Srivastava
5. Mr Anoop Peter







# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding



Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

<b>S.No.</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhanpal
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal
5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal

7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal
17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh

20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal

  
  
**Kadambri Educational and Charitable Trust**  
 (Authorized Signatory)

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 11 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 23,10,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	A comparison of two doses of palonosetron in the prevention of postoperative nausea vomiting in patients undergoing laparoscopic gynecological surgery.	Dr Vinod Kumar Yadav	0.80	12 months	Faculty of Medicine
2	A randomised controlled trial to compare Dexmedetomidine and propofol at different sedation depths during drug-induced sleep endoscopy	Dr Anshul Gaur	1.20	12 months	Faculty of Medicine
3	A randomized controlled trial to compare 5 different laryngoscope blades in ease of intubation and incidence of dental injury during direct laryngoscopy.	Dr Mahima Lakhnpal	1.10	12 months	Faculty of Medicine
4	Role of Fructose Enriched Foods in Metabolic Syndrome and cardiovascular Diseases.	Dr Juhi Aggarwal	0.70	12 months	Faculty of Medicine

5	Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy	Dr Jyoti Batra	1.00	24 months	Faculty of Medicine
6	Demographic profile of patients with right ventricular failure admitted in tertiary care center.	Dr Deepika Agarwal	0.60	6 Months	Faculty of Medicine
7	A cross-sectional observational study to assess the perceived effect of increased pricing on smoked tobacco products quit rates	Mr Pradhumn Katara	0.60	6 Months	Faculty of Medicine
8	An In-Vitro Analysis of Root Fracture Strength Using Single File Systems	Dr Shivani Mangal	1.20	24 months	Faculty of Dentistry
9	Incidence and Intensity of Pain Following Endodontic Treatment by Different Instrumentation Techniques in Teeth With Periapical Lesion	Dr Avdesh Sharma	0.60	12 months	Faculty of Dentistry
10	The relationship between continuous and long term use of mobile phones and hearing aids among adults	Dr Abhay Kumar Singh	3.60	24 months	Faculty of Medicine
11	A randomized clinical trial to evaluate the Clinical and radiographic success of immediate implants using commercially available bone augmentation materials: A two year follow up study.	Dr SV Singh	1.10	12 months	Faculty of Dentistry
12	Utility of Microbiology Culture in Pediatric Appendicitis to Risk Stratify Patients	Dr Ashutosh Rawat	0.80	12 months	Faculty of Medicine
13	A Randomized controlled trial to investigate the effect of Postoperative Pain on Early Initiation of Breastfeeding and Ambulation After Cesarean Section	Dr Alpana Agrawal	0.80	12 months	Faculty of Medicine
14	A retrospective cohort study to identify clinical characteristics of patients with hypertensive disorders of pregnancy associated with requiring multiple anti-hypertensive medications to optimize blood pressure in the postpartum setting.	Dr Gunjan Gulati Bhagat	0.60	6 Months	Faculty of Medicine
15	Manifestations of cardiac myopathy Imaging studies with pathologic correlations	Dr Ashish Kumar Sukla	1.20	18 months	Faculty of Medicine
16	A prospective study to examine the effect of site and shape of scleral incisions for cataract surgery on corneal curvature	Dr Sarita Agrawal	1.40	18 months	Faculty of Medicine

17	A comparative study to assess the lumbar intervertebral disc parameters in patients with chronic low back pain and healthy individuals	Dr Rajeev Anand	0.90	18 months	Faculty of Medicine
18	Efficacy of Cefazolin versus Ceftriaxone for Extremity Open Fracture Management	Dr Amit Dwivedi	0.80	18 months	Faculty of Medicine
19	Awareness, knowledge and perception on Organ donation among students of health care profession	Dr Swati Singh	0.60	6 Months	Faculty of Medicine
20	A comparative study on deciduous teeth eruption among infants born after low-risk pregnancy compared to infants diagnosed with intrauterine growth restriction	Dr Natasha Gambhir	0.50	6 Months	Faculty of Dentistry
21	Epidemiology of Acute Gastroenteritis Caused by Rotavirus Among Children Less than Five Years Old Admitted in a tertiary care center in Northern Indian region	Dr Alka Agrawal	1.60	18 months	Faculty of Medicine
22	Assessment of serum copper and zinc concentrations in North Indian children with overweight and obesity.	Dr K C Aggarwal	1.40	18 months	Faculty of Medicine



Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.


**Kadambri Educational and Charitable Trust**  
(Authorized Signatory)

CC to:

1. Dr Vinod Kumar Yadav
2. Dr Anshul Gaur
3. Dr Mahima Lakhanpal
4. Dr Juhi Aggarwal
5. Dr Jyoti Batra
6. Dr Deepika Agarwal
7. Mr Pradhumn Katara
8. Dr Shivani Mangal
9. Dr Avdesh Sharma
10. Dr Abhay Kumar Singh
11. Dr SV Singh
12. Dr Ashutosh Rawat
13. Dr Alpana Agrawal
14. Dr Gunjan Gulati Bhagat
15. Dr Ashish Kumar Sukla
16. Dr Sarita Agrawal
17. Dr Rajeev Anand
18. Dr Amit Dwivedi
19. Dr Swati Singh
20. Dr Natasha Gambhir
21. Dr Alka Agrawal
22. Dr K C Aggarwal

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVE OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005



## Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 22/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh
3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg
6	Cissus Quadrangular is as callus Enhancer -CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi

7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth - A CBCT study	Dr Akshay Bhargava
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal
12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav

22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul
23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu



*Ronita Kumari*

Kadambri Educational and Charitable Trust  
(Authorized Signatory)

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 13 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 19,62,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal	0.40	6 Months	Faculty of Medicine
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh	1.30	18 months	Faculty of Medicine


3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi	2.20	18 months	Faculty of Medicine
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu	0.40	6 Months	Faculty of Dentistry
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg	0.45	6 Months	Faculty of Medicine
6	Cissus Quadrangular is as callus Enhancer-CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi	0.25	6 Months	Faculty of Medicine
7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra	0.75	12 months	Faculty of Dentistry
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal	1.95	12 months	Faculty of Dentistry
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth - A CBCT study	Dr Akshay Bhargava	1.62	12 months	Faculty of Dentistry
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore	0.25	6 Months	Faculty of Medicine
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal	1.70	18 Months	Faculty of Medicine

12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora	1.70	6 Months	Faculty of Medicine
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh	0.40	6 Months	Faculty of Medicine
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal	0.40	6 Months	Faculty of Medicine
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora	0.40	6 Months	Faculty of Medicine
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra	0.60	6 Months	Faculty of Medicine
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai	0.20	6 Months	Faculty of Medicine
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.	0.40	6 Months	Faculty of Medicine
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya	0.20	6 months	Faculty of Medicine
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal	0.40	6 months	Faculty of Medicine
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav	0.25	4 months	Faculty of Medicine
22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul	0.95	12 months	Faculty of Medicine

23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu	2.45	12 months	Faculty of Dentistry
----	------------------------------------------------------------------------------------------------------	----------------	------	-----------	----------------------

Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

  
*Promila Kumari*  
**Kadambri Educational and Charitable Trust**  
 (Authorized Signatory)

CC to:

1. Dr Veenu Agrawal
2. Dr Archana Singh
3. Dr. Amit Dwivedi
4. Dr Mohit Dadu
5. Dr V K Garg
6. Dr Amit Dwivedi
7. Dr Neeti Mittal, Dr Kush Kalra
8. Dr Priyanka Aggarwal
9. Dr Akshay Bhargava
10. Dr Raina Rathore
11. Dr Sarita Agrawal
12. Dr Latika Arora
13. Dr Abhay Kumar Singh
14. Dr Sarita Agrawal
15. Dr Yogesh Chander Arora
16. Dr Preeti Sharma, Dr Jyoti Batra
17. Dr Sanjay Sahai
18. Dr Mahendran. C.S.
19. Dr Shikha Pawaiya
20. Dr KC Agrawal
21. Dr Virendra Yadav
22. Dr Nisha Kaul
23. Dr. Mohit Dadu

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVERNMENT OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005



Date: 24/07/2021

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>SNo</b>	<b>Title</b>	<b>Name of Principal investigator</b>
<b>1</b>	A prospective study to investigate the impact of long-term aerobic and combined exercises in modulating hunger, satiety and energy intake in type 2 diabetes mellitus (T2DM).	Dr Rinku Garg



**Simerjit Kaur**  
**(Authorized Signatory)**

Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 1,00,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1.	A prospective study to investigate the impact of long-term aerobic and combined exercises in modulating hunger, satiety and energy intake in type 2 diabetes mellitus (T2DM).	Dr Rinku Garg	1	18 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.


Thank you and regards.

PAN: DFLPK8815L  
Address: A.No.348, Old Housing  
Board Colony, Sector-13,  
Karnal. Haryana-132001

  
Simerjit Kaur  
(Authorized Signatory)

CC to:

1. Dr Rinku Garg



**भारत सरकार**  
Unique Identification Authority of India  
Government of India

नामांकन क्रम/ Enrolment No.: 1218/23010/02872

Download Date: 08/08/2018

To  
Simerjit Kaur  
D/O Manjit Singh  
H.No. 348 old housing board colony Sector-13  
Kamal  
Kamal  
Kamal Haryana - 132001  
9034104282


Generation Date: 23/02/2011

QR Code with Photograph

Signature Not Verified

आपका आधार क्रमांक / Your Aadhaar No. :  
**8613 8553 8344**  
VID : 9158 7910 4146 2148

मेरा आधार, मेरी पहचान



**भारत सरकार**  
Unique Identification Authority of India  
Government of India

पहचान का प्रमाण है, नागरिकता का नहीं।  
पहचान का प्रमाण ऑनलाइन ऑथेंटिकेशन द्वारा प्राप्त करें।  
यह एक इलेक्ट्रॉनिक प्रक्रिया द्वारा बना हुआ पत्र है।

is a proof of identity, not of citizenship.  
To establish identity, authenticate online.  
This is electronically generated letter.

आधार देश भर में मान्य है।  
आधार भविष्य में सरकारी और गैर-सरकारी सेवाओं का लाभ उठाने में उपयोगी होगा।  
Aadhaar is valid throughout the country.  
Aadhaar will be helpful in availing Government and Non-Government services in future.

QR Code with Photograph

भारत सरकार  
Unique Identification Authority of India

पता:  
D/O मंजीत सिंह, प.न. 348 ओल्ड हाउसिंग बोर्ड कॉलोनी  
सेक्टर-13, कमल, करनाल,  
हरियाणा - 132001

Address:  
D/O Manjit Singh, H.No. 348 old housing  
board colony Sector-13, Kamal, Kamal,  
Haryana - 132001

QR Code with Photograph

**8613 8553 8344**  
VID : 9158 7910 4146 2148

मेरा आधार, मेरी पहचान

**आयकर विभाग**  
INCOME TAX DEPARTMENT  
SIMERJIT KAUR  
MANJIT SINGH  
20/03/1991  
Permanent Account Number  
DFLPK8815L

*Simerjit Kaur*  
Signature



**भारत सरकार**  
GOVT. OF INDIA

QR Code with Photograph

29082013

## Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 22/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh
3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg
6	Cissus Quadrangular is as callus Enhancer -CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi

7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth - A CBCT study	Dr Akshay Bhargava
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal
12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav

22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul
23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu



*Ronita Kumari*

Kadambri Educational and Charitable Trust  
(Authorized Signatory)

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 13 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 19,62,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal	0.40	6 Months	Faculty of Medicine
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh	1.30	18 months	Faculty of Medicine

3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi	2.20	18 months	Faculty of Medicine
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu	0.40	6 Months	Faculty of Dentistry
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg	0.45	6 Months	Faculty of Medicine
6	Cissus Quadrangular is as callus Enhancer-CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi	0.25	6 Months	Faculty of Medicine
7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra	0.75	12 months	Faculty of Dentistry
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal	1.95	12 months	Faculty of Dentistry
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth - A CBCT study	Dr Akshay Bhargava	1.62	12 months	Faculty of Dentistry
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore	0.25	6 Months	Faculty of Medicine
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal	1.70	18 Months	Faculty of Medicine




12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora	1.70	6 Months	Faculty of Medicine
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh	0.40	6 Months	Faculty of Medicine
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal	0.40	6 Months	Faculty of Medicine
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora	0.40	6 Months	Faculty of Medicine
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra	0.60	6 Months	Faculty of Medicine
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai	0.20	6 Months	Faculty of Medicine
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.	0.40	6 Months	Faculty of Medicine
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya	0.20	6 months	Faculty of Medicine
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal	0.40	6 months	Faculty of Medicine
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav	0.25	4 months	Faculty of Medicine
22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul	0.95	12 months	Faculty of Medicine

23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu	2.45	12 months	Faculty of Dentistry
----	------------------------------------------------------------------------------------------------------	----------------	------	-----------	----------------------

Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

  
*Promila Kumari*  
**Kadambri Educational and Charitable Trust**  
 (Authorized Signatory)

CC to:

1. Dr Veenu Agrawal
2. Dr Archana Singh
3. Dr. Amit Dwivedi
4. Dr Mohit Dadu
5. Dr V K Garg
6. Dr Amit Dwivedi
7. Dr Neeti Mittal, Dr Kush Kalra
8. Dr Priyanka Aggarwal
9. Dr Akshay Bhargava
10. Dr Raina Rathore
11. Dr Sarita Agrawal
12. Dr Latika Arora
13. Dr Abhay Kumar Singh
14. Dr Sarita Agrawal
15. Dr Yogesh Chander Arora
16. Dr Preeti Sharma, Dr Jyoti Batra
17. Dr Sanjay Sahai
18. Dr Mahendran. C.S.
19. Dr Shikha Pawaiya
20. Dr KC Agrawal
21. Dr Virendra Yadav
22. Dr Nisha Kaul
23. Dr. Mohit Dadu

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVERNMENT OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005

Date: 14/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No</b>	<b>Name of the Project</b>	<b>Name of the Principal Investigator</b>
1	A cross-sectional observational study to assess the impact of psychiatric co-morbidity on adherence to anti tubercular treatment in a northern Indian region	Dr Mahendran. C.S.
2	A randomized controlled trial to assess and compare self-reported tobacco quit status and biochemically verified cotinine levels among TB patients using two tobacco cessation methods	Dr Prachi Saxena

*Jaspreet Singh*

**Jaspreet Singh**  
**(Authorized Signatory)**

Date: 07/01/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 1,50,000 towards following projects by your faculty.

S.No	Name of the Project	Name of the Principal Investigator	Funds provided (INR in Lakhs)	Duration of Project
1	A cross-sectional observational study to assess the impact of psychiatric co-morbidity on adherence to anti tubercular treatment in a northern Indian region	Dr Mahendran C.S.	0.40	6 Months
2	A randomized controlled trial to assess and compare self-reported tobacco quit status and biochemically verified cotinine levels among TB patients using two tobacco cessation methods	Dr Prachi Saxena	1.10	18 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.

CC to:

1. Dr Mahendran C.S.
2. Dr Prachi Saxena



**Jaspreet Singh**  
(Authorized Signatory)



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

Enrolment No.: 0000/00156/52667

To  
Jaspreet Singh  
S/O Gurbachan Singh  
H. No- 8851  
Street No - 4  
KOT BABA DEEP SINGH  
Amritsar -1  
Amritsar Punjab - 143006  
7838578767

Signature Not Verified  
Digital Signature  
AUTHORITY: UIDAI  
Date: 03/01/2016 08:38:27  
UID



आपका आधर क्रमांक / Your Aadhaar No. :

**8186 9761 9984**

VID : 9186 8141 9046 3287

मेरा आधर, मेरी पहचान



भारत सरकार  
Government of India



Issue Date: 05/11/2016



Jaspreet Singh  
Date of Birth/DOB: 03/01/1986  
Male/ MALE

**8186 9761 9984**

VID : 9186 8141 9046 3287

मेरा आधर, मेरी पहचान



सूचना / INFORMATION

- आधर पहचान का प्रमाण है, नागरिकता का नहीं।
- आधर विशिष्ट और सुरक्षित है।
- सुरक्षित क्यूआर कोड/ऑफलाइन एक्सएमएल/ऑनलाइन प्रमाणीकरण का उपयोग करके पहचान सत्यापित करें।
- आधर के सभी रूप जैसे आधर पत्र, पीवीसी कार्ड, e-आधर और m-आधर समान रूप से मान्य हैं। 12 अंकों की आधर संख्या के स्थान पर आभासी (वर्चुअल) आधर पहचान (VID) का भी उपयोग किया जा सकता है।
- 10 साल में कम से कम एक बार आधर अपडेट जरूर करें।
- आधर आपको विभिन्न सरकारी और गैर-सरकारी योजनाओं /सेवाओं का लाभ उठाने में मदद करता है।
- आधर में अपना मोबाइल नंबर और ई-मेल आईडी अपडेट रखें।
- आधर सेवाओं का लाभ उठाने के लिए स्मार्टफोन पर mAadhaar ऐप डाउनलोड करें।
- आधर/बायोमेट्रिक्स को लॉक/अनलॉक करने की विशेषता का उपयोग सुरक्षा सुनिश्चित करने के लिए करें।
- आधर (पत्र/ नंबर) वाहने वाली संस्थायों को उचित सहमति लेने के लिए बाध्य किया गया है।
- Aadhaar is a proof of identity, not of citizenship.
- Aadhaar is unique and secure.
- Verify identity using secure QR code/offline XML/online Authentication.
- All forms of Aadhaar like Aadhaar letter, PVC Cards, eAadhaar and mAadhaar are equally valid. Virtual Aadhaar Identity (VID) can also be used in place of 12 digit Aadhaar number.
- Update Aadhaar at least once in 10 years.
- Aadhaar helps you avail various Government and Non-Government benefits/services.
- Keep your mobile number and email id updated in Aadhaar.
- Download mAadhaar app on smart phones to avail Aadhaar Services.
- Use the feature of lock/unlock Aadhaar/biometrics to ensure security.
- Entities seeking Aadhaar are obligated to seek due consent.



भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India



Address:  
S/O Gurbachan Singh, H. No- 8851, Street No  
- 4, KOT BABA DEEP SINGH, Amritsar -1,  
Amritsar,  
Punjab - 143006

Download Date: 31/03/2016



**8186 9761 9984**

VID : 9186 8141 9046 3287

1947 | help@uidai.gov.in | www.uidai.gov.in



आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

JASPREET SINGH

GURBACHAN SINGH

03/01/1986

Permanent Account Number

BSJPS9763A

*Jaspreet Singh*

Signature



14022008

## Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 22/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh
3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg
6	Cissus Quadrangular is as callus Enhancer -CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi



7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth - A CBCT study	Dr Akshay Bhargava
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal
12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav

22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul
23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu



*Ronita Kumari*

Kadambri Educational and Charitable Trust  
(Authorized Signatory)

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 13 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 19,62,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal	0.40	6 Months	Faculty of Medicine
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh	1.30	18 months	Faculty of Medicine


3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi	2.20	18 months	Faculty of Medicine
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu	0.40	6 Months	Faculty of Dentistry
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg	0.45	6 Months	Faculty of Medicine
6	Cissus Quadrangular is as callus Enhancer –CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi	0.25	6 Months	Faculty of Medicine
7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra	0.75	12 months	Faculty of Dentistry
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal	1.95	12 months	Faculty of Dentistry
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth – A CBCT study	Dr Akshay Bhargava	1.62	12 months	Faculty of Dentistry
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore	0.25	6 Months	Faculty of Medicine
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal	1.70	18 Months	Faculty of Medicine

12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora	1.70	6 Months	Faculty of Medicine
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh	0.40	6 Months	Faculty of Medicine
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal	0.40	6 Months	Faculty of Medicine
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora	0.40	6 Months	Faculty of Medicine
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra	0.60	6 Months	Faculty of Medicine
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai	0.20	6 Months	Faculty of Medicine
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.	0.40	6 Months	Faculty of Medicine
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya	0.20	6 months	Faculty of Medicine
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal	0.40	6 months	Faculty of Medicine
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav	0.25	4 months	Faculty of Medicine
22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul	0.95	12 months	Faculty of Medicine

23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu	2.45	12 months	Faculty of Dentistry
----	------------------------------------------------------------------------------------------------------	----------------	------	-----------	----------------------

Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

  
*Promila Kumari*  
**Kadambri Educational and Charitable Trust**  
 (Authorized Signatory)

CC to:

1. Dr Veenu Agrawal
2. Dr Archana Singh
3. Dr. Amit Dwivedi
4. Dr Mohit Dadu
5. Dr V K Garg
6. Dr Amit Dwivedi
7. Dr Neeti Mittal, Dr Kush Kalra
8. Dr Priyanka Aggarwal
9. Dr Akshay Bhargava
10. Dr Raina Rathore
11. Dr Sarita Agrawal
12. Dr Latika Arora
13. Dr Abhay Kumar Singh
14. Dr Sarita Agrawal
15. Dr Yogesh Chander Arora
16. Dr Preeti Sharma, Dr Jyoti Batra
17. Dr Sanjay Sahai
18. Dr Mahendran. C.S.
19. Dr Shikha Pawaiya
20. Dr KC Agrawal
21. Dr Virendra Yadav
22. Dr Nisha Kaul
23. Dr. Mohit Dadu

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVERNMENT OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004


Permanent Account Number

AAATK8461D

08012005



3.2.1



# Lab MICROCARE DIAGNOSTICS INDIA PRIVATE LIMITED

A 1 Shiv Park School Road, Khanpur, New Delhi - 110062  
Ph. : 9810400063, 9958368063 Web : www.microcarediagnostic.com

NOV 2021

To

Dr. Shaktibala Dutta

Prof and HOD Pharmacology

Santosh medical college, Santosh deemed to be university

Ghaziabad NCR

Dear doctor

We are pleased to inform you that following a thorough examination of your project as below

Title	Department	Principal investigator	Amount
1. To assess the efficacy of covid-19 vaccine administered by changes in antibody titre levels of persons vaccinated under vaccination program by Government of India, MOHFW at tertiary care teaching Centre in National Capital Region of India	Pharmacology	Dr. S.B.Dutta	75000/-

Against the above projects, consumables worth Rs.75000 (seventy-five thousands) supplied to the department/college. Please send us a detailed report on your result after the assignment is complete.

Best regards & thank you for your time & attention

Copy to:

1. Academic section
2. Dean research office

From

Director



ISO 15189:2012



# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 22/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert after review committee's decision.

<b>S.No.</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh
3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg
6	Cissus Quadrangular is as callus Enhancer -CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi

7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth - A CBCT study	Dr Akshay Bhargava
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal
12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav

22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul
23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu



*Ronita Kumari*

Kadambri Educational and Charitable Trust  
(Authorized Signatory)

# Kadambri Educational and Charitable Trust

Plot No.5, IInd Floor, BN Block(W), Central market, Shalimar Bagh, New Delhi-110088

Date: 13 Jan., 2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Madam,

This is in reference to our ongoing discussions on funding research for health sciences projects for your esteemed institution.

I am pleased to inform you that as at Kadambri Educational and Charitable Trust, **we are committed to contribute to research and development by providing monetary support, our board has approved** a fund of INR 19,62,000/- towards research grant for the following projects.

S.No.	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Duration of the project	Funds provided (INR in Lakhs)	Department of Principal Investigator/ Co Investigator
1	Comparison of Blood Pressure Measurements by Currently Available Multiparameter Monitors and Mercury Column Sphygmomanometer in Pediatric Patients Admitted in Intensive Care Unit	Dr Veenu Agrawal	0.40	6 Months	Faculty of Medicine
2	An observational study to investigate the association of changes in GS over 1 year and the second (2D) and fourth (4D) digit lengths in young children using the 4D as a covariate	Dr Archana Singh	1.30	18 months	Faculty of Medicine


3	A clinical Dilemma on Ankylosing Spondylitis of Hip Joint in Arthritis patients	Dr. Amit Dwivedi	2.20	18 months	Faculty of Medicine
4	A qualitative study to assess Oral healthcare-related perception, utilization, and barriers among schoolteachers	Dr Mohit Dadu	0.40	6 Months	Faculty of Dentistry
5	A Phase III Multicentric, Randomized, double Blind, Parallel, Group, Comparative, Clinical Study to Evaluate the efficacy and Safety of Bilastine Tablets 40 MG for the Treatment of Chronic Spontaneous Urticaria.	Dr V K Garg	0.45	6 Months	Faculty of Medicine
6	Cissus Quadrangular is as callus Enhancer –CT Scan based study comparing Patient groups for callus status, Union in Trauma Settings	Dr Amit Dwivedi	0.25	6 Months	Faculty of Medicine
7	Prevalence of erosion and its risk factors in school going children of Gautam Budh Nagar	Dr Neeti Mittal, Dr Kush Kalra	0.75	12 months	Faculty of Dentistry
8	To evaluate and compare the efficacy of Anorganic bovine bone matrix with Bioactive synthetic Bone graft particulate in treatment of intrabony defects	Dr Priyanka Aggarwal	1.95	12 months	Faculty of Dentistry
9	Evaluation of stability of stainless steel and Titanium miniscrew implants used as an anchorage for retraction of maxillary and mandibular anterior teeth – A CBCT study	Dr Akshay Bhargava	1.62	12 months	Faculty of Dentistry
10	Comprehensive study of micro debrider assisted endoscopic sinus surgery in CRSwNP.	Dr Raina Rathore	0.25	6 Months	Faculty of Medicine
11	Evaluation of Clinical & Microbiological Parameters In Infective Corneal Ulcers	Dr Sarita Agrawal	1.70	18 Months	Faculty of Medicine

12	Pathophysiological changes in cord blood & Placenta in hypertensive & anemic pregnant women	Dr Latika Arora	1.70	6 Months	Faculty of Medicine
13	Intratympanic steroid therapy for treatment of idiopathic sudden sensory neural hearing loss.	Dr Abhay Kumar Singh	0.40	6 Months	Faculty of Medicine
14	Corelation of tear function test and conjunctival impression cytology in dry eye.	Dr Sarita Agrawal	0.40	6 Months	Faculty of Medicine
15	Clinicopathological and immunological correlation in viral conjunctivitis.	Dr Yogesh Chander Arora	0.40	6 Months	Faculty of Medicine
16	Alzheimer's and Role of Serum Homocysteine Level in its Prognosis	Dr Preeti Sharma, Dr Jyoti Batra	0.60	6 Months	Faculty of Medicine
17	Evaluation of Lung Health of the Workers Occupationally Exposed to Petroleum Products	Dr Sanjay Sahai	0.20	6 Months	Faculty of Medicine
18	Role of LABA and Ultra-LABA in Asthma Symptom Control	Dr Mahendran. C.S.	0.40	6 Months	Faculty of Medicine
19	Incidence, Risk Factors & Outcomes of retinopathy of prematurity in North Indian rural and suburban population	Dr Shikha Pawaiya	0.20	6 months	Faculty of Medicine
20	An investigation of relationship between severe malaria and malnutrition in pediatric age group.	Dr KC Agrawal	0.40	6 months	Faculty of Medicine
21	An observational study to determine the microbial aetiology and possible risk factors of diarrhoea in children less than five years of age	Dr Virendra Yadav	0.25	4 months	Faculty of Medicine
22	A radiological study on Metacarpal lengths & ratios as a marker of sexual dimorphism in population of Ghaziabad district	Dr Nisha Kaul	0.95	12 months	Faculty of Medicine

23	Effect of Pollution on the oral health in the children of age group 1 to 5 years in Ghaziabad region	Dr. Mohit Dadu	2.45	12 months	Faculty of Dentistry
----	------------------------------------------------------------------------------------------------------	----------------	------	-----------	----------------------

Please share the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

  
**Kadambri Educational and Charitable Trust**  
 (Authorized Signatory)

CC to:

1. Dr Veenu Agrawal
2. Dr Archana Singh
3. Dr. Amit Dwivedi
4. Dr Mohit Dadu
5. Dr V K Garg
6. Dr Amit Dwivedi
7. Dr Neeti Mittal, Dr Kush Kalra
8. Dr Priyanka Aggarwal
9. Dr Akshay Bhargava
10. Dr Raina Rathore
11. Dr Sarita Agrawal
12. Dr Latika Arora
13. Dr Abhay Kumar Singh
14. Dr Sarita Agrawal
15. Dr Yogesh Chander Arora
16. Dr Preeti Sharma, Dr Jyoti Batra
17. Dr Sanjay Sahai
18. Dr Mahendran. C.S.
19. Dr Shikha Pawaiya
20. Dr KC Agrawal
21. Dr Virendra Yadav
22. Dr Nisha Kaul
23. Dr. Mohit Dadu

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVERNMENT OF INDIA

KADAMBRI EDUCATIONAL AND  
CHARITABLE TRUST



01/12/2004

Permanent Account Number

AAATK8461D

08012005



Date: 20/08/2021


To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Pattern of caries in adolescents	Dr. Mohit Dadu
2	A Comparative Assessment of the Upper Pharyngeal Airway Dimensions in different facial types : a cephalometric study	Dr Tina Chugh
3	A randomized controlled trial to comparatively evaluate the effect of Silver diamine fluoride and Fluoride varnish on preventing new carious lesions in children with high caries risk	Dr Nidhi Gupta
4	To compare and evaluate the primary and secondary implant stability between calcium phosphate surface coated implants and alumina blasted/acid etched implants using resonance frequency analysis.	Dr Shweta Bali

  
**Dheeraj Mehra**  
 (Authorized Signatory)

Date: 04/02/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,


I am pleased to inform you I am ready to provide you a grant of INR 4,00,000 towards following projects by your faculty

S.No	Name of the Project	Name of the Principal Investigator/Co Investigator	Funds provided (INR in Lakhs)	Duration of the project
1	Pattern of caries in adolescents	Dr. Mohit Dadu	0.40	6 months
2	A Comparative Assessment of the Upper Pharyngeal Airway Dimensions in different facial types : a cephalometric study	Dr Tina Chugh	0.80	12 Months
3	A randomized controlled trial to comparatively evaluate the effect of Silver diamine fluoride and Fluoride varnish on preventing new carious lesions in children with high caries risk	Dr Nidhi Gupta	1.25	9 months
4	To compare and evaluate the primary and secondary implant stability between calcium phosphate surface coated implants and alumina blasted/acid etched implants using resonance frequency analysis.	Dr Shweta Bali	1.55	6 months



Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.

  
**Dheeraj Mehra**  
**(Authorized Signatory)**

CC to:

1. Dr. Mohit Dadu
2. Dr Tina Chugh
3. Dr Nidhi Gupta
4. Dr Shweta Bali

Ref. No.:-SF/JUL/19/2021

Date:-19/07/2021

**Research Grant Project**  
**Approval Letter**

Dr. Parvinder Kaur,  
Professor  
Orthodontics  
Santosh Dental College and Hospital  
Santosh Deemed to be University  
Ghaziabad, U.P.

Subject: Sanctioning of Research Project Grant


Dear Dr.Parvinder Kaur,

We are pleased to inform you that your application regarding approval of funding grant for the Research project titled “**Prevalence of congenitally missing teeth in permanent dentition in Delhi NCR region**” for 12 months has been considered for funding grants by our Expert Committee after review.

The above said project is hereby approved by the Competent Authority and sanctioned a total amount of Rs.9,000/- (Nine Thousand Only).

Thank You and Regards

— Foundation —



(Authorized Signatory)

**CC to:**

- 1) Dean Research, Santosh University, Ghaziabad, UP
- 2) Office copy

Date: 21/06/2021

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No.	Title	Name of Principal investigator
1.	Oral Health related quality of life among School going Children in District Ghaziabad	Dr Mohit Dadu
2.	Prevalence of TMJ disorders in the local population of Ghaziabad City	Dr Chandni Batra
3.	Study of Histopathological Changes in Placenta In Pre-Eclampsia/Eclampsia	Dr Mayurika Tyagi
4.	Analyzing serum IL-6 in Oral Squamous Cell Carcinoma as a diagnostic marker	Dr Neeraj Grover



Mrs. Sheetal Rawat

(Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1.	Oral Health related quality of life among School going Children in District Ghaziabad	Dr Mohit Dadu	0.90	18 months
2.	Prevalence of TMJ disorders in the local population of Ghaziabad City	Dr Chandni Batra	1.25	18 months
3.	Study of Histopathological Changes in Placenta In Pre-Eclampsia/Eclampsia	Dr Mayurika Tyagi	1.70	12 months
4.	Analyzing serum IL-6 in Oral Squamous Cell Carcinoma as a diagnostic marker	Dr Neeraj Grover	1.15	18 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

CC to:

1. Dr Mohit Dadu
2. Dr Chandni Batra
3. Dr Mayurika Tyagi
4. Dr Shweta Bali

Mrs. Sheetal Rawat  
(Authorized Signatory)

आयकर विभाग  
INCOME TAX DEPARTMENT

भारत सरकार  
GOVT. OF INDIA

SHEETAL RAWAT

PURAN SINGH RAWAT

20/06/1989  
Permanent Account Number  
CBNPR1582A

*Sheetal*  
Signature



18122015





GSTN No 09ABKPD7746F1ZH

Mob: 9810612151

Email: purnimasci@yahoo.com



## Purnima Scientific Traders

**Authorized stockiest for:**

RANKEM RANGE OF FINE CHEMICALS, FISHER, WHATMAN FILTER PAPERS  
BOROSIL, GLASSWARES, SILICAWARES & ALL KINDS OF LAB-AID ITEMS

**568(540/511), SADDIQ NAGAR, NOOR NAGAR, BESIDE CHSP PUBLIC SCHOOL  
, NH-58 MEERUT ROAD, GHAZIABAD-201003(UP)**

**Ref. No- PST/ 2021-22**

**DATE- 17/07/2021**

**Dr. Brijesh Saran,**

Assistant Professor

Psychiatry

Santosh Medical College and Hospital

Santosh Deemed to be University Ghaziabad, U.P.

Dear Dr. Brijesh Saran,

We are pleased to inform you that your application regarding approval of funding grant for the Research project titled **“Evaluation of stigma in patients with Schizophrenia”** for 12 months has been considered for funding grants by our Expert Committee after review.

The above said project is hereby approved by the Competent Authority and sanctioned total amount of Rs.9,000/- (Nine Thousand only).

Thank you and regards

For Purnima Scientific Traders

For Purnima Scientific Traders

AD Roy

Date: 12/05/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>
<b>1</b>	Identification of characteristics of TB inpatients with diabetes mellitus and COPD	Dr Sanjay Sahai
<b>2</b>	A study to assess the practices related to Bio-Medical Waste Management among healthcare workers in a tertiary care centre	Dr Ritu Jain, DrRinku Garg
<b>3</b>	A Comparative Evaluation of Stress Distribution and Deformation in Prosthetic Screw in Different Implant Configuration as Evaluated by FEM	Dr Priyanka Thukral
<b>4</b>	An interventional study to evaluate the role of dietary supplementation of omega-3 fatty acids in dry eye syndrome	Dr Pratibha Gupta
<b>5</b>	A cross-sectional study to evaluate the genomic diversity of rotavirus strain in children with diarrhoea visiting the tertiary care hospital	Dr Vishrut Singh
<b>6</b>	A study to assess the spectrum of lesions of upperGIT through endoscopic biopsies and determine incidence of H. pylori among gastric lesions	Dr Malay Bajpai
<b>7</b>	A cross-sectional study to find out the prevalence and associated factors of exclusive breastfeeding in urban areas of Ghaziabad, Uttar Pradesh	Ms Namrata Soni

<b>8</b>	Assessment of mental wellbeing of school going adolescents using GHQ-12 questionnaire	Dr Amoolya Seth
<b>9</b>	A cross-sectional study to evaluate the predictive ability of mid-upper arm circumference (MUAC) for detecting severe wasting (weight-for-height Z-score (WHZ) <-3) among children aged 6-59 months.	Mr Pradhumn Katara
<b>10</b>	A case control study to analyse the association between UA and markers of oxidative stress and inflammation in diabetic nephropathy.	Dr Jyoti Batra
<b>11</b>	A prospective study to compare Acceptability, Safety and Continuation rate of Copper T 380A during immediate post placental insertion vs. Insertion within 48 hours of delivery	Dr Manisha Gupta
<b>12</b>	Bone turn over markers in diabetics and non diabetics	Dr Juhi Aggarwal, Dr Jyoti Batra
<b>13</b>	A study of an association between obesity in children and hypertension in adults	Dr Ritesh Kamal
<b>14</b>	A prospective study to compare ultrasonographic findings with clinical and radiographic findings in osteoarthritis (OA)-Affected knee joints	Dr Rakesh Gujjar
<b>15</b>	An observation of the bacteriological profile and antimicrobial susceptibility pattern of uropathogens with special reference to (Extended Spectrum beta Lactamase) ESBL producing strains.	Dr Shalabh Gupta

  
 Himanshu Shukla  
 (Authorized Signatory)

Date: 14/12/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research Funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 10,70,000 towards following projects by your faculty.

<b>S.No</b>	<b>Name of the Project, Clinical Trial, Endowment, Chairs</b>	<b>Name of the Principal Investigator/Co Investigator</b>	<b>Department of Principal Investigator/ Co Investigator</b>	<b>Funds provided (INR in Lakhs)</b>	<b>Duration of the project</b>
<b>1</b>	Identification of characteristics of TB inpatients with diabetes mellitus and COPD	Dr Sanjay Sahai	Faculty of Medicine	4.50	18 months
<b>2</b>	A study to assess the practices related to Bio-Medical Waste Management among healthcare workers in a tertiary care centre	Dr Ritu Jain, Dr Rinku Grag	Faculty of Medicine	0.30	24 months
<b>3</b>	A Comparative Evaluation of Stress Distribution and Deformation in Prosthetic Screw in Different Implant Configuration as Evaluated by FEM	Dr Priyanka Thukral	Faculty of Dentistry	1.50	12 months
<b>4</b>	An interventional study to evaluate the role of dietary supplementation of omega-3 fatty acids in dry eye syndrome	Dr Pratibha Gupta	Faculty of Medicine	0.20	6 months

<b>5</b>	A cross-sectional study to evaluate the genomic diversity of rotavirus strain in children with diarrhoea visiting the tertiary care hospital	Dr Vishrut Singh	Faculty of Medicine	0.15	6 months
<b>6</b>	A study to assess the spectrum of lesions of upperGIT through endoscopic biopsies and determine incidence of H. pylori among gastric lesions	Dr Malay Bajpai	Faculty of Medicine	0.15	6 months
<b>7</b>	A cross-sectional study to find out the prevalence and associated factors of exclusive breastfeeding in urban areas of Ghaziabad, Uttar Pradesh	Ms Namrata Soni	Faculty of Medicine	0.30	6 months
<b>8</b>	Assessment of mental wellbeing of school going adolescents using GHQ-12 questionnaire	Dr Amoolya Seth	Faculty of Medicine	0.90	12 months
<b>9</b>	A cross-sectional study to evaluate the predictive ability of mid-upper arm circumference (MUAC) for detecting severe wasting (weight-for-height Z-score (WHZ) <-3) among children aged 6-59 months.	Mr Pradhumn Katara	Faculty of Medicine	0.40	6 months
<b>10</b>	A case control study to analyse the association between UA and markers of oxidative stress and inflammation in diabetic nephropathy.	Dr Jyoti Batra	Faculty of Medicine	0.60	6 months
<b>11</b>	A prospective study to compare Acceptability, Safety and Continuation rate of Copper T 380A during immediate post placental insertion vs. Insertion within 48 hours of delivery	Dr Manisha Gupta	Faculty of Medicine	0.70	6 months


<b>12</b>	Bone turn over markers in diabetics and non diabetics	Dr Juhi Aggarwal, Dr Jyoti Batra	Faculty of Medicine	0.20	6 months
<b>13</b>	A study of an association between obesity in children and hypertension in adults	Dr Ritesh Kamal	Faculty of Medicine	0.30	6 months
<b>14</b>	A prospective study to compare ultrasonographic findings with clinical and radiographic findings in osteoarthritis (OA)-Affected knee joints	Dr Rakesh Gujjar	Faculty of Medicine	0.20	6 months
<b>15</b>	An observation of the bacteriological profile and antimicrobial susceptibility pattern of uropathogens with special reference to (Extended Spectrum beta Lactamase) ESBL producing strains.	Dr Shalabh Gupta	Faculty of Medicine	0.30	6 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.

CC to:

1. Dr Sanjay Sahai
2. Dr Ritu Jain, Dr Rinku Grag
3. Dr Priyanka Thukral
4. Dr Pratibha Gupta
5. Dr Vishrut Singh
6. Dr Malay Bajpai
7. Ms Namrata Soni
8. Dr Amoolya Seth
9. Mr Pradhumn Katara
10. Dr Jyoti Batra
11. Dr Manisha Gupta
12. Dr Juhi Aggarwal, Dr Jyoti Batra
13. Dr Ritesh Kamal
14. Dr Rakesh Gujjar
15. Dr Shalabh Gupta

  
Himanshu Shukla  
(Authorized Signatory)

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

HIMANSHU SHUKLA

RAMESH CHANDRA SHUKLA

01/03/1984

Permanent Account Number

BBDPS3520G

*Himanshu Shukla*

Signature



28082009







Dated: 01-Jul-2022

To,

Serial No. 94 to 97

Dr. Jyoti Batra,  
Dean Research  
Santosh Deemed to be University  
Ghaziabad, U.P., India

**Sub.: Approval of Grant/cost for Research Support**

Respected Sir/Madam,

This is in continuation to our past discussions and communications that Nirmal Integrated Consultancy Private Limited (Team-NIC) is pleased to approve a grant/cost of a total amount of 5,00,000 (INR Five Lakh Only) for support of below mentioned research projects at your University.

**List of Approved Projects:**

#	Title of Project	Principal Investigator	Co-Investigator(s)	Amount (In Lakhs)
1.	Oral Health related quality of life among geriatric population in old age home in Ghaziabad City	Dr Kush Kalra	Dr. Mohit Dadu	1.35
2.	Evaluation of hematological profile in Oral Sub mucous fibrosis	Dr. Chandni Batra	Dr. Kanika Bhalla	0.55
3.	Effectiveness of International System for Reporting Serious Fluid Cystology in Routine Practice	Dr. Swati Singh	Dr. Mayurika Tyagi	1.75
4.	"Various Medications Used for Gastritis among Post-operative Patients in Surgery IPD in a Tertiary Care Hospital."	Dr. Shaktibala Dutta	Dr. Jyotsna Sharma	1.35

**Terms of Grant/cost:**

- The grant/cost has been approved for consumption and deliveries within 12 month of release of this letter.
- The utilization details, progress reports, and the interim/final results of the investigations are required to be submitted to undersigned periodically for their reviews and comments.
- The respective departments of the University set free to choose the research team with the mentioned Principal Investigator/Co-Investigator(s). The respective team is expected to submit the expected project plan to Team-NIC within 30-days of release of this letter.
- Team-NIC reserves the right of using the outcomes of the research without further permissions/consents/intimations to/from the researcher(s) and at the same time it sets free the researcher and their affiliating organizations for the same.
- The research team is expected to share the complete and unbiased outcomes of the research within the timeline of the projects.
- 50% of the approved grant/cost would be released to the institution within 90-days of release of this letter whereas the balance would be released after receiving the satisfactory outcomes of the research or as to be mutually agreed.
- Team-NIC is free to cancel the balance grant/cost anytime without any obligation of clarifications to the research team/organization and at the same time there is no obligation on the research team/organization about refund of the released grant/cost for any reasons.

Kindly feel free to connect to undersigned for any further clarifications or support.

Best regards,  
Prof. (Dr.) D. Jain  
Hon. Chief Advisor

01/07/2022



**Transforming Consultancy Globally  
Since 2001**





## ← Re: Santosh Medical- Customer Preference Study



Hi Dr. Shweta, Kindly share your c...

[View message](#)



Amitav Ash

to Me & 2 more

Yesterday, 9:29 AM



Hi Shweta, please find details of Rs 25,000 paid towards incidental expenses. The toothpaste samples have also been dispatched to the address provided.

LP NDHN3TRF0IRN	SANTOSH 23575XK00JTR /6816402724 HSBCN21002726461 2021/01/02 180728	NONREF	TRANSFER	<u>25,000.00</u>
--------------------	---------------------------------------------------------------------------------	--------	----------	------------------

Warm regards

Amitav Ash

**Disclaimer:** This email message may contain confidential, proprietary or legally privileged information. Anyone who is not intended recipient should not use it. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges that Clove Dental is unable to exercise control to ensure or guarantee the integrity of / over the contents of the information contained in the email transmission and that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Clove Dental.

[Show more](#)



Reply



Reply all



More



Delete



Archive



Move



Reply all



More



## Tax Invoice

<b>TODAYS HEALTHCARE INDIA PRIVATE LIMITED</b> F 29/6, 1st Floor, Okhla Industrial Area, Phase-2, New Delhi 110029 GST:07AADCT1211A1Z7 Delhi - 110020, India State Name : Delhi, Code : 07 E-Mail : tax@clovedental.in	Invoice No. <b>20-21/TP/00071</b>	Dated <b>2-Jan-2021</b>
Buyer <b>Star Dental Centre Pvt Ltd-Warehouse-Delhi</b> F 29/6, 1st Floor , Okhla Industrial Area , Phase-II, New Delhi-110020 Delhi-110020 GSTIN/UIN : 07AAPCS5927C1Z5 State Name : Delhi, Code : 07	Delivery Note	Mode/Terms of Payment
	Supplier's Ref.	Other Reference(s)
	Buyer's Order No.	Dated
	Despatch Document No.	Delivery Note Date
	Despatched through	Destination
Terms of Delivery		

Sl No.	Description of Goods	HSN/SAC	Quantity	Rate	per	Amount	
1	<b>Toothpaste Power 40G</b>	3306	<b>1,008 Unit</b>	14.52	Unit	<b>14,636.16</b>	
2	<b>Toothpaste Sensitive 40G</b>	3306	<b>1,008 Unit</b>	15.12	Unit	<b>15,240.96</b>	
						29,877.12	
<b>CGST Payable</b>						<b>9 %</b>	<b>2,688.94</b>
<b>SGST Payable</b>						<b>9 %</b>	<b>2,688.94</b>
Total			<b>2,016 Unit</b>			<b>35,255.00</b>	

Amount Chargeable (in words)

E. &amp; O.E

**INR Thirty Five Thousand Two Hundred Fifty Five Only**

	Taxable Value	Central Tax		State Tax		Total Tax Amount
		Rate	Amount	Rate	Amount	
	29,877.12	9%	2,688.94	9%	2,688.94	5,377.88
<b>Total:</b>	<b>29,877.12</b>		<b>2,688.94</b>		<b>2,688.94</b>	<b>5,377.88</b>

 Tax Amount (in words) : **INR Five Thousand Three Hundred Seventy Seven and Eighty Eight paise Only**
**Declaration**

We declare that this invoice shows the actual price of the goods described and that all particulars are true and correct.

**for TODAYS HEALTHCARE INDIA PRIVATE LIMITED**

Authorised Signatory

SUBJECT TO SUBJECT TO DELHI JURISDICTION JURISDICTION

This is a Computer Generated Invoice

# DHANVANTRA HEALTH CARE PRIVATE LIMITED

Registered office & Corporate office : NH 45 Trichy Chennai Trunk Road, Near Samayapuram Toll Plaza,  
Samayapuram Post, Tiruchirappalli - 621 112, Fax : +91 431 2675353



To,

Date : 20<sup>th</sup> January, 2022

Dr Jyoti Batra (Dean Research)

Santosh Deemed to be University

Ghaziabad, U.P., India

Sub.: Grant for Research Support

Respected Sir/Madam,

This is to inform you that after thorough review of your research proposals submitted, we are pleased to approve a grant/donation of a total amount of 12,80,000 (INR) for support of your below mentioned research projects:

S.No	Title	Name of Principal Investigator	Amount Sanctioned (INR)
1	Mucin 4 expression in Oral Leukoplakia : An immunohistochemical study	Dr Kanika Bhalla Prabhat	0.85
2	An evaluation of changes in anxiety and behavior profile of children treated under inhalation sedation using nitrous oxide over 2-6 sequential follow up treatment visits	Dr Neeti Mittal	0.80
3	A randomized clinical trial to compare the clinical performance of indirect composite onlays and preformed zirconia crown for full coverage restoration of primary molars post-pulpectomy	Dr Shweta Bali	1.95
4	Prevalence of TMJ disorders in the local population of Ghaziabad City	Dr Chandni Batra, Dr Kanika Bhalla, Dr Priyanka Bhushan	1.35
5	Effect of premedication with three oral analgesics on the success of inferior alveolar nerve block in patients with symptomatic irreversible pulpitis - randomize control trial	Dr Chetna Arora	0.49
6	Oral Health related quality of life among School going Children in District Ghaziabad	Dr Mohit Dadu	0.09
7	To detect and assess DNA damage by Comet Assay from buccal epithelial cells of Smokeless tobacco users and non user.	Dr Shreya Singh	2.12
8	Prevalence of non-alcoholic fatty liver diseases in children	Dr Veenu Aggarwal	1.20
9	Efficacy of aminophylline versus caffeine for preventing apnea of prematurity	Dr Alka Aggarwal	1.10
10	Acute renal failure in full term neonates with perinatal asphyxia	Dr Veenu Aggarwal	1.85
11	Ageing and Levels of Leptin in Our Body	Dr Jyoti Batra	1.00

**Terms of Grant:**

- The utilization details and the final results of the investigations are required to be submitted to undersigned at project completion for their reviews and comments.
- The respective departments of the University are free to choose the research team with the mentioned Principal Investigator/Co-Investigator(s).

Kindly feel free to connect to undersigned for any further clarifications or support.



Best regards  
Authorized Signatory



GSTIN : 07AAACE0709K1ZV

**SILVER JUBILEE YEAR 2010**

Date: 01/03/2022

Ref. No. EDPL/SH/21-22

To,

Dr. Geeta Gupta , Dr.Dakshina Bisht, Dr.Ritu Jain &Dr.Ashutosh Rawat  
 Department of Microbiology  
 Santosh Medical College and Hospital  
 Santosh Deemed to be University  
 Ghaziabad, U.P.

Dear Doctor,

We are pleased to inform you that following a thorough examination of your project titled as below :

Title	Department	Principal Investigator	Amount
Surveillance of drug resistant gram negative bacteria in tertiary care hospital	Microbiology	Dr. Geeta Gupta	50,000/-
Virulence factors in candida species from various clinical samples	Microbiology	Dr.Dakshina Bisht	50,000/-
Fungal infection in CSOM	Microbiology	Dr.Ritu Jain	25,000/-
Prevalence of candidiasis in school going children	Microbiology	Dr.AshutoshTawat	25,000/-
			1,50,000/-

Against the above projects, consumables worth Rs.150,000.00 (Rs. One Lakh Fifty Thousand Only ) have been supplied to the Hospital /College.

Please send us a detailed report of your results after the assignment is complete.

Best Regards, and thank you for your time and attention

Copy to-

- 1) Academic section
- 2) Dean Research office

From Embee Diagnostics Pvt.Ltd

  
 Director



Date: 20/08/2021


To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Pattern of caries in adolescents	Dr. Mohit Dadu
2	A Comparative Assessment of the Upper Pharyngeal Airway Dimensions in different facial types : a cephalometric study	Dr Tina Chugh
3	A randomized controlled trial to comparatively evaluate the effect of Silver diamine fluoride and Fluoride varnish on preventing new carious lesions in children with high caries risk	Dr Nidhi Gupta
4	To compare and evaluate the primary and secondary implant stability between calcium phosphate surface coated implants and alumina blasted/acid etched implants using resonance frequency analysis.	Dr Shweta Bali

  
**Dheeraj Mehra**  
(Authorized Signatory)



Date: 04/02/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding


Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 4,00,000 towards following projects by your faculty

S.No	Name of the Project	Name of the Principal Investigator/Co Investigator	Funds provided (INR in Lakhs)	Duration of the project
1	Pattern of caries in adolescents	Dr. Mohit Dadu	0.40	6 months
2	A Comparative Assessment of the Upper Pharyngeal Airway Dimensions in different facial types : a cephalometric study	Dr Tina Chugh	0.80	12 Months
3	A randomized controlled trial to comparatively evaluate the effect of Silver diamine fluoride and Fluoride varnish on preventing new carious lesions in children with high caries risk	Dr Nidhi Gupta	1.25	9 months
4	To compare and evaluate the primary and secondary implant stability between calcium phosphate surface coated implants and alumina blasted/acid etched implants using resonance frequency analysis.	Dr Shweta Bali	1.55	6 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.

  
**Dheeraj Mehra**  
**(Authorized Signatory)**

CC to:

1. Dr. Mohit Dadu
2. Dr Tina Chugh
3. Dr Nidhi Gupta
4. Dr Shweta Bali

Date: 11/06/2021

To,

Dr. Jyoti Batra

Dean Research


Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee' s decision.

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	To evaluate and compare the disinfection achieved in canals by single file system (Hyflex EDM-B) using two different irrigants in removal of smear layer.	Dr Shubhra Malik Juneja
2	A comparative evaluation of the efficacy of electrocautery versus radiofrequency cautery for incisions in surgical removal of mandibular third molar.	Dr Amit B Lall



Mr Harish Yadav  
(Authorized Signatory)

To,  
21.01.2022

Dated:

Dr Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

<b>S.No.</b>	<b>Title</b>	<b>Name of Principal investigator</b>	<b>Amount (INR in Lakhs)</b>	<b>Study duration</b>
1	To evaluate and compare the disinfection achieved in canals by single file system (Hyflex EDM-B) using two different irrigants in	Dr Shubhra Malik Juneja	2.10	24 months



	removal of smear layer.			
2	A comparative evaluation of the efficacy of electrocautery versus radiofrequency cautery for incisions in surgical removal of mandibular third molar.	Dr Amit B Lall	2.90	24 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards

हरीश

CC to.

1. Dr Shubhra Malik Juneja
2. Dr Amit B Lall

Mr Harish Yadav  
(Authorized Signatory)







 भारत सरकार  
Government of India

 हरीश यादव  
Harish Yadav  
जन्म तिथि/ DOB: 01/04/1993  
पुरुष / MALE



5865 0577 6412


मेरा आधार, मेरी पहचान

 **एनटीयू विशिष्ट पहचान प्राधिकरण**  
Unique Identification Authority of India

**पता:**  
S/O राम सुरेन्द्र, किच्छा  
रोड, बॉर्ड न-4, भदईपुरा,  
रुद्रपुर, रुद्रपुर, उधम सिंह  
नगर,  
उत्तराखंड - 263153

**Address:**  
S/O Ram Surendra, Kichha  
Road, Ward No-4, Bhadaipura,  
Rudrapur, Rudrapur, Udham  
Singh Nagar,  
Uttarakhand - 263153

5865 0577 6412

 1947  [help@uidai.gov.in](mailto:help@uidai.gov.in)  [www.uidai.gov.in](http://www.uidai.gov.in)

Date: 08/07/2021

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

SNo	Title	Name of the Principal Investigator/Co Investigator
1.	Socket preservation with beta-tricalcium phosphate: a Clinico-radiographic evaluation	Dr Sanjeev Tomar
2.	Evaluation of hematological profile in Oral Sub mucous fibrosis	Dr Chandni Batra
3.	Morphometric and Radiological Analysis of The Size of the Foot and It s Correlation with Stature in Different Age Groups of Indian Population	Dr. Nisha Kaul
4.	Evaluation of examination stress on memory and EEG in male and Female medical students	Dr. Rinku Garg
5.	Effect of yoga on mental health of first year students	Dr. Navpreet Mann

*Radha yadav*

**Radha Yadav**

(Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

SNo	Title	Name of the Principal Investigator/Co Investigator	Funds Provided (INR in Lakhs)	Duration of the Project
1.	Socket preservation with beta-tricalcium phosphate: a Clinico-radiographic evaluation	Dr Sanjeev Tomar	1.32	12 Months
2.	Evaluation of hematological profile in Oral Sub mucous fibrosis	Dr Chandni Batra	0.68	6 Months
3.	Morphometric and Radiological Analysis of The Size of the Foot and Its Correlation with Stature in Different Age Groups of Indian Population	Dr. Nisha Kaul	1.00	12 Months
4.	Evaluation of examination stress on memory and EEG in male and Female medical students	Dr. Rinku Garg	1.00	12 Months
5.	Effect of yoga on mental health of first year students	Dr. Navpreet Mann	1.00	12 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

*Radha yadav*

**Radha Yadav**  
**(Authorized Signatory)**

CC to:

1. Dr Sanjeev Tomar
2. Dr Chandni Batra
3. Dr Nisha Kaul
4. Dr Rinku Garg
5. Dr Navpreet Mann

आयकर विभाग  
INCOME TAX DEPARTMENT

भारत सरकार  
GOVT. OF INDIA

RADHA YADAV

VIJAY KUMAR

20/06/1995

Permanent Account Number

APLPY8112K

*Radha yadan*  
Signature

17122016

भारत सरकार  
Government of India

राधा यादव  
Radha Yadav

जन्म तिथि/ DOB: 20/06/1995

महिला / FEMALE

9046 3479 5386

मेरा आधार, मेरी पहचान

Date: 11/06/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Findings in prostate cancer patients by Magnetic resonance spectroscopy (MRS)	Dr Ashish Kumar Shukla



Anupama Khanna  
(Authorized Signatory)



Date: 25/01/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 1,15,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1.	Findings in prostate cancer patients by Magnetic resonance spectroscopy (MRS)	Dr Ashish Kumar Shukla	1.15	24 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.



**CC to:**

1. Dr Ashish Kumar Shukla

**Anupama Khanna  
(Authorized Signatory)**

स्थायी लेखा संख्या /PERMANENT ACCOUNT NUMBER

AAXPK7804M



नाम /NAME

ANUPAMA KHANNA

पिता का नाम /FATHER'S NAME

GULZARI LAL MARWAH

जन्म तिथि /DATE OF BIRTH

24-05-1966

हस्ताक्षर /SIGNATURE

Akhanna

*Alu*

आयकर आयुक्त, मेरठ

COMMISSIONER OF INCOME-TAX, MEERUT



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रम/ Enrolment No.: 0651/91260/01783

To  
अनुपमा खन्ना  
Anupama Khanna  
C/O: Rajeev Khanna  
House no-5-A/3 Ganpati Enclave  
Opp P A C Roorkee Road Saufpur  
Meerut Cantt  
Meerut Uttar Pradesh - 250001  
9997124004

Signature Not Verified



आपका आधार क्रमांक / Your Aadhaar No. :

**2142 9572 0004**

VID : 9165 2576 8689 3348

मेरा आधार, मेरी पहचान



भारत सरकार  
Government of India



अनुपमा खन्ना  
Anupama Khanna  
जन्म तिथि/DOB: 24/05/1966  
लिंग/ GENDER: FEMALE

Home Data: 21/10/2014

**2142 9572 0004**

VID : 9165 2576 8689 3348

मेरा आधार, मेरी पहचान



Government of India



### सूचना

- आधार पहचान का प्रमाण है, नागरिकता का नहीं।
- सुरक्षित QR कोड / ऑफलाइन XML / ऑनलाइन ऑथेंटिकेशन से पहचान प्रमाणित करें।
- यह एक इलेक्ट्रॉनिक प्रक्रिया द्वारा बना हुआ पत्र है।

### INFORMATION

- Aadhaar is a proof of identity, not of citizenship.
- Verify identity using Secure QR Code/ Offline XML/ Online Authentication.
- This is electronically generated letter.

- आधार देश भर में मान्य है।
- आधार कई सरकारी और गैर सरकारी सेवाओं को पाना आसान बनाता है।
- आधार में मोबाइल नंबर और ईमेल ID अपडेट रखें।
- आधार को अपने स्मार्ट फोन पर रखें, mAadhaar App के साथ।

- Aadhaar is valid throughout the country.
- Aadhaar helps you avail various Government and non-Government services easily.
- Keep your mobile number & email ID updated in Aadhaar.
- Carry Aadhaar in your smart phone – use mAadhaar App.



भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India



पता:  
द्वारा: अनुपमा खन्ना, भारत न-5-ए/3 गणपती एन्क्लेव, ऑप  
पी ए सी रूकड़ी रोड साफपुर, मेरठ कैंट, मेरठ,  
उत्तर प्रदेश - 250001

Address:  
C/O: Rajeev Khanna, House no-5-A/3 Ganpati  
Enclave, Opp P A C Roorkee Road Saufpur,  
Meerut Cantt, Meerut,  
Uttar Pradesh - 250001



**2142 9572 0004**

VID : 9165 2576 8689 3348

1947 | 100% Digital | www.uidai.gov.in

Date: 08/07/2021

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No.	Title	Name of Principal investigator
1.	Comparative study between conventional adenoidectomy and powered instrument adenoidectomy	Dr Vandana Singh

**Mani Khanna**

**(Authorized Signatory)**



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 1,50,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1.	Comparative study between conventional adenoidectomy and powered instrument adenoidectomy	Dr Vandana Singh	1.50	24 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

*Mahi Khanna*

**Mahi Khanna**

**(Authorized Signatory)**

**CC to:**

1. Dr Vandana Singh




भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रम/ Enrolment No.: 0000/00652/20445

To  
श्रीमती खन्ना  
Mani Khanna  
Wife of Akhilesh Khanna  
C011 Harmony Tower The Peaceful Homes  
Near Tulip Chowk  
Sec 70 A  
Patna(164)  
Gurgaon Haryana - 122101  
9720210191



आपका आधार क्रमांक / Your Aadhaar No. :

**8457 7311 3469**

VID : 9182 1974 7511 3907

मेरा आधार, मेरी पहचान



भारत सरकार  
Government of India



Issue Date: 10-10-2013



श्रीमती खन्ना  
Mani Khanna  
जन तिथि/DOR: 21/08/1991  
लिंग/ FEMALE

**8457 7311 3469**

VID : 9182 1974 7511 3907

मेरा आधार, मेरी पहचान



### सूचना

- आधार पहचान का प्रमाण है, नागरिकता का नहीं।
- सुरक्षित QR कोड / ऑफलाइन XML / ऑनलाइन ऑथेंटिकेशन से पहचान प्रमाणित करें।
- यह एक इलेक्ट्रॉनिक प्रक्रिया द्वारा बना हुआ पत्र है।

### INFORMATION

- **Aadhaar** is a proof of identity, not of citizenship.
- Verify identity using Secure QR Code/ Offline XML/ Online Authentication.
- This is electronically generated letter.

- **आधार** देश भर में मान्य है।
- **आधार** कई सरकारी और गैर सरकारी सेवाओं को पाना आसान बनाता है।
- **आधार** में मोबाइल नंबर और ईमेल ID अपडेट रखें।
- **आधार** को अपने स्मार्ट फोन पर रखें, **mAadhaar App** के साथ।

- **Aadhaar** is valid throughout the country.
- **Aadhaar** helps you avail various Government and non-Government services easily.
- Keep your mobile number & email ID updated in **Aadhaar**.
- Carry Aadhaar in your smart phone – use **mAadhaar App**.




भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India



पता:  
पुस्तक शौच: अखिलेश खन्ना, C01111111 टावर वे  
पेसिफिक होम्स, नज़र तुलप चौक, सेक 70 A,  
पटना(164), गुर्गाँव,  
हरियाणा - 122101

Address:  
Wife of Akhilesh Khanna, C011 Harmony  
Tower The Peaceful Homes, Near Tulip  
Chowk, Sec 70 A, Patna(164), Gurgaon,  
Haryana - 122101



**8457 7311 3469**

VID : 9182 1974 7511 3907

1047 | help@uidai.gov.in | www.uidai.gov.in



ई- स्थायी लेखा संख्या कार्ड  
e - Permanent Account Number (e-PAN) Card  
AYZPG3134E

नाम / Name	MANI KHANNA		
पिता का नाम / Father's name	DEVENDRA KUMAR GARG		
जनम की तारीख / Date of Birth	21/08/1991		
लिंग / Gender	Female		
 हस्ताक्षर / Signature <small>ई-आयकर (ई-एन) कार्ड का उपयोग केवल डिजिटल सत्यापन के लिए किया जाना चाहिए।</small>		Signature Not Verified Digitally signed by Income Tax Dept. Date: 2022.03.17 07:53:49 IST	

- ✓ Permanent Account Number (PAN) facilitate Income Tax Department linking of various documents, including payment of taxes, assessment, tax demand tax arrears, matching of information and easy maintenance & retrieval of electronic information etc. relating to a taxpayer. स्थायी लेखा संख्या (पैन) एक कस्तुरी से संबंधित विभिन्न दस्तावेजों को जोड़ने में आयकर विभाग को सहायक होता है, जिसमें करों के चुकाव, आकलन, कर मांग, देय बकाया, सूचना के विस्तार और इलेक्ट्रॉनिक जानकारी का आसान संचालन में बहाली अदि भी शामिल है।
- ✓ Quoting of PAN is now mandatory for several transactions specified under Income Tax Act, 1961 (Refer Rule 114B of Income Tax Rules, 1962) आयकर अधिनियम, 1961 के तहत निर्दिष्ट कई लेनदेन के लिए स्थायी लेखा संख्या (पैन) का उद्धरण अब अनिवार्य है। (आयकर नियम, 1962 के नियम 114B, का संदर्भ लें)
- ✓ Possessing or using more than one PAN is against the law & may attract penalty of upto Rs. 10,000. एक से अधिक स्थायी लेखा संख्या (पैन) का उद्घाटन या उपयोग करना, कानून के विरुद्ध है और इसके लिए 10,000 रुपये तक का दंड लगाया जा सकता है।
- ✓ The PAN Card enclosed contains Enhanced QR Code which is readable by a specific Android Mobile App. Keyword to search this specific Mobile App on Google Play Store is "Enhanced QR Code Reader for PAN Card. संलग्न पैन कार्ड में एक एंहांसड क्यूआर कोड शामिल है जो एक विशिष्ट एंड्रॉइड मोबाइल ऐप द्वारा पठनीय है। Google Play Store पर इस विशिष्ट मोबाइल ऐप को खोजने के लिए कीवर्ड "Enhanced QR Code Reader for PAN Card" है।



Electronically issued and Digitally signed ePAN is a valid mode of issue of Permanent Account Number (PAN) post amendments in clause (b) in the Explanation occurring after sub-section (8) of Section 138A of Income Tax Act, 1961 and sub-rule (8) of Rule 114 of the Income Tax Rules, 1962.



Date: 24/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

SNo.	Title of the Project	Name of the Principal Investigator
1	Evaluation of role of high density porous polyethylene implants in correction of chin deformities	Dr Mayank Singhal
2	Pattern of suicide in Females with mental disorders	Dr. Shilpa Singh
3	To evaluate and compare the Apical transportation and canal centering ability in the Mesio- buccal root of maxillary first molar using three different rotary file systems (Protaper gold, Hyflex EDM and Trunatomy)	Dr Sumita Giri
4	Reduction in incidence of postoperative sore throat after endotracheal intubation in middle ear surgeries by preoperative gargling with ketamine	Dr Anil Kumar
5	Evaluation of early Menopause symptoms in Post-Hysterectomy and Premature Ovarian insufficiency in women of reproductive age group	Dr Alpana Aggarwal
6	A randomized clinical trial to comparatively evaluate the clinical efficacy of LMA Supreme™, and Ambu AuraGain™ in adult patients during general anesthesia	Dr Debpriya Sarkar



**Mr Dharmendra Yadav  
(Authorized Signatory)**

Date: 21/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding


Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

<b>Title of the Project</b>	<b>Name of the Principal Investigator</b>	<b>Funds provided (INR in Lakhs)</b>	<b>Duration of the project</b>
Evaluation of role of high density porous polyethylene implants in correction of chin deformities	Dr Mayank Singhal	1.27	9 months
Pattern of suicide in Females with mental disorders	Dr. Shilpa singh	1.6	24 Months
To evaluate and compare the Apical transportation and canal centering ability in the Mesio-buccal root of maxillary first molar using three different rotary file systems(Protaper gold,Hyflex EDM and Trunatomy)	Dr Sumita Giri	1.13	12 Months
Reduction in incidence of postoperative sore throat after endotracheal intubation in middle ear surgeries by preoperative gargaling with ketamine	Dr Anil Kumar	0.3	24 months
Evaluation of early Menopause symptoms in Post-Hysterectomy and Premature Ovarian insufficiency in women of reproductive age group	Dr Alpana Aggarwal	0.4	24 months
A randomized clinical trial to comparatively evaluate the clinical efficacy of LMA Supreme™, and Ambu AuraGain™ in adult patients during general anesthesia	Dr Debpriya Sarkar	0.3	24 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.



Mr Dharmendra Yadav  
**(Authorized Signatory)**

**CC to:**

1. Dr Mayank Singhal
2. Dr Shilpa Singh
3. Dr Sumita Giri
4. Dr Anil Kumar
5. Dr Alpana Aggarwal
6. Dr Debpriya Sarkar


आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

**MINOR**

स्थायी लेखा संख्या कार्ड  
Permanent Account Number Card  
AYMPY6442Q



नाम / Name  
DHARMENDRA YADAV

पिता का नाम / Father's Name  
RAM SURENDRA

जन्म की तारीख /  
Date of Birth  
06/08/2003

राम सुरेन्द्र  
हस्ताक्षर / Signature

19112018



Date: 08/07/2021

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

SNo	Title	Name of the Principal Investigator/Co Investigator
1.	Socket preservation with beta-tricalcium phosphate: a Clinico-radiographic evaluation	Dr Sanjeev Tomar
2.	Evaluation of hematological profile in Oral Sub mucous fibrosis	Dr Chandni Batra
3.	Morphometric and Radiological Analysis of The Size of the Foot and It s Correlation with Stature in Different Age Groups of Indian Population	Dr. Nisha Kaul
4.	Evaluation of examination stress on memory and EEG in male and Female medical students	Dr. Rinku Garg
5.	Effect of yoga on mental health of first year students	Dr. Navpreet Mann

*Radha Yadav*

**Radha Yadav**

(Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

SNo	Title	Name of the Principal Investigator/Co Investigator	Funds Provided (INR in Lakhs)	Duration of the Project
1.	Socket preservation with beta-tricalcium phosphate: a Clinico-radiographic evaluation	Dr Sanjeev Tomar	1.32	12 Months
2.	Evaluation of hematological profile in Oral Sub mucous fibrosis	Dr Chandni Batra	0.68	6 Months
3.	Morphometric and Radiological Analysis of The Size of the Foot and Its Correlation with Stature in Different Age Groups of Indian Population	Dr. Nisha Kaul	1.00	12 Months
4.	Evaluation of examination stress on memory and EEG in male and Female medical students	Dr. Rinku Garg	1.00	12 Months
5.	Effect of yoga on mental health of first year students	Dr. Navpreet Mann	1.00	12 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

*Radha yadav*

**Radha Yadav**  
**(Authorized Signatory)**

CC to:

1. Dr Sanjeev Tomar
2. Dr Chandni Batra
3. Dr Nisha Kaul
4. Dr Rinku Garg
5. Dr Navpreet Mann

आयकर विभाग  
INCOME TAX DEPARTMENT

भारत सरकार  
GOVT. OF INDIA

RADHA YADAV

VIJAY KUMAR

20/06/1995

Permanent Account Number

APLPY8112K

*Radha yadan*  
Signature

17122016

भारत सरकार  
Government of India

राधा यादव  
Radha Yadav

जन्म तिथि/ DOB: 20/06/1995

महिला / FEMALE

9046 3479 5386

मेरा आधार, मेरी पहचान

Date: 24/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

SNo.	Title of the Project	Name of the Principal Investigator
1	Evaluation of role of high density porous polyethylene implants in correction of chin deformities	Dr Mayank Singhal
2	Pattern of suicide in Females with mental disorders	Dr. Shilpa singh
3	To evaluate and compare the Apical transportation and canal centering ability in the Mesio- buccal root of maxillary first molar using three different rotary file systems (Protaper gold, Hyflex EDM and Trunatomy)	Dr Sumita Giri
4	Reduction in incidence of postoperative sore throat after endotracheal intubation in middle ear surgeries by preoperative gargling with ketamine	Dr Anil Kumar
5	Evaluation of early Menopause symptoms in Post-Hysterectomy and Premature Ovarian insufficiency in women of reproductive age group	Dr Alpana Aggarwal
6	A randomized clinical trial to comparatively evaluate the clinical efficacy of LMA Supreme™, and Ambu AuraGain™ in adult patients during general anesthesia	Dr Debpriya Sarkar



**Mr Dharmendra Yadav  
(Authorized Signatory)**



Date: 21/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

<b>Title of the Project</b>	<b>Name of the Principal Investigator</b>	<b>Funds provided (INR in Lakhs)</b>	<b>Duration of the project</b>
Evaluation of role of high density porous polyethylene implants in correction of chin deformities	Dr Mayank Singhal	1.27	9 months
Pattern of suicide in Females with mental disorders	Dr. Shilpa singh	1.6	24 Months
To evaluate and compare the Apical transportation and canal centering ability in the Mesio-buccal root of maxillary first molar using three different rotary file systems(Protaper gold,Hyflex EDM and Trunatomy)	Dr Sumita Giri	1.13	12 Months
Reduction in incidence of postoperative sore throat after endotracheal intubation in middle ear surgeries by preoperative gargaling with ketamine	Dr Anil Kumar	0.3	24 months
Evaluation of early Menopause symptoms in Post-Hysterectomy and Premature Ovarian insufficiency in women of reproductive age group	Dr Alpana Aggarwal	0.4	24 months
A randomized clinical trial to comparatively evaluate the clinical efficacy of LMA Supreme™, and Ambu AuraGain™ in adult patients during general anesthesia	Dr Debpriya Sarkar	0.3	24 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.



Mr Dharmendra Yadav  
**(Authorized Signatory)**

**CC to:**

1. Dr Mayank Singhal
2. Dr Shilpa Singh
3. Dr Sumita Giri
4. Dr Anil Kumar
5. Dr Alpana Aggarwal
6. Dr Debpriya Sarkar




आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

**MINOR**

स्थायी लेखा संख्या कार्ड  
Permanent Account Number Card  
**AYMPY6442Q**



नाम / Name  
DHARMENDRA YADAV

पिता का नाम / Father's Name  
RAM SURENDRA

जन्म की तारीख /  
Date of Birth  
06/08/2003

राम सुरेन्द्र  
हस्ताक्षर / Signature

19112018



Date: 24/07/2021


To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>SNo</b>	<b>Title</b>	<b>Name of Principal investigator</b>
<b>1</b>	Bacteriological Study of Conjunctivitis.	Dr Somesh Ranjan



**Akhilesh Khanna**  
**(Authorized Signatory)**

Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 1,50,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1.	Bacteriological Study of Conjunctivitis.	Dr Somesh Ranjan	1,50,000/-	24 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.



**Akhilesh Khanna**  
**(Authorized Signatory)**

**CC to.**

1. Dr Somesh Ranjan

आयकर विभाग

INCOME TAX DEPARTMENT



भारत सरकार

GOVT. OF INDIA

AKHILESH KHANNA

RAJEEV KHANNA

14/09/1990

Permanent Account Number

BLIPK8874N

*Akhilesh*

Signature



14112009



भारत सरकार  
Government of India

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

नामांकन क्रम/ Enrolment No.: 0000/00120/80273

To  
अश्लोक खन्ना  
Akhlesh Khanna  
C 011 Harmony tower  
AIRL The peaceful homes  
Sec 70 A  
Palra(164)  
Gurgaon Haryana - 122101  
9045850009

Valid unknown  
QR Code



आपका **आधार** क्रमांक / Your **Aadhaar** No. :

**2555 5247 7710**

VID : 9101 8558 2378 0894

मेरा **आधार**, मेरी पहचान



भारत सरकार  
Government of India



अश्लोक खन्ना  
Akhlesh Khanna  
जन्म तिथि/DOB: 14/09/1990  
पुरुष/ MALE

Issue Date: 04-03-2012

**2555 5247 7710**

VID : 9101 8558 2378 0894

मेरा **आधार**, मेरी पहचान



### सूचना

- आधार पहचान का प्रमाण है, नागरिकता का नहीं।
- सुरक्षित QR कोड / ऑफलाइन XML / ऑनलाइन ऑथेंटिकेशन से पहचान प्रमाणित करें।
- यह एक इलेक्ट्रॉनिक प्रक्रिया द्वारा बना हुआ पत्र है।

### INFORMATION

- **Aadhaar** is a proof of identity, not of citizenship.
- Verify identity using Secure QR Code/ Offline XML/ Online Authentication.
- This is electronically generated letter.

- **आधार** देश भर में मान्य है।
- **आधार** कई सरकारी और गैर सरकारी सेवाओं को पाना आसान बनाता है।
- **आधार** में मोबाइल नंबर और ईमेल ID अपडेट रखें।
- **आधार** को अपने स्मार्ट फोन पर रखें, **mAadhaar App** के साथ।

- **Aadhaar** is valid throughout the country.
- **Aadhaar** helps you avail various Government and non-Government services easily.
- Keep your mobile number & email ID updated in **Aadhaar**.
- Carry Aadhaar in your smart phone – use **mAadhaar App**.



भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India



पता:  
सी 011 हार्मनी टॉवर, एयर से कौस्तुभ डेमा, सेक्टर 70  
ए, पलरा(164), गुरुगढ़,  
हरियाणा - 122101

Address:  
C 011 Harmony tower, AIRL The peaceful  
homes, Sec 70 A, Palra(164), Gurgaon,  
Haryana - 122101



**2555 5247 7710**

VID : 9101 8558 2378 0894

मेरा **आधार**, मेरी पहचान



Date: 26/08/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No.</b>	<b>Title</b>	<b>Name of Principal investigator</b>
1	Comparison of results of silastic intra nasal splint and merocel nasal pack in septoplasty	Dr Sushil Gaur
2	A Study on the Correlation Between Type 2 Diabetes Mellitus and Osteoporosis with reference to Osteopontin Levels	Dr Jyoti Batra
3	Preferred Medications Used among neonates admitted to NICU in Santosh Medical College & Hospital, Santosh Deemed to be University, Ghaziabad.	Dr Jyotsna Sharma



(Authorized Signatory)

Jitender Kumar

Date: 21/02/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 4,30,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1	Comparison of results of silastic intra nasal splint and merocel nasal pack in septoplasty	Dr Sushil Gaur	1.60	24 Months
2	A Study on the Correlation Between Type 2 Diabetes Mellitus and Osteoporosis with reference toOsteopontin Levels	Dr Jyoti Batra	0.70	12 Months
3	Preferred Medications Used among neonates admitted to NICU in Santosh Medical College & Hospital, Santosh Deemed to be University, Ghaziabad.	Dr Jyotsna Sharma	2.00	24 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

  
(Authorized Signatory)  
Jitendra Kumar

CC to:

1. Dr Sushil Gaur
2. Dr Jyoti Batra
3. Dr Jyotsna Sharma

Date: 24/07/2021

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>SNo</b>	<b>Title</b>	<b>Name of Principal investigator</b>
<b>1</b>	Role of Polysomnography in Detection of Overlap Syndrome in COPD Patients	Dr. Prachi Saxena



**Anuj Ahuja**  
**(Authorized Signatory)**

Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 2,50,000.

<b>S.No.</b>	<b>Title</b>	<b>Name of Principal investigator</b>	<b>Amount (INR in Lakhs)</b>	<b>Study duration</b>
1.	Role of Polysomnography in Detection of Overlap Syndrome in COPD Patients	Dr. Prachi Saxena	2.50	24 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.



**Anuj Ahuja**

**(Authorized Signatory)**

CC to:

1. Prachi Saxena

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA


ANUJ AHUJA

VINOD AHUJA

06/05/1978

Permanent Account Number

AFIPA7753D

  
Signature



12062012




भारतीय विशिष्ट पहचान प्राधिकरण  
**भारत सरकार**  
 Unique Identification Authority of India  
 Government of India

न्यायिक क्रम/ Enrolment No.: 1218/23361/03097

To  
 अनज आहुजा  
 Anuj Ahuja  
 S/O: Vinod Ahuja  
 Flat No.601, Tower-1  
 Vipul Belmonte, Golf Course Road  
 Sector-53  
 Near HDFC Bank  
 Gurgaon Sector 56  
 Gurgaon Sector 56  
 Gurgaon Haryana - 122011  
 9810117654

Generation Date: 31/08/2018

Signature Not Verified  
 Digitally signed by  
 ANUJ AHUJA  
 DN: cn=ANUJ AHUJA, o=UIDAI, email=ANUJ.AHUJA@uidai.gov.in, c=IN  
 Date: 2018.08.31 15:33:14 +05'30'



QR Code with Photograph

आपका आधार क्रमांक / Your Aadhaar No. :

**6229 3138 2666**

VID : 9161 4010 2537 8649

मेरा आधार, मेरी पहचान



भारत सरकार  
 Government of India



अनुज आहुजा  
 Anuj Ahuja  
 जन्म तिथि/DOB: 06/05/1978  
 पुरुष/ MALE



**6229 3138 2666**

VID : 9161 4010 2537 8649

मेरा आधार, मेरी पहचान



- सूचना
- आधार पहचान का प्रमाण है, नागरिकता का नहीं।
  - पहचान का प्रमाण ऑनलाइन ऑथेंटिकेशन द्वारा प्राप्त करें।
  - यह एक इलेक्ट्रॉनिक प्रक्रिया द्वारा बना हुआ पत्र है।

**INFORMATION**

- **Aadhaar** is a proof of identity, not of citizenship.
- To establish identity, authenticate online.
- This is electronically generated letter.

- आधार देश भर में मान्य है।
- आधार भविष्य में सरकारी और गैर-सरकारी सेवाओं का लाभ उठाने में उपयोगी होगा।
- Aadhaar is valid throughout the country.
- Aadhaar will be helpful in availing Government and Non-Government services in future.



भारतीय विशिष्ट पहचान प्राधिकरण  
 Unique Identification Authority of India

पता:  
 S/O: विनोद आहुजा, फ्लैट नं. 601, टावर-1, विपुल बेलमोंटे,  
 गॉल्फ कोर्स रोड, सेक्टर-53, एचडीएफसी बैंक के पास,  
 गुरुग्राव सेक्टर 56, गुरुग्राव,  
 हरियाणा - 122011

**Address:**  
 S/O: Vinod Ahuja, Flat No.601, Tower-1,  
 Vipul Belmonte, Golf Course Road, Sector-  
 53, Near HDFC Bank, Gurgaon Sector 56,  
 Gurgaon,  
 Haryana - 122011



QR Code with Photograph

**6229 3138 2666**

VID : 9161 4010 2537 8649

*Handwritten signature*



Date: 11/06/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S. No.	Title of the Project	Name of the Principal Investigator
1	Evaluation of Cognitive Dysfunction in Recovered Bipolar Disorder Patients Compared with Biological Marker	Dr Brijesh Saran
2	Diagnosis of Schizophrenic with Biological Marker and MRI	Dr Amoolya Seth
3	Study of Spectrum of Lesions in Bone Marrow Aspiration and Terphine Biopsy from a Tertiary Care Center	Dr Prem Garg
4	Importance of Family Studies with High Performance Liquid Chromatography (HPLC) in Hemoglobin Disorders	Dr Abhishek Pathre
5	Various Medications Used for Gastritis among Post-operative Patients in Surgery IPD in a Tertiary Care Hospital	Dr Vivek Tejvir Yadav

Chandra Shekhar Mittal  
(Authorized Signatory)

Date: 30/01/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research

funding Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 7,50,000 towards following projects by your faculty

<b>Title of the Project</b>	<b>Name of the Principal Investigator</b>	<b>Funds provided (INR in Lakhs)</b>	<b>Duration of the project</b>
Evaluation of Cognitive Dysfunction in Recovered Bipolar Disorder Patients Compared with Biological Marker	Dr Brijesh Saran	2.00	24 Months
Diagnosis of Schizophrenic with Biological Marker and MRI	Dr Amoolya Seth	1.00	12 Months
Study of Spectrum of Lesions in Bone Marrow Aspiration and Terphine Biopsy from a Tertiary Care Center	Dr Prem Garg	1.50	24 Months
Importance of Family Studies with High Performance Liquid Chromatography (HPLC) in Hemoglobin Disorders	Dr Abhishek Pathre	1.50	24 Months

Various Medications Used for Gastritis among Post-operative Patients in Surgery IPD in a Tertiary Care Hospital	Dr Vivek Tejvir Yadav	1.50	18 Months
-----------------------------------------------------------------------------------------------------------------	-----------------------	------	-----------

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



Chandra Shekhar Mittal  
(Authorized Signatory)

CC to:

1. Dr Brijesh Saran
2. Dr Amoolya Seth
3. Dr Prem Garg
4. Dr Abhishek Pathre
5. Dr Vivek Tejvir Yadav

आयकर विभाग

INCOME TAX DEPARTMENT



भारत सरकार

GOVT OF INDIA

CHANDRA SHEKHAR MITTAL  
SURESH CHANDRA MITTAL



03/10/1964

Permanent Account Number

AEYPM8326D

Signature





भारत सरकार  
GOVERNMENT OF INDIA



चन्द्र शेखर मित्तल  
Chandra Shekhar Mittal  
DOB: 03-10-1964  
Gender: Male



9144 6343 0065

आधार - आम आदमी का अधिकार



भारतीय विशिष्ट पहचान प्राधिकरण  
UNIQUE IDENTIFICATION AUTHORITY OF INDIA

S/O सुरेश चन्द्र मित्तल, एसआरबी-  
36 ए, शिप्रा रिवेरा, सेंट थोमस स्कूल वे;  
पास, ज्ञान खण्ड-3, इन्दिरापुरम, शिप्रा  
सन सिटी, गाजियाबाद, उत्तर प्रदेश,  
201014


Address:


S/o Suresh Chandra Mittal, Srb-36  
A, Shipra Riviera, Near St. Thomas  
School, Gyan Khand-3,  
Indirapuram, Shipra Sun City,  
Ghaziabad, Uttar Pradesh, 201014



  
1947  
1800 300 1947

  
help@uidai.gov.in

  
www.uidai.gov.in

  
P.O. Box No. 1947,  
Bengaluru-560 001



Date: 26/07/2021


To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No.	Title	Name of Principal Investigator
1.	Prevalence of Selenium deficiency among pregnant females in District Ghaziabad- a cross-sectional study	Dr Anupama Singh
2.	Impact of Selenium deficiency on birth outcomes in pregnant females- A case-control study	Dr Deepika Agrawal
3.	Iodine deficiency and its associated factors among pregnant women in District Ghaziabad- a cross-sectional study	Dr Anupama Singh
4.	Rheumatoid arthritis and its associated factors among adult population of District Ghaziabad- a comparative study	Dr Deepika Agrawal



Mr Mithun Malik

(Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1.	Prevalence of Selenium deficiency among pregnant females in District Ghaziabad- a cross-sectional study	Dr Anupama Singh	1.00	24 Months
2.	Impact of Selenium deficiency on birth outcomes in pregnant females- A case-control study	Dr Deepika Agrawal	1.00	12 Months
3.	Iodine deficiency and its associated factors among pregnant women in District Ghaziabad- a cross-sectional study	Dr Anupama Singh	1.00	12 Months
4.	Rheumatoid arthritis and its associated factors among adult population of District Ghaziabad- a comparative study	Dr Deepika Agrawal	2.00	12 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.



Mr Mithun Malik

**(Authorized Signatory)**

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

MITHUN MALLIK

RANJEET MALLIK

01/01/1996

Permanent Account Number

CWRPM5815J

Signature



28102015





Date: 08/07/2021

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Epidemiology, clinical characteristics and outcome of confirmed covid19 cases presented to the emergency department	Dr Manish Sabbarwal
2	Local Drug Delivery System in Osteomyelitis Search for Novel Antibiotic Combinations Covering Common Orthopaedic Flora - A Pharmacoclinical Study	Dr Apporva Agarwal
3	Estimation of Serum Pseudocholinesterase in Acute Organo Phosphate Poisoning and its Correlation to Mortality	Dr Vishwajeet Singh
4	Trends of Serum Alkaline Phosphatase in Post-Menopausal Females and its Relation to BMD, Response to Osteopenia Treatment	Dr Amit Dwivedi
5	A study to assess the minimal clinically important difference (MCID) and minimal detectable change (MDC) in the functional ability of patients with chronic low back pain (CLBP) undergoing multimodal physical therapy treatment.	Dr Rajeev Anand
6	Variation of Harmonics to Noise Ratio from the Age Range of 9-18 Years Old in both the Genders	Dr Vineet Gupta
7	A case control study to assess lipoprotein-a and PAI-1 in women with polycystic ovary syndrome	Dr Jyoti Batra, Dr Rinku Garg
8	Morphometric analysis and types of articular facets on human dry tali and calcanei of North Indian origin	Dr Swati Yadav



<b>9</b>	Virtual Anthropology: Useful Radiological Tools for Age Assessment in Clinical Forensic Medicine and Toxicology	Dr Shilpa Singh
<b>10</b>	Regulation of Calcium Homeostasis in Acute Kidney Injury: A Prospective Observational Study	Dr Rohit Bhagat
<b>11</b>	Role of Intravenous Tranexamic Acid in Reducing Blood Loss during Caesarean Delivery	Dr Gunjan Gulati Bhagat
<b>12</b>	A cross sectional survey on physical fitness, mental health and associated factors in mothers of children with special needs	Dr Rani Srivastava
<b>13</b>	Chest computed tomography in immunocompromised patients with COPD	Dr Ashish Kumar Shukla

*Mohit*

**Mohit Gupta**  
(Authorized Signatory)



Date: 30/01/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 3,70,000 towards following projects by your faculty

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Department of Principal Investigator / Co Investigator	Funds provided (INR in Lakhs)	Duration of the project
1	Epidemiology, clinical characteristics and outcome of confirmed covid19 cases presented to the emergency department	Dr Manish Sabbarwal	Faculty of Medicine	0.10	24 Months
2	Local Drug Delivery System in Osteomyelitis Search for Novel Antibiotic Combinations Covering Common Orthopaedic Flora - A Pharmacoclinical Study	Dr Apporva Agarwal	Faculty of Medicine	0.10	3 months
3	Estimation of Serum Pseudocholinesterase in Acute Organo Phosphate Poisoning and its Correlation to Mortality	Dr Vishwajeet Singh	Faculty of Medicine	0.20	3 months
4	Trends of Serum Alkaline Phosphatase in Post-Menopausal Females and its Relation to BMD, Response to Osteopenia Treatment	Dr Amit Dwivedi	Faculty of Medicine	0.20	3 months

<b>5</b>	A study to assess the minimal clinically important difference (MCID) and minimal detectable change (MDC) in the functional ability of patients with chronic low back pain (CLBP) undergoing multimodal physical therapy treatment.	Dr Rajeev Anand	Faculty of Medicine	0.20	3 months
<b>6</b>	Variation of Harmonics to Noise Ratio from the Age Range of 9-18 Years Old in both the Genders	Dr Vineet Gupta	Faculty of Medicine	0.30	3 months
<b>7</b>	A case control study to assess lipoprotein-a and PAI-1 in women with polycystic ovary syndrome	Dr Jyoti Batra, Dr Rinku Garg	Faculty of Medicine	0.20	3 months
<b>8</b>	Morphometric analysis and types of articular facets on human dry tali and calcanei of North Indian origin	Dr Swati Yadav	Faculty of Medicine	0.20	3 months
<b>9</b>	Virtual Anthropology: Useful Radiological Tools for Age Assessment in Clinical Forensic Medicine and Toxicology	Dr Shilpa Singh	Faculty of Medicine	0.10	3 months
<b>10</b>	Regulation of Calcium Homeostasis in Acute Kidney Injury: A Prospective Observational Study	Dr Rohit Bhagat	Faculty of Medicine	0.35	3 months
<b>11</b>	Role of Intravenous Tranexamic Acid in Reducing Blood Loss during Caesarean Delivery	Dr Gunjan Gulati Bhagat	Faculty of Medicine	0.20	3 months
<b>12</b>	A cross sectional survey on physical fitness, mental health and associated factors in mothers of children with special needs	Dr Rani Srivastava	Faculty of Medicine	0.10	3 months
<b>13</b>	Chest computed tomography in immunocompromised patients with COPD	Dr Ashish Kumar Shukla	Faculty of Medicine	1.45	24 months



Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Mohit Gupta**  
(Authorized Signatory)

CC to:

1. Dr Manish Sabbarwal
2. Dr Apporva Agarwal
3. Dr Vishwajeet Singh
4. Dr Amit Dwivedi
5. Dr Rajeev Anand
6. Dr Vineet Gupta
7. Dr Jyoti Batra, Dr Rinku Garg
8. Dr Swati Yadav
9. Dr Shilpa Singh
10. Dr Rohit Bhagat
11. Dr Gunjan Gulati Bhagat
12. Dr Rani Srivastava
13. Dr Asahish Kumar Shukla

आयकर विभाग

INCOME TAX DEPARTMENT

MOHIT GUPTA

NARENDRA KUMAR

30/11/1990

Permanent Account Number

BCLPG4359N

*Mohit*  
Signature




भारत सरकार

GOVT. OF INDIA



27052016





Date: 26/07/2021

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No.	Title	Name of Principal Investigator
1.	A Study of Estimation of Stature by Anthropometric Measurements of Head	Dr Shilpa Singh

Mr Mohit Aggarwal  
(Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 1,00,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1.	A Study of Estimation of Stature by Anthropometric Measurements of Head	Dr Shilpa Singh	1	12 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

Mr Mohit Aggarwal  
(Authorized Signatory)

CC to:

1. Dr Shilpa Singh

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA


MOHIT AGGARWAL


BHARAT BHUSHAN AGGARWAL

19/05/1991







Permanent Account Number

BFKPA3817H

  
Signature



19012013

 	  
<p style="text-align: center;"><b>भारत सरकार</b> Government of India</p>	
<p style="text-align: center;"><b>भारतीय विशिष्ट पहचान प्राधिकरण</b> Unique Identification Authority of India</p>	
<p style="text-align: center;">नामांकन क्रम/ Enrolment No.: 0812/10005/23305</p>	
<p>Download Date: 08/06/2021</p> <p>To मोहित अग्रवाल Mohit Aggarwal S/O Bharat Bhushan Aggarwal 1/9379-A GURUDWARA VALI GALI NO.7 WEST ROHTASH NAGAR Shahdara S.O East Delhi Delhi - 110032 9953477773</p> <p>Issue Date: 03/02/2021</p> <p>Signature Not Verified Date: 03/02/2021 STATUS: SUCCESS AUTHOR: UIDAI DOB: 19/05/1991 BT</p>  <p style="text-align: center;"><b>आपका आधार क्रमांक / Your Aadhaar No. :</b> <b>5531 0441 9513</b> VID : 9141 3880 2129 1788</p> <p style="text-align: center;"><b>मेरा आधार, मेरी पहचान</b></p>	<p style="text-align: center;"><b>सूचना</b></p> <ul style="list-style-type: none"> <li>■ आधार पहचान का प्रमाण है, नागरिकता का नहीं।</li> <li>■ सुरक्षित QR कोड / ऑफलाइन XML / ऑनलाइन ऑथेंटिकेशन से पहचान प्रमाणित करें।</li> <li>■ यह एक इलेक्ट्रॉनिक प्रक्रिया द्वारा बना हुआ पत्र है।</li> </ul> <p style="text-align: center;"><b>INFORMATION</b></p> <ul style="list-style-type: none"> <li>■ <b>Aadhaar</b> is a proof of identity, not of citizenship.</li> <li>■ Verify identity using Secure QR Code/ Offline XML/ Online Authentication.</li> <li>■ This is electronically generated letter.</li> </ul> <div style="border: 1px solid black; padding: 5px;"> <ul style="list-style-type: none"> <li>■ <b>आधार</b> देश भर में मान्य है।</li> <li>■ <b>आधार</b> कई सरकारी और गैर सरकारी सेवाओं को पाना आसान बनाता है।</li> <li>■ <b>आधार</b> में मोबाइल नंबर और ईमेल ID अपडेट रखें।</li> <li>■ <b>आधार</b> को अपने स्मार्ट फोन पर रखें, <b>mAadhaar App</b> के साथ।</li> </ul> <ul style="list-style-type: none"> <li>■ <b>Aadhaar</b> is valid throughout the country.</li> <li>■ <b>Aadhaar</b> helps you avail various Government and non-Government services easily.</li> <li>■ Keep your mobile number &amp; email ID updated in <b>Aadhaar</b>.</li> <li>■ Carry Aadhaar in your smart phone – use <b>mAadhaar App</b>.</li> </ul> </div>
<p style="text-align: center;"><b>भारत सरकार</b> Government of India</p>	
<p style="text-align: center;"><b>भारतीय विशिष्ट पहचान प्राधिकरण</b> Unique Identification Authority of India</p>	
<p>Download Date: 08/06/2021</p>  <p>मोहित अग्रवाल Mohit Aggarwal जन्म तिथि/DOB: 19/05/1991 पुरुष: MALE</p> <p>Issue Date: 03/02/2021</p> <p style="text-align: center;"><b>5531 0441 9513</b> VID : 9141 3880 2129 1788</p> <p style="text-align: center;"><b>मेरा आधार, मेरी पहचान</b></p>	<p>पता: S/O भारत भूषण अग्रवाल, 1/9379-ए, गुरुद्वारा वाली गली नं.७, वेस्ट रोहताश नगर, शाहदरा स.ओ, ईस्ट दिल्ली, दिल्ली - 110032</p> <p>Address: S/O Bharat Bhushan Aggarwal, 1/9379-A, GURUDWARA VALI GALI NO.7, WEST ROHTASH NAGAR, Shahdara S.O, East Delhi, Delhi - 110032</p>  <p style="text-align: center;"><b>5531 0441 9513</b> VID : 9141 3880 2129 1788</p> <p style="text-align: center;"><b>मेरा आधार, मेरी पहचान</b></p> <p style="text-align: center;">1947   help@uidai.gov.in   www.uidai.gov.in</p>



Date: 08/07/2021

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

SNo	Title	Name of the Principal Investigator/Co Investigator
1.	NSAIDs preferred among NVD - episiotomy Females attending O & G Department	Dr Shaktibala Dutta
2.	Comparing Efficacy of Teriparatide, Zoledronic Acid and Alendronate with BMD Recovery Trend in Patients Treated for Bone Quality Enhancement	Dr Nishit Palo
3.	Clinicoetiological Study of Dermatophytes	Dr V.K. Garg

**Rupali Bisht**

(Authorized Signatory)

Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 5,00,000.

SNo	Title	Name of the Principal Investigator/Co Investigator	Funds provided (INR in Lakhs)	Duration of the project
1.	NSAIDs preferred among NVD - episiotomy Females attending O & G Department	Dr Shaktibala Dutta	1.00	24 Months
2.	Comparing Efficacy of Teriparatide, Zolendronic Acid and Alendronate with BMD Recovery Trend in Patients Treated for Bone Quality Enhancement	Dr Nishit Palo	2.00	24 Months
3.	Clinicoetiological Study of Dermatophytes	Dr V.K. Garg	2.00	24 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.

Thank you and regards.

**Rupali Bisht**  
**(Authorized Signatory)**

CC to:

1. Dr Shaktibala Dutta
2. Dr Nishit Palo
3. Dr V.K. Garg



आयकर विभाग  
INCOME TAX DEPARTMENT

भारत सरकार  
GOVT. OF INDIA

स्थायी लेखा संख्या कार्ड  
Permanent Account Number Card

BGZPB2181D

नाम/ Name  
RUPALI BISHT

पिता का नाम/ Father's Name  
HARENDRA BISHT

जन्म की तारीख/ Date of Birth  
05/05/1993

हस्ताक्षर/ Signature

10022017

भारत सरकार  
GOVERNMENT OF INDIA

रुपाली बिष्ट  
Rupali Bisht

जन्म तिथि/DOB: 05/05/1993

महिला/ FEMALE

Mobile No: 8979357040

7386 7715 2932

VID : VID : 9181 9449 5274 5585

मेरा आंधार, मेरी पहचान

Download Date: 07/11/2021

Issue Date: 22/01/2015



Date: 22/06/2021


To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project	Name of the Principal Investigator/Co Investigator
1	The Pattern of Arterial Supply of human Brain & its Variations As Seen In "Magnetic Resonance Angiography of Brain" in North Indian population	Dr Nisha Kaul
2	Immunomorphological pattern of regional lymph nodes and role of angiogenesis mast cells in oral squamous cell carcinoma	Dr Shweta Chaudhary
3	Clinicoetiological Study of Sexually Transmitted Disease in a Tertiary Care Hospital	Dr Sameer Mishra
4	Acute pain abdomen in the emergency department- clinical characteristics and outcome, a prospective observational study.	Dr Manish Sabbarwal
5	Use of Intravenous-Gadolinilum-based Contrast Media in Patients with Kidney Disease	Dr Ashish Kr Shukla
6	Increasing Opportunities for Trainees of Santosh Radiology Department to engage in Global Health Radiology: Radiology Training	Dr Sumit Kumar Ghosh
7	Spectrum of CECT abdomen findings in patients of acute abdomen in a tertiary care hospital	Dr Sarthak Kesarwani
8	Role of inflammatory markers in Prognosis of COVID - 19	Dr Ritu Jain, Dr Rinku Garg
9	Assessment of psychopathology in Medical Students using internet	Dr Ravindra Kumar Bansal
10	Prevalence of childhood depression and anxiety in senior secondary class students	Dr Brijesh Saran
11	Age Estimation by Radiographic Appearance of Root Development of Mandibular Third Molar	Dr Vishwajeet Singh

  
**Sangam Aggarwal**  
(Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,


I am pleased to inform you I am ready to provide you a grant of INR 2,25,000 towards following projects by your faculty.

S.No	Name of the Project	Name of the Principal Investigator/Co Investigator	Funds provided (INR in Lakhs)	Duration of the project
1	The Pattern of Arterial Supply of human Brain & its Variations As Seen In "Magnetic Resonance Angiography of Brain" in North Indian population	Dr Nisha Kaul	0.20	3 months
2	Immunomorphological pattern of regional lymph nodes and role of angiogenesis mast cells in oral squamous cell carcinoma	Dr Shweta Chaudhary	0.20	3 months
3	Clinicoetiological Study of Sexually Transmitted Disease in a Tertiary Care Hospital	Dr Sameer Mishra	0.20	3 months
4	Acute pain abdomen in the emergency department- clinical characteristics and outcome, a prospective observational study.	Dr Manish Sabbarwal	0.20	3 months
5	Use of Intravenous-Gadolinium-based Contrast Media in Patients with Kidney Disease	Dr Ashish Kr Shukla	0.30	3 months
6	Increasing Opportunities for Trainees of Santosh Radiology Department to engage in Global Health Radiology: Radiology Training	Dr Sumit Kumar Ghosh	0.15	3 months
7	Spectrum of CECT abdomen findings in patients of acute abdomen in a tertiary care hospital	Dr Sarthak Kesarwani	0.15	3 months
8	Role of inflammatory markers in Prognosis of COVID -19	Dr Ritu Jain, Dr Rinku Garg	0.25	3 months
9	Assessment of psychopathology in Medical Students using internet	Dr Ravindra Kumar Bansal	0.20	3 months

<b>10</b>	Prevalence of childhood depression and anxiety in senior secondary class students	Dr Brijesh Saran	0.20	3 months
<b>11</b>	Age Estimation by Radiographic Appearance of Root Development of Mandibular Third Molar	Dr Vishwajeet Singh	0.20	3 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Sangam Aggarwal**  
(Authorized Signatory)

CC to:

1. Dr Nisha Kaul
2. Dr Shweta Chaudhary
3. Dr Sameer Mishra
4. Dr Manish Sabbarwal
5. Dr Ashish Kr Shukla
6. Dr Sumit Kumar Ghosh
7. Dr Sarthak Kesarwani
8. Dr Ritu Jain, Dr Rinku Garg
9. Dr Ravindra Kumar Bansal
10. Dr Brijesh Saran
11. Dr Vishwajeet Singh





भारत सरकार  
GOVERNMENT OF INDIA



संगम अग्रवाल  
Sangam Aggarwal  
जन्म तिथि/ DOB: 29/01/1990  
पुरुष / MALE



8268 1862 4008

आधार-आम आदमी का अधिकार



भारतीय विशिष्ट पहचान प्राधिकरण  
UNIQUE IDENTIFICATION AUTHORITY OF INDIA

पता:

S/O सुनील कुमार अग्रवाल,  
567, विजय भवन, बुरमिद  
कौंपांड, प्रेम नगर,  
बुलंदशहर, बुलंदशहर,  
उत्तर प्रदेश - 203001

Address:

S/O, Sunil Kumar Aggarwal, 567,  
Vijay Bhawan, Buzmy Compound,  
Prem Nagar, Bulandshahr,  
Bulandshahr,  
Uttar Pradesh - 203001



1947  
1800 200 1947

help@uidai.gov.in

www.uidai.gov.in

P.O. Box No. 1947,  
Bengaluru-560 901

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

SANGAM AGGARWAL

SUNIL KUMAR AGGARWAL

29/01/1990  
Permanent Account Number

ANRPA8697D

*Sangam*

Signature



Ref. No.: -SF/JUL/17/2021

Date: -17/07/2021

**Research Grant Approval Letter**

Dr. Srishti Aggarwal,  
Faculty  
Dermatology  
Santosh Medical College and Hospital  
Santosh Deemed to be University Ghaziabad, U.P.

Dear Dr. Srishti Aggarwal,

We are pleased to inform you that your application regarding approval of funding grant for the Research project titled **“A comparative analysis of treatment response with tofacitinib, oral corticosteroids and methotrexate in Alopecia areata.”** for 3 months has been considered for funding grants by our Expert Committee after review.

The above said project is hereby approved by the Competent Authority and sanctioned total amount of Rs.25,000/- (Twenty Five thousand).

Thank you and Regards



(Authorized Signatory)

**CC to:**

- 1) Dean Research, Santosh University, Ghaziabad, UP
- 2) Office copy



Date: 22/06/2021


To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project	Name of the Principal Investigator/Co Investigator
1	The Pattern of Arterial Supply of human Brain & its Variations As Seen In "Magnetic Resonance Angiography of Brain" in North Indian population	Dr Nisha Kaul
2	Immunomorphological pattern of regional lymph nodes and role of angiogenesis mast cells in oral squamous cell carcinoma	Dr Shweta Chaudhary
3	Clinicoetiological Study of Sexually Transmitted Disease in a Tertiary Care Hospital	Dr Sameer Mishra
4	Acute pain abdomen in the emergency department- clinical characteristics and outcome, a prospective observational study.	Dr Manish Sabbarwal
5	Use of Intravenous-Gadolinilum-based Contrast Media in Patients with Kidney Disease	Dr Ashish Kr Shukla
6	Increasing Opportunities for Trainees of Santosh Radiology Department to engage in Global Health Radiology: Radiology Training	Dr Sumit Kumar Ghosh
7	Spectrum of CECT abdomen findings in patients of acute abdomen in a tertiary care hospital	Dr Sarthak Kesarwani
8	Role of inflammatory markers in Prognosis of COVID - 19	Dr Ritu Jain, Dr Rinku Garg
9	Assessment of psychopathology in Medical Students using internet	Dr Ravindra Kumar Bansal
10	Prevalence of childhood depression and anxiety in senior secondary class students	Dr Brijesh Saran
11	Age Estimation by Radiographic Appearance of Root Development of Mandibular Third Molar	Dr Vishwajeet Singh

  
**Sangam Aggarwal**  
(Authorized Signatory)



Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,


I am pleased to inform you I am ready to provide you a grant of INR 2,25,000 towards following projects by your faculty.

S.No	Name of the Project	Name of the Principal Investigator/Co Investigator	Funds provided (INR in Lakhs)	Duration of the project
1	The Pattern of Arterial Supply of human Brain & its Variations As Seen In "Magnetic Resonance Angiography of Brain" in North Indian population	Dr Nisha Kaul	0.20	3 months
2	Immunomorphological pattern of regional lymph nodes and role of angiogenesis mast cells in oral squamous cell carcinoma	Dr Shweta Chaudhary	0.20	3 months
3	Clinicoetiological Study of Sexually Transmitted Disease in a Tertiary Care Hospital	Dr Sameer Mishra	0.20	3 months
4	Acute pain abdomen in the emergency department- clinical characteristics and outcome, a prospective observational study.	Dr Manish Sabbarwal	0.20	3 months
5	Use of Intravenous-Gadolinium-based Contrast Media in Patients with Kidney Disease	Dr Ashish Kr Shukla	0.30	3 months
6	Increasing Opportunities for Trainees of Santosh Radiology Department to engage in Global Health Radiology: Radiology Training	Dr Sumit Kumar Ghosh	0.15	3 months
7	Spectrum of CECT abdomen findings in patients of acute abdomen in a tertiary care hospital	Dr Sarthak Kesarwani	0.15	3 months
8	Role of inflammatory markers in Prognosis of COVID -19	Dr Ritu Jain, Dr Rinku Garg	0.25	3 months
9	Assessment of psychopathology in Medical Students using internet	Dr Ravindra Kumar Bansal	0.20	3 months

<b>10</b>	Prevalence of childhood depression and anxiety in senior secondary class students	Dr Brijesh Saran	0.20	3 months
<b>11</b>	Age Estimation by Radiographic Appearance of Root Development of Mandibular Third Molar	Dr Vishwajeet Singh	0.20	3 months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.



**Sangam Aggarwal**  
(Authorized Signatory)

CC to:

1. Dr Nisha Kaul
2. Dr Shweta Chaudhary
3. Dr Sameer Mishra
4. Dr Manish Sabbarwal
5. Dr Ashish Kr Shukla
6. Dr Sumit Kumar Ghosh
7. Dr Sarthak Kesarwani
8. Dr Ritu Jain, Dr Rinku Garg
9. Dr Ravindra Kumar Bansal
10. Dr Brijesh Saran
11. Dr Vishwajeet Singh





भारत सरकार  
GOVERNMENT OF INDIA



संगम अग्रवाल  
Sangam Aggarwal  
जन्म तिथि/ DOB: 29/01/1990  
पुरुष / MALE



8268 1862 4008

आधार-आम आदमी का अधिकार



भारतीय विशिष्ट पहचान प्राधिकरण  
UNIQUE IDENTIFICATION AUTHORITY OF INDIA

पता:

S/O सुनील कुमार अग्रवाल,  
567, विजय भवन, बुरमिद  
कौंपांड, प्रेम नगर,  
बुलंदशहर, बुलंदशहर,  
उत्तर प्रदेश - 203001

Address:

S/O, Sunil Kumar Aggarwal, 567,  
Vijay Bhawan, Buzmy Compound,  
Prem Nagar, Bulandshahr,  
Bulandshahr,  
Uttar Pradesh - 203001



1947  
1800 200 1947

help@uidai.gov.in

www.uidai.gov.in

P.O. Box No. 1947,  
Bengaluru-560 901

आयकर विभाग  
INCOME TAX DEPARTMENT



भारत सरकार  
GOVT. OF INDIA

SANGAM AGGARWAL

SUNIL KUMAR AGGARWAL

29/01/1990  
Permanent Account Number

ANRPA8697D

*Sangam*

Signature





Date: 08/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No.	Title	Name of Principal investigator
1	Oral health indicators of oral health related quality of life among Indian elderly: A cross-sectional study	Dr Mansi Singh, Dr Priyanka Bhushan
2	A randomized, double-blind clinical trial was to evaluate the effect of preoperative administration of intraligamentary injections of diclofenac sodium and dexamethasone on the anesthetic efficacy of 2% lidocaine given as an inferior alveolar nerve block in the endodontic management of symptomatic irreversible pulpitis	Dr Nidhi Gupta, Dr Neeti Mittal
3	A study to evaluate and compare the accuracy of two age estimation methods in Indian children by using the open apex method proposed by Cameriere et al and the London Atlas of Tooth Development.	Dr Natasha Gambhir
4	An assessment of the incidence of postoperative pain, treatment time and analgesic intake after single visit endodontic treatment of mandibular molars using XP-endo Shaper, 2Shape and ProTaper Gold rotary systems.	Dr Deepika Yadav
5	Effect of nonsurgical periodontal therapy on gingival crevicular fluid levels of Interleukin-35 in patients with periodontitis	Dr Aruna Nautiyal
6	A study to assess the impact of age on osteometric measurements of patella.	Dr Sumit Tellewar
7	Influence of Parenting Styles and Peer Attachment on Life Satisfaction Among Adolescents: Mediating Role of Self-Esteem	Dr Parul Gairola

8	A randomised controlled trial to evaluate the anaesthetic efficacy of 2% lidocaine with different concentrations of epinephrine (1:80,000 and 1:200,000) in intraligamentary injection after a failed primary inferior alveolar nerve block	Dr Manoj Goyal
9	The pattern of road accident and trauma in Ghaziabad	Dr. Manish Sabbharwal
10	Effect of addition of dexmedetomidine on local anesthesia efficacy: a randomised controlled trial	Dr Neeti Mittal
11	Reliability of Self evaluation of treatment needs index for endodontic intervention	Dr Chetna Arora

*Neel Singh*

**Neel Singh**  
**(Authorized Signatory)**

Date: 16/02/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 6,00,000 towards following projects by your faculty.

S.No.	Title	Name of Principal investigator	Funds Provided (INR in Lakhs)	Duration of the Project
1	Oral health indicators of oral health related quality of life among Indian elderly: A cross-sectional study	Dr Mansi Singh, Dr Priyanka Bhushan	0.30	3 months
2	A randomized, double-blind clinical trial was to evaluate the effect of preoperative administration of intraligamentary injections of diclofenac sodium and dexamethasone on the anesthetic efficacy of 2% lidocaine given as an inferior alveolar nerve block in the endodontic management of symptomatic irreversible pulpitis	Dr Nidhi Gupta, Dr Neeti Mittal	0.50	6 Months
3	A study to evaluate and compare the accuracy of two age estimation methods in Indian children by using the open apex method proposed by Cameriere et al and the London Atlas of Tooth Development.	Dr Natasha Gambhir	0.45	6 Months
4	An assessment of the incidence of postoperative pain, treatment time and analgesic intake after single visit endodontic treatment of mandibular molars using XP-endo Shaper, 2Shape and ProTaper Gold rotary systems.	Dr Deepika Yadav	0.55	6 Months
5	Effect of nonsurgical periodontal therapy on gingival crevicular fluid levels of Interleukin-35 in patients with periodontitis	Dr Aruna Nautiyal	1.45	24 months
6	A study to assess the impact of age on osteometric measurements of patella.	Dr Sumit Tellewar	0.20	3 Months

7	Influence of Parenting Styles and Peer Attachment on Life Satisfaction Among Adolescents: Mediating Role of Self-Esteem	Dr Parul Gairola	0.15	3 Months
8	A randomised controlled trial to evaluate the anaesthetic efficacy of 2% lidocaine with different concentrations of epinephrine (1:80,000 and 1:200,000) in intraligamentary injection after a failed primary inferior alveolar nerve block	Dr Manoj Goyal	0.60	6 Months
9	The pattern of road accident and trauma in Ghaziabad	Dr. Manish Sabbharwal	0.65	6 Months
10	Effect of addition on dexmedetomidine on local anesthesia efficacy: a randomised controlled trial	Dr Neeti Mittal	0.75	6 Months
11	Relability of Self evaluation of treatment needs index for endodontic intervention	Dr Chetna Arora	0.40	6 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as was the outcome/impact of the project.

Thank you and regards.

*Neel Singh*  
**Neel Singh**  
**(Authorized Signatory)**

**CC to:**

1. Dr Mansi Singh, Dr Priyanka Bhushan
2. Dr Nidhi Gupta, Dr Neeti Mittal
3. Dr Natasha Gambhir
4. Dr Deepika Yadav
5. Dr Aruna Nautiyal
6. Dr Sumit Tellewar
7. Dr Parul Gairola
8. Dr Manoj Goyal
9. Dr Manish Sabbarwal
10. Dr Neeti Mittal
11. Dr Chetna Arora

**आयकर विभाग**  
INCOME TAX DEPARTMENT

**भारत सरकार**  
GOVT. OF INDIA

स्थायी लेखा संख्या कार्ड  
Permanent Account Number Card

**MMKPS9093R**

नाम / Name  
**NEEL SINGH**

पिता का नाम / Father's Name  
**SATYA PAL SINGH**

जन्म की तारीख / Date of Birth  
**10/02/1999**

*Neel Singh*  
हस्ताक्षर / Signature

11133




भारत सरकार  
Government of India

आधार  
AADHAAR

भारतीय विशिष्ट पहचान प्राधिकरण  
Unique Identification Authority of India

पता:  
आत्मज: सत्य पाल सिंह, ग्राम शहजादपुर पोस्ट  
भरबिसतपुर, तिलहर, शाहजहाँपुर,  
उत्तर प्रदेश - 242407

Address:  
S/O: Satya Pal Singh, vill shahjadpur post  
bhamibasantpur, Tilhar, Shahjahanpur,  
Uttar Pradesh - 242407



8432 6951 2759  
VID : 9102 7445 8550 8206

मेरा आधार, मेरी पहचान

Download Date: 22/12/2020

Issue Date: 02/11/2019

1947 | help@uidai.gov.in | www.uidai.gov.in



Date: 12/07/2021

To,  
 Dr. Jyoti Batra  
 Dean Research  
 Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator
1	Fixed dexmedetomidine infusion versus fixed-dose midazolam bolus as primary sedative for maintaining intra-procedural sedation during endobronchial ultrasound-guided transbronchial needle aspiration: a double blind randomized controlled trial	Dr Suveer Sharma
2	Influence of epidural ropivacaine with or without dexmedetomidine on postoperative analgesia and patient satisfaction after thoraco-lumbar spine instrumentation: a randomized, comparative, and double-blind study	Dr Mahima Lakhnpal
3	A retrospective cohort study to investigate the effect of smoking on rates of progressive visual field (VF) damage over time in glaucoma	Dr Priya Singh
4	A study to check the reliability of human dental pulp for identification of gender using Barr bodies.	Dr Shobroze Tantray
5	The effect of Neonicotinoid on Chick Embryos and its development	Dr. Yogesh Yadav
6	An invirto study was to evaluate the accuracy of the apex locator in the presence of different irrigating solutions	Dr Avdesh Sharma
7	A randomised controlled trial to assess the efficacy of holistic approaches (naturopathy and yoga) alone as well as in combination with pharmacological therapy in the treatment of chronic orofacial pain of non-odontogenic origin	Dr Swati Verma, Dr Priyanka Bhushan
8	A prospective, cluster-randomized, examiner-masked, 3-arm trial to evaluate the efficacy of time outdoors per school day over 2 years on myopia onset and shift.	Dr Sarita Agrawal

*Viplav Bhatt*  
**Viplav Bhatt**  
 (Authorized Signatory)

Date: 30/01/2022

To,  
Dr. Jyoti Batra  
Dean Research  
Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you I am ready to provide you a grant of INR 5,00,000 towards following projects by your faculty

S.No	Name of the Project, Clinical Trial, Endowment, Chairs	Name of the Principal Investigator/Co Investigator	Department of Principal Investigator/ Co Investigator	Funds provided (INR in Lakhs)	Duration of the project
1	Fixed dexmedetomidine infusion versus fixed-dose midazolam bolus as primary sedative for maintaining intra-procedural sedation during endobronchial ultrasound-guided transbronchial needle aspiration: a double blind randomized controlled trial	Dr Suveer Sharma	Faculty of Medicine	0.40	6 Months
2	Influence of epidural ropivacaine with or without dexmedetomidine on postoperative analgesia and patient satisfaction after thoraco-lumbar spine instrumentation: a randomized, comparative, and double-blind study	Dr Mahima Lakhanpal	Faculty of Medicine	0.30	6 Months
3	A retrospective cohort study to investigate the effect of smoking on rates of progressive visual field (VF) damage over time in glaucoma	Dr Priya Singh	Faculty of Medicine	0.40	6 Months
4	A study to check the reliability of human dental pulp for identification of gender using Barr bodies.	Dr Shobroze Tantray	Faculty of Dentistry	0.70	6 Months
5	The effect of Neonicotinoid on Chick Embryos and its development	Dr. Yogesh Yadav	Faculty of medicine	0.70	6 Months
6	An invitro study was to evaluate the accuracy of the apex locator in the presence of different irrigating solutions	Dr Avdesh Sharma	Faculty of Dentistry	0.85	12 months



<b>7</b>	A randomised controlled trial to assess the efficacy of holistic approaches (naturopathy and yoga) alone as well as in combination with pharmacological therapy in the treatment of chronic orofacial pain of non-odontogenic origin	Dr Swati Verma, Dr Priyanka Bhushan	Faculty of Dentistry	1.35	24 months
<b>8</b>	A prospective, cluster-randomized, examiner-masked, 3-arm trial to evaluate the efficacy of time outdoors per school day over 2 years on myopia onset and shift.	Dr Sarita Agrawal	Faculty of Medicine	0.30	3 months


Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion as well as the outcome/impact of the project.

Thank you and regards.

*Viplav Bhatt*  
**Viplav Bhatt**  
**(Authorized Signatory)**

CC to:

1. Dr Suveer Sharma
2. Dr Mahima Lakhanpal
3. Dr Priya Singh
4. Dr Shobroze Tantray
5. Dr. Yogesh Yadav
6. Dr Avdesh Sharma
7. Dr Swati Verma, Dr Priyanka Bhushan
8. Dr Sarita Agrawal





Clinical Trial Details (PDF Generation Date :- Tue, 28 Mar 2023 10:26:03 GMT)

<b>CTRI Number</b>	CTRI/2021/05/033791 [Registered on: 25/05/2021] - <b>Trial Registered Prospectively</b>		
<b>Last Modified On</b>	26/04/2022		
<b>Post Graduate Thesis</b>	No		
<b>Type of Trial</b>	Interventional		
<b>Type of Study</b>	Drug		
<b>Study Design</b>	Randomized, Parallel Group, Active Controlled Trial		
<b>Public Title of Study</b>	A Clinical Trial Evaluating Niclosamide for the Treatment of Covid-19 Disease.		
<b>Scientific Title of Study</b>	A Multicentric Phase II Randomized Open Label Clinical Study to Evaluate Efficacy Safety and Tolerability of Niclosamide for the Treatment of Hospitalized Corona Virus Disease (COVID-19) Patients		
<b>Secondary IDs if Any</b>	<b>Secondary ID</b>	<b>Identifier</b>	
	ICS/LAX/2020-006 Version 3.0 Dated 28 Mar 2021	Protocol Number	
<b>Details of Principal Investigator or overall Trial Coordinator (multi-center study)</b>	<b>Details of Principal Investigator</b>		
	<b>Name</b>	Dr R M Chhabra	
	<b>Designation</b>	Medical Monitor/Trial Coordinator	
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.	
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West Delhi, India Not Applicable North West DELHI 110034 India	
	<b>Phone</b>	011-49049115	
	<b>Fax</b>	011-49049115	
	<b>Email</b>	Chhabradrrm@gmail.com	
	<b>Details Contact Person (Scientific Query)</b>	<b>Details Contact Person (Scientific Query)</b>	
		<b>Name</b>	Dr R M Chhabra
<b>Designation</b>		Medical Monitor/Trial Coordinator	
<b>Affiliation</b>		Insignia Clinical Services Pvt. Ltd.	
<b>Address</b>		Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West Delhi, India Not Applicable North West DELHI 110034 India	
<b>Phone</b>		011-49049115	
<b>Fax</b>		011-49049115	
<b>Email</b>		Chhabradrrm@gmail.com	
<b>Details Contact Person (Public Query)</b>	<b>Details Contact Person (Public Query)</b>		
	<b>Name</b>	Dr R M Chhabra	
	<b>Designation</b>	Medical Monitor/Trial Coordinator	
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.	
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West Delhi, India Not Applicable North West	





	DELHI 110034 India
<b>Phone</b>	011-49049115
<b>Fax</b>	011-49049115
<b>Email</b>	Chhabradrrm@gmail.com

**Source of Monetary or Material Support**

Source of Monetary or Material Support	
> Laxai Life Sciences Pvt. Ltd. Third Floor, Ventureast Plaza, Plot # 40 & 41, Road No. 02, Financial District, Nanakramguda, Ranga Reddy District, Telangana 500032 India	

**Primary Sponsor**

Primary Sponsor Details	
<b>Name</b>	Laxai Life Sciences Pvt Ltd
<b>Address</b>	Third Floor, Ventureast Plaza, Plot # 40 & 41, Road No. 02, Financial District, Nanakramguda, Ranga Reddy District, Telangana 500032 India
<b>Type of Sponsor</b>	Pharmaceutical industry-Indian

**Details of Secondary Sponsor**

Name	Address
Council Of Scientific And Industrial Research Indian Institute Of Chemical Technology CSIRIICT	Uppal Road, IICT Colony, Tamaka, Hyderabad, Telangana 500007

**Countries of Recruitment**

List of Countries
India

**Sites of Study**

Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
Dr A Thumjaa	Aarupadai Veedu Medical College and Hospital	Ground Floor, Department of Paediatrics, Aarupadai Veedu Medical College and Hospital, Kirumampakkam, Puducherry- 607403 Pondicherry PONDICHERRY	914132615246 thumjaa@gmail.com
Dr B L Shashi Bhushan	Bangalore Medical College and Research Institute	Room No 50 B Block Department of Pulmonary Medicine Victoria Hospital Fort KR Road Bangalore KARNATAKA	080-26701150 ShashiBhushanBL@Yahoo.com
Dr Aneesh Raj	Noorul Islam Institute of Medical Science (NIMS) and Research Foundation	Covid Care Center, Aush Block , NIMS Medicity, Aralummoodu P.O. Neyyattinkara, Trivandrum, Kerala-695123 Thiruvananthapuram KERALA	04712222115 draneeshraj@gmail.com
Dr Pravin Soni	PCMCs PGI Yashwant Rao Chavan Memorial Hospital	Covid Blocks 64A Ground Floor and 111 First Floor PCMCs PGI Yashwant Rao Chavan Memorial Hospital Sant Tukaram Nagar, Pimpri, Pune 411018 Pune	020-67332200 020-67332200 DrPravinSoni18@Gmail.com



		MAHARASHTRA	
Dr Vijaykumar Barge	RCSM Government Medical College and CPR Hospital	Room 01, Department of Medicine, Dasara Chowk, Bhausingji Road, Town Hall, Kolhapur 416012 Kolhapur MAHARASHTRA	0231-2644233 0231-2644233 DrVijayBarge12@Gmail.com
Dr Ashok Kumar	Santosh Medical College Hospital	First Floor, Department of General Medicine, Santosh Medical College Hospital #1, Ambedkar Road Ghaziabad, UTTAR PRADESH Ghaziabad UTTAR PRADESH	0120-2741141 0120-2741141 SMCHGZB@Gmail.com
Dr Vishal Gupta	SMS Medical College & Attached Hospital	Room # 04, PRT Wing, Dhanwantri Block, SMS Medical College & Attached Hospital Jaipur RAJASTHAN	020-67332222 DrVishalGuptaMD@Rediffmail.com
Dr Changalva Premdeep	Vijaya Super Speciality Hospital	Ground Floor, Room No. 7 Department of Pulmonology, Vijaya Super Speciality Hospital, 16-II/41 A Raghava Cine Complex Road, Pogathota, Nellore, Andhra Pradesh-524001, India Nellore ANDHRA PRADESH	08612321828 dr.premdeep88@gmail.com

**Details of Ethics Committee**

Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
Ethics Committee of Bangalore Medical College & Research Institute	Approved	18/06/2021	No
Ethics Committee SMS Medical College Jaipur	Approved	14/07/2021	No
Institutional Ethics Committee, Yashwantrao Chavan Memorial Hospital, Pimpri, Pune, Maharashtra	Approved	14/07/2021	No
Institutional Human Ethical Committee Aarupadai Veedu Medical College and Hospital	Approved	11/11/2021	No
NIMS IEC	Approved	12/10/2021	No
Rajarshee Chhatrapati Shahu Maharaj Govt Medical College and	Approved	14/07/2021	No



Chhatarpati Pramila Raje Hospital, Kolhapur Institutional Ethics Committee 2			
Society for Academic, Scientific & Translational Research Advancement	Approved	20/05/2021	Yes
Society for Academic, Scientific & Translational Research Advancement	Approved	20/05/2021	Yes
Vijaya Ethics Committee	Approved	17/01/2022	No

**Regulatory Clearance Status from DCGI**

Status	Date
Approved/Obtained	20/04/2021

**Health Condition / Problems Studied**

Health Type	Condition
Patients	Coronavirus as the cause of diseases classified elsewhere
Patients	Other specified respiratory disorders

**Intervention / Comparator Agent**

Type	Name	Details
Intervention	Niclosamide 2000 mg orally Plus Standard of Care	Niclosamide 2000 mg orally Plus Standard of Care Treatment Duration for 07 Days
Comparator Agent	Standard Of Care	Standard Of Care

**Inclusion Criteria**

Inclusion Criteria	
Age From	18.00 Year(s)
Age To	65.00 Year(s)
Gender	Both
Details	Male & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized, or practicing a reliable   method of birth control during the duration of the study) patients with ages ranging from 18 to 65 years (both inclusive).    Clinically stable condition for at least 6 months before enrollment.    Confirmed diagnosis of moderate COVID-19 symptoms demonstrated by:    Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens.    Presence of dyspnea and/or hypoxia, fever, cough, including SpO2 < 93% (range 90-93%) on room air, Respiratory Rate > 24 and < 30 breaths per minute. Patients with SpO2 < 90% to be excluded from the study.    Signs of pneumonia (lung injury/lung involvement) confirmed by Chest X-Ray at the time of study entry.    Disease severity score between Grade 4 to 5 on the WHO 9-point ordinal scale & patient requires   hospitalization for management of the disease.     Within 7 days from symptom onset or within 72 hours of laboratory diagnosis of SARS-CoV2 via RT-PCR test.    Able to take oral tablets at the time of study entry and agree not to participate in any other study for   duration of participation in this study.     Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent then the same should be obtained from a legally acceptable representative (LAR). 

**Exclusion Criteria**

Exclusion Criteria	
Details	Subjects will be excluded from the study for any of the following



reasons:

Subjects with known allergy or hypersensitivity to Niclosamide or any of its components.

Patients who have previously had a disease severity score of 6 or 7 on the WHO 9-point ordinal scale.

Evidence of severe or critical illness, defined by at least 1 of the following:

Respiratory failure requiring at least 1 of the following:

Endotracheal intubation and mechanical ventilation, oxygen delivered by high flow nasal cannula

Extracorporeal membrane oxygenation (ECMO) or clinical diagnosis of respiratory failure

Shock (defined by systolic blood pressure (BP) 5times ULN].

Subjects with oxygen saturation (SpO<sub>2</sub>) >90%.

Respiration Rate >30 breaths per minute at the time of enrolment.

History of refractory nausea, vomiting, or chronic gastrointestinal disorders, inability to swallow the study drug, or having undergone extensive bowel resection which may affect adequate absorption of study medications.

Inability to swallow tablets (administration via nasogastric tube is permitted in patients who become unable to swallow after starting the study drug).

Patients who require IL-6 inhibitors for management of inflammation at the time of study entry.

Female subjects who are pregnant or involved in breastfeeding.

Subject was using adrenocorticosteroids (except topical or inhaled preparations) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists, or interleukin receptor blockers) within one week prior to study entry.

Subject has a serious chronic disease (e.g., human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus, cancer requiring chemotherapy within the preceding 6 months, unstable cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days.

Has a history of alcohol or drug abuse in the previous 6 months.

Subject has a psychiatric disease that is not well controlled where controlled is defined as stable on a regimen for more than one year.

Subject already treated with another COVID 19 therapy but has relapsed with a positive diagnosis.

Hospital discharge is anticipated in >24 hours.



	Anticipated transfer to another hospital which is not a study site within 72 hours.  Participated in any other clinical trial or taken an investigational drug within 1 month.								
<b>Method of Generating Random Sequence</b>	Computer generated randomization								
<b>Method of Concealment</b>	Pre-numbered or coded identical Containers								
<b>Blinding/Masking</b>	Open Label								
<b>Primary Outcome</b>	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>Time to Clinical Improvement of 2-points on WHO 8-Point Ordinal Scale</td> <td>Baseline, Day 03, Day 05, Day 07, Day 14, Day 21</td> </tr> </tbody> </table>	Outcome	Timepoints	Time to Clinical Improvement of 2-points on WHO 8-Point Ordinal Scale	Baseline, Day 03, Day 05, Day 07, Day 14, Day 21				
Outcome	Timepoints								
Time to Clinical Improvement of 2-points on WHO 8-Point Ordinal Scale	Baseline, Day 03, Day 05, Day 07, Day 14, Day 21								
<b>Secondary Outcome</b>	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>Secondary outcome measures for this study will include: Time to respiratory viral clearance</td> <td>Time frame : 3, 7, 10, 14 days</td> </tr> <tr> <td>Improvement in lung injury on Chest X-Ray</td> <td>Time frame: Baseline, 14, 21 days</td> </tr> <tr> <td>Other outcome measures for this study will include: All-cause mortality</td> <td>Time frame: 21 days</td> </tr> </tbody> </table>	Outcome	Timepoints	Secondary outcome measures for this study will include: Time to respiratory viral clearance	Time frame : 3, 7, 10, 14 days	Improvement in lung injury on Chest X-Ray	Time frame: Baseline, 14, 21 days	Other outcome measures for this study will include: All-cause mortality	Time frame: 21 days
Outcome	Timepoints								
Secondary outcome measures for this study will include: Time to respiratory viral clearance	Time frame : 3, 7, 10, 14 days								
Improvement in lung injury on Chest X-Ray	Time frame: Baseline, 14, 21 days								
Other outcome measures for this study will include: All-cause mortality	Time frame: 21 days								
<b>Target Sample Size</b>	<b>Total Sample Size=96</b> <b>Sample Size from India=96</b> <b>Final Enrollment numbers achieved (Total)=Applicable only for Completed/Terminated trials</b> <b>Final Enrollment numbers achieved (India)=Applicable only for Completed/Terminated trials</b>								
<b>Phase of Trial</b>	Phase 2								
<b>Date of First Enrollment (India)</b>	01/06/2021								
<b>Date of First Enrollment (Global)</b>	No Date Specified								
<b>Estimated Duration of Trial</b>	<b>Years=0</b> <b>Months=6</b> <b>Days=0</b>								
<b>Recruitment Status of Trial (Global)</b>	Not Applicable								
<b>Recruitment Status of Trial (India)</b>	Closed to Recruitment of Participants								
<b>Publication Details</b>	NIL								
<b>Brief Summary</b>	<p>This is a Phase II, Randomized, Multi-centric, Open Label clinical study to evaluate the efficacy, safety &amp; tolerability of Niclosamide when used alongside Standard of Care (SOC) for the treatment of hospitalized patients with coronavirus disease (COVID-19).</p> <p>The proposed study is a two phase clinical study wherein first phase, i.e, Treatment Phase will began when either a male or female (non-pregnant, non-lactating) patients between 18 to 65 years (both inclusive) with clinically confirmed &amp; documented diagnosis of moderate coronavirus disease (COVID-19) with severity rating of Grade 4 or Grade 5 at the time of study entry as per WHO ordinal score and who require hospitalization for management of the disease will be screened and enrolled for participation in the study as per study protocol.</p>								





The treatment period with investigational product in test group will be 7 days. It is however necessary that all patients in either test or control groups be allowed to take concomitant SOC as per the prescribed schedule for entire duration of the study, as applicable. Follow-up Phase shall begin from EOT (Day 8) and will continue for another 2 weeks for each patient. During Follow-up Phase, all patients in both test and/or control groups will take SOC as advised per individual treatment plan and will be asked to monitor signs & symptoms of disease, status of clinical recovery and adverse events, if any.



**INSIGNIA CLINICAL SERVICES PVT LTD (from 1-Apr-22)**

**Santosh Hospital Ghazibad**

Ledger Account

1-Apr-22 to 4-Mar-24

Page 1

Date	Particulars	Vch Type	Vch No.	Debit	Credit
1-Apr-22	Dr <b>Opening Balance</b>				<b>8,39,347.00</b>
2-May-22	Cr STATE BANK OF INDIA 30 PERCENT PAYMENT NICLOSAMIDE	Payment	138	<b>66,217.00</b>	
6-Jun-22	Cr STATE BANK OF INDIA 30% payment colcochine	Payment	259	1,10,472.00	
3-Feb-23	Dr (as per details) Ec Fees ( Hypertension) 8,05,330.00 Dr TDS PAYABLE U/S 94J 80,533.00 Cr 01001 TO 01082	Journal	432		7,24,797.00
19-Mar-23	Cr STATE BANK OF INDIA	Payment	1408	2,50,000.00	
	Cr STATE BANK OF INDIA	Payment	1409	2,50,000.00	
				6,76,689.00	15,64,144.00
	Cr <b>Closing Balance</b>			8,87,455.00	
				<b>15,64,144.00</b>	<b>15,64,144.00</b>



Clinical Trial Details (PDF Generation Date :- Tue, 28 Mar 2023 10:25:32 GMT)

<b>CTRI Number</b>	CTRI/2021/04/032555 [Registered on: 06/04/2021] - <b>Trial Registered Prospectively</b>	
<b>Last Modified On</b>	26/10/2022	
<b>Post Graduate Thesis</b>	No	
<b>Type of Trial</b>	Interventional	
<b>Type of Study</b>	Drug	
<b>Study Design</b>	Randomized, Parallel Group Trial	
<b>Public Title of Study</b>	A Clinical Trial to Assess the Efficacy, Safety and tolerability of Colchicine for Covid-19 Disease Treatment in Indian Patients.	
<b>Scientific Title of Study</b>	A prospective, pilot, clinical trial to evaluate the efficacy and safety of Colchicine for improvement of clinical outcomes during Coronavirus (COVID-19) disease treatment in high-risk Indian patients.	
<b>Secondary IDs if Any</b>	<b>Secondary ID</b>	<b>Identifier</b>
	ICS/LAX/2021-001 Version 1.0 Dated 18 Jan 2021	Protocol Number
<b>Details of Principal Investigator or overall Trial Coordinator (multi-center study)</b>	<b>Details of Principal Investigator</b>	
	<b>Name</b>	Dr R M Chhabra
	<b>Designation</b>	Medical Monitor/Trial Coordinator
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512,Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India North West DELHI 110034 India
	<b>Phone</b>	011-49049115
	<b>Fax</b>	011-49049115
	<b>Email</b>	Chhabradrrm@gmail.com
<b>Details Contact Person (Scientific Query)</b>	<b>Details Contact Person (Scientific Query)</b>	
	<b>Name</b>	Dr R M Chhabra
	<b>Designation</b>	Medical Monitor/Trial Coordinator
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512,Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India North West DELHI 110034 India
	<b>Phone</b>	011-49049115
	<b>Fax</b>	011-49049115
	<b>Email</b>	Chhabradrrm@gmail.com
<b>Details Contact Person (Public Query)</b>	<b>Details Contact Person (Public Query)</b>	
	<b>Name</b>	Dr R M Chhabra
	<b>Designation</b>	Medical Monitor/Trial Coordinator
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512,Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India North West



	DELHI 110034 India
<b>Phone</b>	011-49049115
<b>Fax</b>	011-49049115
<b>Email</b>	Chhabradrrm@gmail.com

**Source of Monetary or Material Support**

Source of Monetary or Material Support	
> Laxai Life Sciences Pvt Ltd Third Floor, Ventureast Plaza, Plot # 40 & 41, Road No. 2, Financial District, Nanakramguda, Ranga Reddy District, Telangana 500032 India	

**Primary Sponsor**

Primary Sponsor Details	
<b>Name</b>	Laxai Life Sciences Pvt Ltd
<b>Address</b>	Third Floor, Ventureast Plaza, Plot No. 40 and 41, Road No.2, Financial District, Nanakramguda, Ranga Reddy District, Telangana - 500032 India
<b>Type of Sponsor</b>	Pharmaceutical industry-Indian

**Details of Secondary Sponsor**

Name	Address
Council Of Scientific And Industrial Research Indian Institute Of Chemical Technology CSIRIICT	Uppal Rd, IICT Colony, Tarnaka, Hyderabad, Telangana 500007

**Countries of Recruitment**

List of Countries
India

**Sites of Study**

Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
Dr R N Sechassayana	Aarupadai Veedu Medical College and Hospital	Ground Floor, Department of Paediatrics, Aarupadai Veedu Medical College and Hospital, Kirumampakkam, Puducherry- 607403 Pondicherry PONDICHERRY	914132615246 narayanassamysheshasayan28@gmail.com
Dr B L Shashi Bhushan	Bangalore Medical College and Research Institute	Room No 50 B Block Department of Pulmonary Medicine Victoria Hospital Fort KR Road Bangalore KARNATAKA	080-26701150 ShashiBhushanBL@Yahoo.com
Dr Sushila Kataria	Medanta - The Medicity	Department of Internal Medicine Division Internal Medicine Room No 30 Sector - 38, Gurgaon, Haryana 122001 India Gurgaon HARYANA	0124-4141414 0124-4834111 Mukul.Manchanda@Medanta.org
Dr Aneesh Raj	Noorul Islam Institute of Medical Science (NIMS) and Research Foundation	Covid Care Center, Aush Block , NIMS Medicity, Aralummoodu P.O. Neyyattinkara, Trivandrum-695123 Thiruvananthapuram KERALA	04712222115 draneeshraj@gmail.com





Dr Pravin Nagulal Soni	PCMC PGI Yashwantrao Chavan Memorial Hospital	Room 01 Third Floor Department of Medicine PCMC PGI Yashwantrao Chavan Memorial Hospital Sant Tukaran Nagar Vallabhnagar Pimpri Pune Pune MAHARASHTRA	020-67332222  DrPravinSoni18@Gmail .com
Dr Vijaykumar Barge	RCSM Government Medical College and CPR Hospital	Room 01, Department of Medicine, Dasara Chowk, Bhausingji Road, Town Hall, Kolhapur 416012 Kolhapur MAHARASHTRA	0231-2644233 0231-2644233 DrVijayBarge12@Gmail .com
Dr Shivani Bansal	Santosh Medical College Hospital	Fifth Floor, Covid Ward, Santosh Medical College Hospital#1, Ambedkar Road Ghaziabad, UTTAR PRADESH Ghaziabad UTTAR PRADESH	0120-2741141 0120-2741141 smchgzb@gmail.com
Dr Vishal Gupta	SMS Medical College & Attached Hospital	Room # 04, PRT Wing, Dhanwantri Block, SMS Medical College & Attached Hospital Jaipur RAJASTHAN	0141-2518370  DrVishalGuptaMD@Re diffmail.com
Dr Changalva Premdeep	Vijaya Super Speciality Hospital	Ground Floor, Room No. 7 Department of Pulmonology, Vijaya Super Speciality Hospital, 16-II/41 A Raghava Cine Complex Road, Pogathota, Nellore, -524001 Nellore ANDHRA PRADESH	08612321828  dr.premdeep88@gmail. com

**Details of Ethics  
Committee**

Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
Ethics Committee for Human Research	Submitted/Under Review	No Date Specified	No
Ethics Committee of Bangalore Medical College & Research Institute	Approved	18/06/2021	No
Ethics Committee SMS Medical College Jaipur	Approved	14/07/2021	No
Institutional Ethical Committee Vinayaka Missions Medical College	Approved	11/11/2021	No
Institutional Ethics Committee Vinayaka Missions Kirupananda	Approved	11/11/2021	No



Variyar Medical College and Hospitals			
Institutional Ethics Committee, Govt. Medical College Govt. General Hospital	Approved	23/06/2021	No
Institutional Human Ethical Committee Aarupadai Veedu Medical College and Hospital	Approved	11/11/2021	No
Medanta Institutional Ethics Committee	Approved	15/06/2021	No
NIMS IEC	Approved	12/10/2021	No
PGMCs PGI YCMH Ethics Committee	Approved	04/05/2021	No
Rajarshee Chhatarpati Shahu Maharaj Govt Medical College and Chhatarpati Pramila Raje Hospital, Kolhapur Institutional Ethics Committee 2	Approved	14/07/2021	No
Society for Academic, Scientific & Translational Research Advancement	Approved	31/03/2021	Yes
Vijaya Ethics Committee	Approved	17/01/2022	No

**Regulatory Clearance Status from DCGI**

Status	Date
Approved/Obtained	05/02/2021

**Health Condition / Problems Studied**

Health Type	Condition
Patients	Coronavirus as the cause of diseases classified elsewhere
Patients	Other specified respiratory disorders

**Intervention / Comparator Agent**

Type	Name	Details
Intervention	Colchicine 0.5mg tablets plus Standard of Care	Colchicine 0.5mg tablets plus Standard of Care Dose 0.5 mg, Frequency BID, Route of Administration Oral, Duration of Therapy 28 Days
Comparator Agent	Standard of Care	Standard of Care

**Inclusion Criteria**

Inclusion Criteria	
Age From	40.00 Year(s)
Age To	65.00 Year(s)
Gender	Both
Details	Subjects meeting all the following criteria will be included in the study: 1. Male & Female patients with age ranging from 40 to 65 years (both inclusive) & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized or practicing a reliable method of birth control during the duration of study) 2. Clinically stable condition for at least 6 months before enrollment. 3. Confirmed diagnosis of at least moderate COVID-19 symptoms demonstrated by: a. Positivity in RT-PCR 2019-nCov test on



respiratory tract (nasopharyngeal / oropharyngeal) specimens.<br/>  
b.Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO2 < 94% (range 90-94%) on room air, Respiratory Rate > 24 and < 30 breaths per minute.<br/> <br/>  
4.Significant COVID-19 symptoms, and judged by the treating doctor to be at high risk of progression to severe category due to presence of any of the following:<br/> a.Having at least one of the high-risk criteria, i.e, obesity (BMI ? 30 kg/m2), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure > 90 mm Hg systolic blood pressure ?150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease;<br/> b.Demonstrating signs of cardiac injury due to Elevated troponin level, <br/> <br/> 5.Patients who require hospitalization for control of disease at the time of study entry. <br/> <br/> 6.Within 7 days from symptom onset or within 48 hours of laboratory diagnosis of SARS- CoV2.<br/> <br/> 7.Able to take oral tablets and agreeing not to participate in any other study for duration of participation in this study. <br/> <br/> 8.Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR).<br/>

**Exclusion Criteria**

Exclusion Criteria	
<b>Details</b>	<p>1.History of present illness (will be based on treating physician's opinion)</p> <p>a.Neurological and neurodevelopmental disorders. b.Congenital heart disease c.Severe heart disease or a history of clinically significant arrhythmias which may affect participants safety (According to the ECG or medical history). Corrected QT interval of 450 milliseconds or higher (according to the Bazett formula) on a 12 lead surface ECG / Abnormal ECG (to eliminate concerns that a potential interaction between colchicine and hydroxychloroquine could lead to excess QT prolongation)</p> <p>2.Requirement of oxygen supplementation greater than 8L nasal cannula at the time of enrollment.</p> <p>3.Treating physician clinical judgement that the patient will require mechanical respiratory support within 24 hours.</p> <p>4. Patient currently in Septic shock or with hemodynamic instability requiring vasopressors.</p> <p>5.History of cirrhosis.</p> <p>6.A subject undergoing hemodialysis.</p> <p>7.Severe gastrointestinal failure, severe gastrointestinal disorders, or stomach ulcer.</p> <p>8.Patient is currently taking colchicine for other indications (gout or Familial Mediterranean Fever).</p> <p>9.Patient with inflammatory bowel disease (Crohns disease or ulcerative colitis), chronic diarrhea or malabsorption</p> <p>10.Severe Hepatic Insufficiency (ALT or AST greater than 5 times ULN) or Renal Failure (eGFR using the MDRD equation for all</p>



	<p>subjects less than 30 mL per min).</p> <p>11. Patient received Remdesivir, Sarilumab, Tocilizumab, Lopinavir, Ritonavir or other immunomodulator given for COVID-19 treatment prior to study entry.</p> <p>12. Patient is on (and cannot discontinue) a strong CYP3A4 inhibitor (e.g. clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, atazanavir), a moderate CYP3A4 inhibitor (e.g. diltiazem, verapamil, fluconazole, amprenavir, aprepitant, fosamprenavir) or a Pgp Inhibitor (e.g. cyclosporine, ranolazine).</p> <p>13. Patients who may require IL 6 inhibitors as per clinical judgment of the investigator for management of inflammation at the time of study entry.</p> <p>14. Pregnant or lactating women women of a childbearing age with a positive pregnancy test</p>
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<b>Method of Generating Random Sequence</b>	Computer generated randomization	
<b>Method of Concealment</b>	Pre-numbered or coded identical Containers	
<b>Blinding/Masking</b>	Not Applicable	
<b>Primary Outcome</b>	<b>Outcome</b>	<b>Timepoints</b>
	Time to clinical improvement of 2-points on WHO 8-point ordinal scale	28 days (4 weeks)
<b>Secondary Outcome</b>	<b>Outcome</b>	<b>Timepoints</b>
	Improvement in cardiac & biochemical inflammatory markers	28 days
	Time to discharge from hospital	28 days
	Rate of viral clearance	28 days
	Patients requiring auxiliary oxygen therapy (non-invasive/invasive) & time on auxiliary oxygen therapy.	28 days
	All-cause mortality.	28 days
	Adverse events (Serious, Expected/Unexpected, Related/Non-Related).	28 days
<b>Target Sample Size</b>	<b>Total Sample Size=84</b> <b>Sample Size from India=84</b> <b>Final Enrollment numbers achieved (Total)=Applicable only for Completed/Terminated trials</b> <b>Final Enrollment numbers achieved (India)=Applicable only for Completed/Terminated trials</b>	
<b>Phase of Trial</b>	Phase 2	
<b>Date of First Enrollment (India)</b>	07/04/2021	
<b>Date of First Enrollment (Global)</b>	No Date Specified	
<b>Estimated Duration of Trial</b>	<b>Years=0</b> <b>Months=6</b> <b>Days=0</b>	



<b>Recruitment Status of Trial (Global)</b>	Not Applicable
<b>Recruitment Status of Trial (India)</b>	Closed to Recruitment of Participants
<b>Publication Details</b>	NIL
<b>Brief Summary</b>	<p>This is a Pilot Phase II, randomized, open label, prospective, comparative, two-arm, multi-center clinical study to evaluate the efficacy and safety of Colchicine for improvement of overall clinical outcomes when added to Standard of Care (SOC) treatment in high-risk Indian patients suffering with coronavirus (COVID-19) disease.</p> <p>The proposed study is a two phase clinical study wherein first phase is Treatment Phase of 28 days followed by Follow-up Phase of 14 days. High risk patients with clinically confirmed &amp; documented diagnosis of moderate coronavirus disease (COVID-19) as per MOH Criteria who require hospitalization for management of the disease, i.e.,</p> <ul style="list-style-type: none"> <li>• Confirmed diagnosis of COVID-19 demonstrated by positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens.</li> <li>• Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO<sub>2</sub> &lt; 94% (range 90-94%) on room air, Respiratory Rate &gt; 24 and &lt; 30 breaths per minute</li> <li>• Age above 40 to 65 years (both inclusive).</li> <li>• Having at least one of the high-risk criteria, i.e, obesity (BMI ≥ 30 kg/m<sup>2</sup>), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure &gt; 90 mm Hg &amp; systolic blood pressure ≥ 150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease.</li> </ul> <p>will be screened and enrolled for participation in the study as per study protocol.</p> <p>The treatment period with investigational product in test group will be 28 days from the day of first dose. It is however necessary that all patients in either test or control groups be allowed to take concomitant SOC as per the prescribed schedule for entire duration of the study, as applicable.</p>



**INSIGNIA CLINICAL SERVICES PVT LTD (from 1-Apr-22)**


**Sundry Creditors**

Group Summary

1-Apr-23 to 4-Mar-24

Page 1

	Closing Balance	
	Debit	Credit
SANTOSH HOSPITAL( ASHOK KUMAR)		71,617.00
SANTOSH HOSPITAL ( DR SHIVANI BANSAL )		44,100.00
Santosh Hospital Ghazibad		8,87,455.00
<b>Grand Total</b>		<b>10,03,172.00</b>




सत्यमेव जयते

# INDIA NON JUDICIAL

## Government of National Capital Territory of Delhi

### e-Stamp

Certificate No. : IN-DL71545171236776T  
 Certificate Issued Date : 09-Apr-2021 04:10 PM  
 Account Reference : IMPACC (IV)/ dl895203/ DELHI/ DL-DLH  
 Unique Doc. Reference : SUBIN-DL89520343822448897302T  
 Purchased by : INSIGNIA CLINICAL SERVICES PRIVATE LIMITED  
 Description of Document : Article 5 General Agreement  
 Property Description : TRI-PARTITE CLINICAL TRIAL AGREEMENT  
 Consideration Price (Rs.) : 0  
 (Zero)  
 First Party : INSIGNIA CLINICAL SERVICES PRIVATE LIMITED  
 Second Party : SANTOSH MEDICAL COLLEGE HOSPITAL GHAZIABAD AND DR SHIVANI BANSAL  
 Stamp Duty Paid By : INSIGNIA CLINICAL SERVICES PRIVATE LIMITED  
 Stamp Duty Amount(Rs.) : 500  
 (Five Hundred only)




.....Please write or type below this line.....



**Dr. Shivani Bansal**  
 M.D. (Medicine)  
 Professor  
 Santosh Medical College And Hospital  
 Ghaziabad (U.P.)  
 MCI-25922

1. The validity of this Stamp certificate should be verified at "www.shrestamp.com" or using a Stamp Jobs App of Stock Holding Corporation of India. The certificate and as available on the website / Mobile App (version 1.0.0) is available to the users of the certificate.



सत्यमेव जयते

# INDIA NON JUDICIAL

## Government of National Capital Territory of Delhi

### e-Stamp

Certificate No. : IN-DL71544920360827T

Certificate Issued Date : 09-Apr-2021 04:10 PM

Account Reference : IMPACC (IV)/ dl895203/ DELHI/ DL-DLH

Unique Doc. Reference : SUBIN-DL89520343824222656950T

Purchased by : INSIGNIA CLINICAL SERVICES PRIVATE LIMITED

Description of Document : Article 5 General Agreement

Property Description : TRI-PARTITE CLINICAL TRIAL AGREEMENT


Consideration Price (Rs.) : 0  
(Zero)

First Party : INSIGNIA CLINICAL SERVICES PRIVATE LIMITED

Second Party : SANTOSH MEDICAL COLLEGE HOSPITAL GHAZIABAD AND DR SHIVANI BANSAL

Stamp Duty Paid By : INSIGNIA CLINICAL SERVICES PRIVATE LIMITED

Stamp Duty Amount(Rs.) : 100  
(One Hundred only)



.....Please write or type below this line.....



**Dr. Shivani Bansal**  
M.D. (Medicine)  
Professor  
Santosh Medical College And Hospital  
Ghaziabad (U.P.)  
MCI-25922

**CLINICAL TRIAL AGREEMENT BY/AND BETWEEN**

**INSIGNIA CLINICAL SERVICES PRIVATE LTD., DELHI  
(CONTRACT RESEARCH ORGANIZATION)**



**AND**

**SANTOSH MEDICAL COLLEGE HOSPITAL,  
GHAZIABAD, (NCR DELHI)  
(TRIAL SITE)**

**AND**

**DR. SHIVANI BANSAL  
(PRINCIPAL INVESTIGATOR)**

**AS OF  
(19<sup>th</sup> May 2021)**

  <b>CRO DELHI</b>	  <b>TRIAL SITE (U.P.)</b>	 <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922 <b>PRINCIPAL INVESTIGATOR</b>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



## CLINICAL TRIAL AGREEMENT

This Clinical Trial Agreement (“**Agreement**”) is made as of this 19<sup>th</sup> day of **May, 2021** (the “**Effective Date**”) by and between:

1. **INSIGNIA CLINICAL SERVICES PRIVATE LTD. (ICS)**, a company incorporated under the laws of India as registered under the Indian Companies Act, 2013 having its business address at Unit No. 512, 5th Floor, Best Sky Tower, Netaji Subhash Place, Pitampura, New Delhi-110034 (hereinafter referred to as “**CRO**”) (which expression unless repugnant to the context includes its associates, administrators, successors in interest and permitted assigns) through **Mr. Amardeep Singh**, who has been authorized by M/s **Laxai Life Sciences Pvt. Ltd.** (hereinafter referred to as “**Sponsor**”) to execute this Agreement on behalf of CRO and Sponsor.

AND

2. **SANTOSH MEDICAL COLLEGE HOSPITAL** i.e. a world class, multispeciality, Teaching and Training Hospital at No.1, Ambedkar Road, Ghaziabad - 201 001 (U.P.) (herein after referred to as “**Trial Site**”) owned and managed by **Santosh Trust** (which expression unless repugnant to the context includes its associates, administrators, successors in interest and permitted assigns) through **Dr. Alpana Agrawal** who has been authorized to execute this Agreement on behalf of Trial Site.



AND

3. **Dr. Shivani Bansal** (hereinafter referred to as the “**Principal Investigator**” or “**PI**”), an independent consultant / employee of the Trial Site, who has been appointed as Principal Investigator for the purpose of conducting clinical trial at Trial Site.

(The “**CRO**”, “**Trial Site**” and “**Principal Investigator**” are hereinafter individually referred to as a “**Party**”, and collectively as “**Parties**”)

### WHEREAS:

- A. ICS is a Delhi-based Contract Research Organization (“**CRO**”) providing services primarily in India, directly or through its affiliates, associates, agents and subsidiaries. The major activities conducted by ICS include design, setup and management of clinical studies with human beings for the owners and / or manufacturers of pharmaceutical products, medical devices and food supplements / nutraceuticals.

 <b>INSIGNIA CLINICAL SERVICES PVT. LTD.</b> <b>DELHI</b> <b>CRO</b>	 <b>TRIAL SITE</b>	<b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor <b>Santosh Medical College And Hospital</b> Ghaziabad (U.P.) MCI-25922 <b>PRINCIPAL INVESTIGATOR</b>
------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------






- B. **Laxai Life Sciences Pvt. Ltd. (Sponsor)** is a pharmaceutical company engaged in the development of pharmaceutical product and desires to carry out a clinical trial involving study drug "**Colchicine Tablets 0.5 mg**", according the **Protocol Title:A prospective, pilot, clinical trial to evaluate the efficacy and safety of COLchicine for improvement of clinical outcomes during COronaVirus (COVID-19) disease treatment in high-risk INdian patients. [Acronym: COLCOVIN Study]** (herein after referred to as '**Study**') incorporated herein by reference as **Exhibit- A** and all subsequent amendments thereto;
- C. Sponsor has appointed CRO to manage the Study and assist Sponsor with site selection, management services for conduct of clinical trials at Trial Site and determine the safety and efficacy of Sponsor's product through submission of all information/documentation provided by Principal Investigator to the CRO under the Agreement;
- D. CRO and Trial Site are related through a **Memorandum of Understanding ("MoU")** dated 19<sup>th</sup> October 2020 for conduct of such Clinical Studies at the Trial Site. This Agreement will be an extension to the said MoU and will cover specific aspects related to terms and conditions of arrangements between CRO, Trial Site and Principal Investigator for the purposes of successful execution of the Study at the Trial Site.
- E. The **Principal Investigator** is a qualified medical practitioner and has been engaged by the Trial Site to participate in the study as an investigator and is responsible to conduct the study, the detailed statement issued by Trial Site attached hereto as Exhibit –C working with the **Trial Site** and has agreed to conduct the Study at the Trial Site only after the prior written approval of **Institutional Review Board/Independent Ethics Committee ("IRB/IEC")** at the Trial Site.
- F. The Trial Site is a medical facility qualified and equipped with adequate resources to undertake the study and the Trial Site and Principal Investigator have agreed to perform the study on the terms and conditions hereinafter set forth.

NOW, THEREFORE in consideration of the premises and the mutual promises and covenants express herein the Parties agree as flows:

**1. SCOPE OF THE AGREEMENT**

1.1 Trial Site and Principal Investigator will undertake an sponsored clinical trial ("**Study**") described in Exhibit-A, i.e. study of drug "**Colchicine Tablets 0.5 mg**", according the **Protocol Title:A prospective, pilot, clinical trial to evaluate the efficacy and safety of COLchicine for improvement of clinical outcomes during COronaVirus (COVID-19)**



 	 	 
CRO	TRIAL SITE	PRINCIPAL INVESTIGATOR

**disease treatment in high-risk INdian patients. [Acronym: COLCOVIN Study].** The Study will be conducted by the Trial Site under the direction of Principal Investigator.

- 1.2 In the event of any conflict between the terms and conditions of this Agreement and the Protocol or between this Agreement and any of its Exhibits, the terms and conditions of the Protocol shall control with respect to matters of the clinical conduct of the Study, and the terms of this Agreement shall control with respect to all other matters.
- 1.3 Unless otherwise agreed to by the Parties, Sponsor and/or CRO will provide to the Trial Site on a timely basis, without charge, the required quantities of properly-labelled Sponsor drug(s) or biologics(s) and other materials (e.g., Principal Investigator's brochure, handling and storage instructions, and, if applicable, placebo) necessary for Trial Site to conduct the Study in accordance with the protocol. Unless stated otherwise in writing by CRO, all such items are and will remain the sole property of CRO/Sponsor until administered or dispensed to Study subjects during the course of the Study. Receipt, storage, and handling of Study drug will be in compliance with all applicable laws and regulations, and CRO's or Sponsor's instructions.
- 1.4 CRO, Trial Site and Principal Investigator shall comply with and conduct all aspects of the Study in compliance with all applicable laws and regulations, including generally accepted standards of good clinical practice relating to exportation of technical data, computer software, laboratory prototypes, and other commodities as applicable. Trial Site and Principal Investigator will only allow individuals who are appropriately trained and qualified to assist in the conduct of the Study.
- 1.5 Trial Site shall obtain approval (if any) for this Study and proof thereof shall be provided to CRO. Trial Site shall obtain from each subject, prior to the subject's participation in the Study, a signed informed consent and necessary authorization to disclose health information to CRO and/or Sponsor in a form approved in writing by the CRO or a waiver of consent as directed by the CRO and further provided that the informed consent is consistent with Trial Site policies.

**2. PERFORMANCE OF THE STUDY:**

**2.1 Compliance with the Agreement:** The purpose of this Agreement is to conduct the Study at the Trial Site. The protocol has been sponsored by the Sponsor and is approved by / or is subject to the approval of the Drug Controller General of India ("DCGI") under the Drugs & Cosmetics Act, 1940 including any amendments thereof (hereinafter referred as "Drugs & Cosmetics Act, 1940") and / or any other law or rules for the time being in force in India as well as approved by the Ethics Committee ("EC"). In the event the protocol is amended,

<p>AS</p> 	 <p>Ghaziabad 201001 TRIAL SITE</p>	<p>Dr. Shivan Kansai M.D. (Medicine) Professor Sankar Medical College And Hospital Ghaziabad (U.P.) MCI-2500</p> <p>PRINCIPAL INVESTIGATOR</p>
-----------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------



such change shall be notified and if required under the law, prior approval of DCGI and/or EC shall be obtained. The Trial Site and the Principal Investigator agree to perform the Study in strict compliance with the protocol and terms and conditions of this Agreement including any amendments thereto. The Principal Investigator shall perform the Study at the study site of the institution. The Trial Site and Principal Investigator further represent, warrant and covenant that the Principal Investigator is and at all times, during the term of this Agreement, shall be (a) in good professional standing, (b) in possession of all requisite professional licenses, approval and permissions, (c) full qualified to conduct the study and to act as Principal Investigator under this Agreement, (d) fully experienced and knowledgeable with respect to all matters pertaining to the study and (e) responsible for supervision of all persons who may assist the Principal Investigator or otherwise be engaged in the Study. In the event that the Trial Site and/or the Principal Investigator use the services of sub-investigator, investigational staff, or other to conduct the Study pursuant to this Agreement, the Principal Investigator and Trial Site shall be responsible that all are appropriately licensed and credentialed and shall conduct the study in compliance with the terms and conditions of this Agreement. The Trial Site and PI shall be liable for any breach of such agreement by such individuals.

**2.2 Replacement of Principle Investigator:** In the event the Principal Investigator is unable to continue, either on account of his death or early termination of engagement from Trial Site or becoming incapacitated, in such circumstances, the Trial Site shall provide a written notice to CRO within three (3) calendar days of becoming aware of Principal Investigator's inability to continue. The Sponsor/ CRO shall then appoint the Co-Investigator as a party to this Agreement by way of amendment/novation to this Agreement. In case the Sponsor /CRO terminate this Agreement, the Trial Site shall take all necessary steps to accommodate the decision.

**2.3 Delegation of Duties:** The Principal Investigator will personally supervise the Study and may not delegate this duty to any other individual without Sponsor/ CRO's prior written approval. Principal Investigator may delegate other duties as necessary to their investigators and qualified personal in accordance with regulatory requirement and upon notice to sponsor/CRO. The Trial Site may not replace the Principal Investigator without Sponsor's/CRO's prior written approval. If the Principal Investigator is to be temporarily absent from the Trial Site, the Trial Site shall designate an investigator qualified and trained to assume such responsibilities to temporarily supervise/continue the Study on behalf of Principal Investigator. All such designation of responsibility will be reported to Sponsor/ CRO in writing and DCGI and/or EC prior to its commencement.

		
CRO, LHI	TRIAL SITE	PRINCIPAL INVESTIGATOR

**2.4 Investigator and Staff Training:** The Trial Site and Principal Investigator shall insure that other investigators and designated staff attend all Study related training conducted by Sponsor/CRO.




**2.5 Use of Study drug:** CRO shall provide the Study drug and all related document and any material wherever require for conduct of Study. Neither the Principal Investigator nor Trial Site shall make use of Study drug, Study related documents and materials, for purposes other than performance of the Study in accordance of the protocol and this Study. The Principal Investigator and Trial Site shall account for and return to CRO or otherwise dispose of in accordance with CRO's Instruction any unused Study drug, materials and equipments and confidential information provided for the purposes of the Study. In case of destruction of Study drug at Trial Site, the Trial Site shall promptly provide certificate of such destruction. This provision does not apply to the documents that should be maintained and retained in secure manner by the Principal Investigator at the Trial Site as per study protocol, the Agreement and/or applicable guidelines laws and regulations.

**2.6 Adverse Event Reporting:** Principal Investigator and Trial Site also agrees to report to Licensing Authority as defined in Clause 3(2) (i), (ii),(iv) of New Drugs and Clinical Trials Rules, 2019 including any amendments thereof, Ethics Committee and CRO immediately, but not later than 24 hours or within such mandatory timelines as amended from time to time and specifically mentioned hereabove, After learning of any adverse event and all other important medical events, including but not limited to adverse reactions, as identified in the protocol, affecting any Study subject. Principal Investigator and Trial Site further agree to follow up such report with detailed written reports in compliance with all applicable legal and regulatory requirements.

**2.7 Additional Research:** Trial Site and Principal Investigator shall not conduct any additional research nor facilitate any third party to conduct any such research on study subject during the study or biological samples collected from Study subjects during the Study, data derived from the Study without prior written concern of Sponsor and CRO.

**3. TRIAL DRUG; MATERIALS TRANSFER; RECORDS RETENTION; INSPECTION:**

**3.1** Trial Site and Principal Investigator acknowledge that the trial drug/device is owned or controlled by Sponsor/CRO and that neither the terms of this Agreement nor the protocol, nor any activities conducted by Trial Site or Principal Investigator for the trial/Study, shall be construed to grant to either Trial Site or Principal Investigator any rights in or to the compound.




		
-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------



- 3.2 Except as otherwise agreed by the Parties, CRO will provide the compound and any control/placebo material to be administered to trial subjects as part of the trial (collectively, the "Trial Drug") free of charge to Trial Site for administering or dispensing solely by or under the supervision of Principal Investigator or sub-investigator to trial subjects at the Trial Site in strict compliance with the protocol.
- 3.3 Trial Site and Principal Investigator shall use the Trial Drug solely to conduct the Trial in strict compliance with the protocol and for no other purpose, and shall not transfer the Trial Drug to any third parties. Trial Site and Principal Investigator shall handle, store, ship and dispose of the Trial Drug as directed by Sponsor/CRO or its designee and in compliance with all applicable laws, rules and regulations.
- 3.4 Trial Site and Principal Investigator will ensure that empty and partially used Trial Drug container and any Trial Drug remaining at the trial close-out visit at the Trial Site or upon early termination of this Agreement are disposed of or returned to CRO in accordance with the protocol.
- 3.5 Neither support of the trial, nor Trials Site's participation in the trial, impose any obligation, express or implied, on Trial Site or Principal Investigator to purchase, prescribe, provide favorable formulary status for or otherwise support Sponsor's/ CRO's products.
- 3.6 Unless required by the Protocol, Trial Site will not modify the Trial Drug or its container. If the Trial Site policy requires any modification to the Trial Drug container, such modification must be approved in advance in writing by Sponsor/CRO.

4. **RECORDS MAINTENANCE AND RETENTION:**

- 4.1 The Trial Site and Principal Investigator shall prepare and maintain records, reports and Data provided in the Protocol, Ethics Committee (EC) requirements, and in accordance with all applicable laws and regulations. Trial Site or Principal Investigator shall cooperate with the Sponsor/CRO in making records, reports and Data developed under this Agreement.
- 4.2 Trial Site or Principal Investigator shall ensure the storage of data related to Study in accordance with the requirements of current Good Clinical Practices, in suitable and secured storage facilities and under appropriate conditions, for a period of time required under the Agreement, applicable laws and regulations in India or until 5 years after completion of all regulatory activity, whichever period is longer, unless to the extent that Sponsor/CRO requires the return or destruction of this data, in which case this request shall be complied with to the extent allowed by applicable laws and regulations. Before the destruction or deletion of such data, Sponsor/CRO's written approval shall be obtained.

		
-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------



**5. PAYMENTS:**

**5.1 Budget and Compensation:** The compensation and fees to be paid by the Sponsor/CRO for this Study is contained in the budget described in **Exhibit- B** attached hereto and incorporated by reference in this Agreement. Payment shall be due and payable in accordance with the schedule set forth in **Exhibit- B**.

**5.2 Fair Market Value:** The Party's acknowledge that the compensation and support provided by the Sponsor/CRO to the Trial Site, subject to provision of this Agreement represents the fair market value for the research service conducted by Trial Site and the Principal Investigator has been negotiated in an arm's length transaction, and has been determined in a manner that takes into account the volume or value of any reference or other business otherwise generated between the Sponsor/CRO and the situation are the principal investigator. The Parties acknowledge that the budget amounts represent an equitable exchange for the conduct of the Study in light of the professional time and expenses required for the performance of the Study.



**5.3 Third Party Pay or Billing:** Neither the Trial Site nor the Principal Investigator shall bill any third party for the Study of the Trial Drug or any other item or services furnished by the Sponsor/CRO in connection with the Study, or any services provided to subjects in connection with the Study for which payment is made as part of the Study except as may be specifically authorised by compensation standard set forth in **Exhibit- B**.

**5.4** No part of any consideration paid hereunder are a prohibited payment for the recommending or arranging of the referral of business or the ordering of item of services; nor are the payments intended to include illegal referrals of business Nothing contained in this Agreement shall be construed connected in any manner as an obligation or inducement for the Trial Site or Principal Investigator to recommend that any person or entity purchase Sponsor's/CRO's product or those of any entity affiliated with the Sponsor/CRO.

**6. TERM & TERMINATION:**

**6.1** This term of this Agreement shall commence upon the Effective Date and terminate upon the completion of the Parties' Study-related activities under the Agreement, unless terminated early as further described in this section.

**6.2** This Agreement will become effective after it is fully executed and signed by all the Parties hereto and shall continue in effect for the full duration of the Study according to the protocol unless extended or sooner terminated in accordance with the provisions of this Agreement.

 <p>INSPIRA CLINICAL SERVICES PVT. LTD. DELHI CRO</p>	 <p>Ghazipur Medical College Ghazipur 201001 TRIAL SITE</p>	<p><i>Munari Bar</i> <b>Dr. Shivani Hansal</b> Professor Ia.D. (Medicine) Santosh Hospital College And Hospital Ghaziabad (U.P.) MCI-2552 PRINCIPAL INVESTIGATOR</p>
--------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



6.3 Unless earlier terminated in accordance with the provisions of this Agreement, the term of this Agreement shall commence on the Effective Date and shall terminate 6 months after completion of Study at Trial Site (hereinafter known as "Expiration Date"). The term of this Agreement shall commence upon the Effective Date and terminate upon the completion of the Parties' Study-related activities under the Agreement, unless terminated early as further described in this section.

6.4 CRO has the right to terminate this Agreement upon thirty (30) days prior written notice to the Trial Site. This Agreement may be terminated immediately at any time for any reason by the Trial Site or CRO when, in their judgment or that of the Principal Investigator, the Ethics Committee, if applicable, or the Drug Controller General of India, it is determined to be inappropriate, impractical, or inadvisable to continue, in order to protect the Study subjects' rights, welfare, and safety, or the committee otherwise disapproves the Study. If for any reason Principal Investigator becomes unavailable to direct the performance of the work under this Agreement, Trial Site shall promptly notify CRO. If the Parties are unable to identify a mutually acceptable successor, this Agreement may be terminated by either Party upon thirty (30) days written notice. Notwithstanding the above a Party may, in addition to any other available remedies:

- a) immediately terminate this Agreement upon the other Party's material failure to adhere to the protocol, except for deviation required to protect the rights, safety, and welfare of Study subjects; and/or
- b) terminate this Agreement upon the other Party's material default or breach of this Agreement, provided that the defaulting/breaching Party fails to remedy such material default, breach, or failure to adhere to the Protocol within thirty (30) business days after written notice thereof.

6.5 In addition to the above, this Agreement may be terminated by Trial Site in the event of a material default or breach of this Agreement by CRO/Sponsor, or by CRO in the event of a material breach of this Agreement by Trial Site, provided that the defaulting/breaching party fails to remedy such material default or breach within thirty (30) business days after written notice thereof. In the event that this Agreement is terminated prior to completion of the Study, for any reason, Trial Site shall:

- a) Notify the appropriate authority that the Study has been terminated;
- b) cease enrolling subject sin the Study;
- c) cease treating Study subjects under the protocol as directed by CRO to the extent

		<p><i>Munawar Bar</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25927</p>
-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------



medically permissible and appropriate;

- d) Terminate, as soon as practicable, all other Study activities; and
- e) Furnish to CRO any required final report for the Study in the form reasonably acceptable to CRO.

6.6 Promptly following any such termination, Trial Site will provide to CRO copies of data collected pursuant to the Study protocol. Upon Sponsor's or CRO's written request, Trial Site shall provide to the requesting Party, at Sponsor's or CRO's expense, all Sponsor's Confidential Information provided under this Agreement provided, however, that Trial Site may retain such copy of Confidential Information for record keeping purposes, monitoring its obligations, and exercising its rights here under, subject to Trial Site's ongoing compliance with the confidentiality and non-use obligations set forth in this Agreement.

6.7 If this Study is terminated early by either Party, the Trial Site shall be reimbursed for all work completed, on a prorate basis, and reasonable costs of bringing the Study to termination incurred through the date of termination, and for non-cancellable commitments properly incurred through that date. Upon receipt of notice of termination, Trial Site will use reasonable efforts to reduce or eliminate further costs and expenses and will cooperate with CRO to provide for an orderly wind-down of the Study. In the event the prepaid any portion of payment for work pursuant to this agreement that is not actually performed as a result of termination of this agreement, the Trial Site and PI shall return such payment for such unperformed services or unexpended or cancelled fees. In the event Trial Site fails to repay such funds in a timely manner, Sponsor/CRO may deduct an equivalent amount from any payment then or later due from Sponsor/CRO to Trial Site under this or any other arrangement between the parties subject to prior intimation and detailed explanation by the Sponsor/CRO.

**7. OWNERSHIP:**

7.1 All reports, data, technical information, (including without limitation, written, printed, graphic video and audio material, any computed data base and computer data readable data form), original works of authorship and all other information generated by the Trial Site, the Principal Investigator, any other designated personnel in the course of conducting the study shall be the sole and exclusive property of Sponsor or its designee i.e. CRO, which may utilise the Data in any way it deems appropriate, subject to and in accordance with applicable laws and regulations of India and the terms of this agreement.

 INSIGNIA CLINICAL SERVICES CRO	 Established 2010 TRIAL SITE Santosh Medical College	 Dr. Shivam Bansal M.D. (Medicine) Professor Santosh Medical College And Hospital Ghazipur (U.P.) MCI-255 PRINCIPAL INVESTIGATOR
--------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

7.2 For the purpose of this Agreement data shall mean all data and information generated / collected by Trial Site and Principal Investigator as a result of conducting the Study in accordance with the approved protocol which may include but not limited to collection of original Study subject or patient medical records, research notebooks, source documents, or other routine internal documents. Any other data / information collected as part of routine internal documents by the Trial Site in its ordinary course of business operations shall remain the sole and exclusive property of the Trial Site. Sponsor owns and has all rights to use only the Study related Data / Information in accordance with the signed informed consent and authorization form, applicable laws, and the terms of this Agreement.

**8. CONFIDENTIALITY:**







8.1 All the Parties agree to treat any confidential information obtained from the other Party, or generated by the Party or its representatives as a sole and direct result of performing the services under this Agreement including, without limitation, confidential commercial, business, scientific, medical and technical information, the study drug, Protocol, Investigator Brochure, Case Report Forms, safety information, and any other data or information generated or resulting from the study recorded and available in any form or on any media (paper, disc, photos, computer systems) (hereinafter “the Confidential Information”)

8.2 All the Parties agree not to divulge the Confidential Information to any third party or Parties, unless necessary as it relates to the performance of duties outlined in the scope of services or use said Confidential Information for any purposes other than understanding and evaluating the performance of those services. Parties further agrees to limit disclosure only to those of its officers, employees, agents, affiliates and consultants as are necessary to carry out the services in this Agreement. Parties shall take all reasonable steps to prevent the disclosure of the Confidential Information as provided herein.

8.3 Parties will ensure that it will incorporate similar confidentiality language (no less restrictive than this Agreement) in its written contracts with all representatives, agents, affiliates and consultants to protect Confidential Information. Any Confidential Information or intellectual property produced for performing services under this Agreement can only be used by the Sponsor/CRO for the specific Study.

8.4 The above provisions of confidentiality shall not apply to that part of the information which any Party is able to demonstrate by documentary evidence:

- a. was fully in their possession prior to receipt from the other Party; or
- b. was in the public domain at the time of receipt; or
- c. becomes part of the public domain through no fault of the Party; or

 	 	 
	<b>TRIAL SITE</b>	<b>PRINCIPAL INVESTIGATOR</b>



- d. is lawfully received by it from a third party having a right of further disclosure; or
- e. is developed by it independent of the Information; or
- f. is required by law or upon a court injunction to be disclosed.

8.5 Trial Site and Principal Investigator may disclose the existence of this Agreement and any additional information necessary to ensure compliance with applicable, regulations, and laws in accordance with Clause 9 of this Agreement. Further data and results generated in the course of conducting the Study are Confidential Information are not allowed for publishing without prior written approval from Sponsor / CRO.

8.6 Parties agree that upon termination or expiration of this Agreement, at the other party's request, it shall return to the other party all Confidential Information, retaining copies of any such Confidential Information as is reasonably necessary for regulatory and insurance purposes or as it deems necessary to demonstrate the satisfaction of its obligations hereunder, all subject to the on-going obligation to maintain the confidentiality of such Confidential Information.

**9. DISCLOSURES:**




9.1 The confidentiality obligation shall not, however, be applied to Confidential Information, which:

- a. Was, as evidenced, in the possession of the receiving Party prior to receipt of the confidential information from the other Party,
- b. The Party has received from a third party without any obligation of confidentiality and which has a right to deliver such information to the other Party, or
- c. On ground of law has to be delivered.

Any party invoking an exception set forth above has the burden of proof with respect to the existence of such an exception.

9.2 Each Party shall promptly return to the other Party all Confidential Information no longer needed for the purposes of this Agreement or if so requested by the other Party.

9.3 Should any third party, e.g. Regulatory Authority demand access to Confidential Information on grounds of law, the party shall without any delay and prior to making such a disclosure notify the other party of such a demand in writing and take prior written consent before making such disclosure. The party may then deliver only the specified Confidential Information, which the request concerns.

 		
CRO	TRIAL SITE	PRINCIPAL INVESTIGATOR



**10. PUBLICATION:**

- 10.1 The Parties also understand and recognize that this Study is part of a multi-site study and that data from all sites will be pooled and analyzed, and agree that premature disclosures of data from a single site may be misleading. Sponsor /CRO, shall have the right to coordinate one or more publications of the aggregate multi-site Study results.
- 10.2 The Trial Site/Principal Investigator will report the findings of the Study to Sponsor/CRO in the form of Study reports, to be submitted to Sponsor/CRO at such stages or intervals in such forms and containing such information as set out in the protocol (including for instance the progress and the number of included patients) and/or as further agreed between the Parties.
- 10.3 The Parties acknowledge that Sponsor/CRO shall have the exclusive right to publish and present the results of the Study. Sponsor/CRO shall take into account that these results represent a joint effort among Sponsor, CRO, Trial Site and Principal Investigator. Sponsor/CRO shall mention the Principal Investigator of the Trial Site in a footnote in the manuscript as one of the participating Principal Investigators of the Study.
- 10.4 The Principal Investigator/Trial Site shall have no right to publish and present the results of the Study unless the prior written consent of Sponsor/CRO has been obtained. Sponsor/CRO recognizes the wishes of Site/PI to publish details of academic research in scientific journals. Sponsor/CRO shall however have the full right to withhold such consent.
- 10.5 Sponsor/CRO shall retain ownership of all original and completed CRFs, data, analyses and reports that result or are derived from the Study.

**11. INVENTIONS& PATENTS:**

- 11.1 Any invention, discovery, or improvement related to Sponsor/CRO's products or technology which is conceived or reduced to practice as a consequence of Trial Site's performance of the services hereunder (the "Inventions") shall be the sole and exclusive property of Sponsor/CRO and shall be used by Sponsor/CRO as Sponsor/CRO deems appropriate. Trial Site agrees to execute and have executed, at Sponsor/CRO's cost, assignments of the inventions to Sponsor/ CRO (including ensuring contracts between Trial Site and its representatives include appropriate assignment language to require its representatives to comply with the terms of this assignment provision and this Agreement), along with other documents that may be necessary or helpful to Sponsor / CRO in filing patent applications, or which may relate to any litigation or interference and/or controversy in connection therewith. The entire control, prosecution, and conduct of any patent application filed by Sponsor shall be outside the jurisdiction of, and without expense to, Trial Site/Principal Investigator or its Representatives. Trial Site/Principal Investigator acknowledges that

	 TRIAL SITE	<p><b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922</p> PRINCIPAL INVESTIGATOR
-------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------

therewith. The entire control, prosecution, and conduct of any patent application filed by Sponsor shall be outside the jurisdiction of, and without expense to, Trial Site/Principal Investigator or its Representatives. Trial Site/Principal Investigator acknowledges that Sponsor / CRO has the exclusive right to file patent applications in connection with the Inventions. Trial Site /PI warrants that it will not, and will ensure (including incorporating similar language in its contracts with study sites and investigators) that its Representatives will not prevent Sponsor / CRO from filing patent applications for, or from applying the results of research carried out for Sponsor / CRO hereunder.



11.2 All reports, data, technical information, original works of authorship and all other information, furnished by or on behalf of Sponsor / CRO, or created specifically for Sponsor / CRO as a deliverable under this Agreement (“**Work Product**”), shall be the sole and exclusive property of Sponsor.

11.3 Notwithstanding the foregoing, Sponsor / CRO acknowledges that Trial Site /Principal Investigator possesses certain inventions, processes, know-how, trade secrets, improvements, other intellectual properties and other assets, including but not limited to analytical methods, procedures and techniques, procedure manuals, personnel data, financial information, computer technical expertise and software, which have been independently developed by Trial Site /Principal Investigator and which relate to its business or operations (collectively “**Trial Site Property**”). Sponsor / CRO and Trial Site /Principal Investigator agree that any Trial Site Property or improvements thereto which are used, improved, modified or developed by Sponsor / CRO under or during the term of this Agreement are the sole and exclusive property of Trial Site and Sponsor / CRO shall be liable for any misuse or unauthorized use/ dissemination of the same. In no event shall Trial Site /Principal Investigator be precluded from use of this property and its general knowledge, skills and experience, and any of its ideas, concepts, know-how and techniques used or developed by it in the course of providing services under this Agreement.

**12. INSURANCE AND INDEMNIFICATION:**

12.1 Trial Site shall maintain medical professional liability insurance with limits in accordance with local standards for each medical professional involved in the Study, or require that each medical professional maintain such insurance.

12.2 The Sponsor/CRO shall indemnify and hold harmless the Trial Site from any and all liability of trial subjects, loss, or damage it may suffer as a result of the Sponsor’s negligence or breach of contract or caused by the investigational medicines, compliance with the protocol written by the Sponsor, or use of the results. Sponsor/CRO will ensure that appropriate medical insurance cover is obtained to cover the financial cost of any liabilities arising out of loss / damages occurring to trial subjects as a result of participation in the clinical trial under

		<p><i>Shivani Bansal</i>  <b>Dr. Shivani Bansal</b>          M.D. (Medicine)          Professor          Santosh Medical College And Hospital          Ghaziabad (U.P.)          MCI-25922</p>
-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



the conditions specified as per the terms of this Agreement.

12.3 The Trial Site and Principal Investigator agrees to indemnify and hold harmless the Sponsor/CRO from any and all liability of trial subject's loss, or damage it may suffer as a result of lack of performance / negligence / harm they may suffer during their routine treatment at Trial Site which is not a part of the present study protocol and is outside the scope of this Agreement.

12.4 The obligation of the Sponsor hereunder shall apply only if the indemnities provides prompt notification upon receipt of notice of any claim or suit, permits the Sponsor and its attorneys and personnel to handle and control the defense of such claims or suits including pretrial , trial or settlement and the indemnitees further agrees that it will not settle or compromise any such claim or suit without the prior written consent of the Sponsor/CRO.

**13. USE OF OTHER PARTIES' NAMES:**

13.1 Neither the Trial Site nor CRO may use the name, trade mark, logo, symbol, or other image or trade name of the other Party or their employees and agents in any advertisement, promotion, or other form of publicity or news release or that in any way implies endorsement without the prior written consent of an authorized representative of the other Party whose name is being used. Such approval will not be unreasonably withheld.

13.2 Trial Site, CRO and Sponsor understand that the amount of any payment made here under may be disclosed and made public by the other party as required by law or regulation, provided that the disclosure clearly designates the payment having been made to Trial Site for research and not to the physician.




**14. NO JOINT VENTURE ETC.:**

14.1 This Agreement shall not constitute, create, or in any way be interpreted as, a joint venture, partnership, or business organization of any kind.

**15. MONITORING; AUDIT; REGULATORY INSPECTIONS:**

15.1 The Principal Investigator and Trial Site shall, permit authorized personnel of the Sponsor/ CRO and any Regulatory Authority including EC to inspect the facilities of the Study site before, during and after the Study.

15.2 The Principal Investigator and Trial Site shall notify to the Sponsor/CRO immediately by telephone or facsimile if the Drugs Controller General-India, or any other governmental or regulatory authority requests permission to or does inspect the Principal Investigator and Trial Site's facilities or research records relating to this Study whenever and will provide in

		
-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------

writing to the inspecting authority copies of all materials, correspondence, statements, forms and records which the Principal Investigator and Trial Site receives, obtains, or generates pursuant to any such study.

15.3 The Principal Investigator and Trial Site will permit the Sponsor/CRO to;

- (a) Examine, inspect and audit the work performed here under and the facilities, systems and equipment at or with which the work is conducted.
- (b) Inspect and copy all data, documents and records related to such work and the Study.

**16. FORCE MAJEURE:**

16.1 Any event occurring after signing the Agreement, which a party could not reasonably have taken into account at the time of the conclusion of the agreement and which prevents or delays the affected party from fulfilling of its obligations under the agreement or makes the fulfillment thereof unreasonably difficult and which cannot be overcome without unreasonable loss of time or cost, shall constitute an event of force majeure. An event of force majeure shall include: strike, war, revolt, import or export prohibition, acts of God, interruption of public traffic or distribution of energy, legal labour dispute, fire, epidemic, pandemic or any other reason having as severe and unusual effects beyond the control of the Party.

16.2 If a party would wish to invoke existence of an event of force majeure as a cause for the non compliance with any of its obligations under the Agreement or delay or exemption from liability, it shall without delay inform the other Party of the delay or termination of its contractual obligation in writing.

**17. NOTICES**

17.1 Any notice, authorization, approval, consent or other communication will be in writing and deemed given:

- a. Upon delivery in person;
- b. Upon delivery by courier;
- c. Upon delivery date by a nationally- recognized overnight delivery service such as Blue Dart/DHL etc.

 <p>CRO DELHI</p>	 <p>TRIAL SITE</p>	 <p><b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Medical College And Hospital Ghaziabad (U.P.) MCI-25922</p> <p>PRINCIPAL INVESTIGATOR</p>
----------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



**If to CRO:**

Insignia Clinical Services Private Limited,  
Attn: Mr. Amardeep Singh  
Designation: Director  
Address: #512, Best Sky Tower, Netaji Subhash Place, Pitampura, Delhi-110034  
Tel: +91-11-4904 9115  
E-MAIL: clinical.operations@insigniacs.com

**If to Trial Site:**

Santosh Medical College Hospital, Ghaziabad  
Attn: Dr. Alpana Agarwal  
Designation: Medical Superintendent  
Address: No.1, Ambedkar Road, Ghaziabad - 201 001 (U.P.)  
Tel: 9811191935  
E-MAIL:alpanaishi@gmail.com

**With a copy to Principal Investigator:**

Attn: Dr. Shivani Bansal  
Designation: Professor, Department of Internal Medicine  
Address: Santosh Medical College Hospital, No.1, Ambedkar Road, Ghaziabad - 201 001  
Tel: 9013451039  
E-MAIL: drshivani2015@gmail.com

**18. GOVERNING LAW:**




18.1 The validity, interpretation, and performance of this Agreement shall be governed and construed in accordance with the laws of India.

**19. JURISDICTION:**

19.1 The place of jurisdiction for any dispute or claim before a court or an arbitrator shall be at New Delhi, notwithstanding any other provision to the contrary in any law in this regard.

**20. ARBITRATION:**

20.1 All disputes or claims whatsoever arising out of or in respect of the terms and conditions of this agreement or relating to the admissibility or liability or quantity of compensation or damages payable to or by any of the parties to this Agreement to the trial subject or his/her legal representative or the nominee shall be referred by the aggrieved party or person to the arbitration of a sole arbitrator to be appointed mutually by the Parties within a period of thirty

		 <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922
-------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



(30) days of the receipt of a written request by the aggrieved. The Arbitration and conciliation Act 1996 as amended from time to time shall be applicable to such arbitration proceedings. The award of the arbitrator shall be final and binding on all the Parties thereto.

**21. AMENDMENT:**

**21.1** This Agreement and protocol may only be amended by the mutual written consent of the Parties hereto. The Parties agree that this Agreement constitutes the sole, full and complete Agreement by and between the Parties and supersedes all other written and oral Agreements and representation between the parties with respect to the Study. No amendments, changes, additions, deletions, or modifications to or of this Agreement shall be valid unless reduced to writing and signed by the Parties. All changes and amendments to this Agreement shall be agreed in writing between the Parties.

**22. ENTIRE AGREEMENT**

**22.1** Section and clause headings are used here in solely for convenience of reference and are not intended as substantive parts of the Parties' Agreement. This Agreement incorporate the Exhibits referenced herein. This written Agreement constitutes the entire a matter, and supersedes all other or prior agreements or understandings, whether written or oral, with respect to that subject matter except for MoU. Any changes made to the terms, conditions or amounts cited in this Agreement require the written approval of each Party's authorized representative.

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed, in triplicate, by their officers, thereunto duly authorized to sign on behalf of their Party.




1. Insignia Clinical Services Pvt. Ltd


2. Santosh Medical College Hospital


3. Principal Investigator  
  
**Dr. Shivani Bansal**  
M.D. (Medicine)  
Professor  
Santosh Medical College And Hospital  
Ghaziabad (U.P.)  
MCI-25922

 CRO	 TRIAL SITE	 <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922 PRINCIPAL INVESTIGATOR
--------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Exhibit-A**

Insignia Clinical Services Pvt. Ltd.

ICS/LAX/2021-001  
Ver. 1.0, 18 Jan. 2021

**PROTOCOL SYNOPSIS**

**TITLE:** A prospective, pilot, clinical trial to evaluate the efficacy and safety of Colchicine for improvement of clinical outcomes during CoronaVirus (COVID-19) disease treatment in high-risk INdian patients.

**STUDY ACRONYM:** COLCOVEN

**PROTOCOL NUMBER:** ICS/LAX/2021-001

**NUMBER OF SUBJECTS TO BE ENROLLED AND RANDOMIZED:** Total of 84 subjects (42 per group) to be screened / enrolled in 1:1 ratio in either of the two study treatment arms to achieve statically powered minimum sample.

**CLINICAL PHASE:** Phase-II Clinical Trial.

**INDICATION:** Coronavirus (COVID-19) Disease.

**STUDY OBJECTIVES:**

Primary Objective:

- To evaluate the efficacy of Colchicine for improvement of overall clinical outcomes in high risk patients infected with coronavirus (COVID-19).

Secondary Objective:

- To evaluate the safety and tolerability of Colchicine when used for improvement of overall clinical outcomes in high risk patients infected with coronavirus (COVID-19).

**STUDY DURATION:**

Total duration of participation for all subjects, who participate in the study will be for a maximum period of 45 days, from the time of beginning of treatment. The total duration of treatment in test and reference groups may vary, however, the daily dosing of Colchicine in Test group may continue up to 28 days from the day of first dose. Based on the Principal

**CONFIDENTIAL**

Page 10 of 74

 <p>INSIGNIA CLINICAL SERVICES PVT. LTD. DELHI CRO</p>	 <p>Medical Superintendent 2021001 (11 P) TRIAL SITE</p>	 <p><b>Dr. Shivam Bansal</b> M.D. (Medicine) Professor Medical College And Hospital Meerut (U.P.) MCI-123456 PRINCIPAL INVESTIGATOR</p>
---------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Page 21 of 42



Investigator discretion, the study medication may be stopped during the study.

**STUDY DESIGN AND METHODOLOGY:**

This is a Pilot Phase II, randomized, open label, prospective, comparative, two-arm, multi-center clinical study to evaluate the efficacy and safety of Colchicine for improvement of overall clinical outcomes when added to Standard of Care (SOC) treatment in high-risk Indian patients suffering with coronavirus (COVID-19) disease.

The proposed study is a two phase clinical study wherein first phase is Treatment Phase of 28 days followed by Follow-up Phase of 14 days. High risk patients with clinically confirmed & documented diagnosis of moderate coronavirus disease (COVID-19) as per MOH Criteria who require hospitalization for management of the disease, i.e.,

- Confirmed diagnosis of COVID-19 demonstrated by positivity in RT-PCR 2019-nCoV test on respiratory tract (nasopharyngeal / oropharyngeal) specimens.
- Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO<sub>2</sub> ≤ 94% (range 90-94%) on 10cm air, Respiratory Rate ≥ 24 and ≤ 30 breaths per minute
- Age above 40 to 65 years (both inclusive)
- Having at least one of the high-risk criteria, i.e., obesity (BMI ≥ 30 kg/m<sup>2</sup>), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure ≥ 90 mm Hg & systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease.




will be screened and enrolled for participation in the study as per study protocol.

The treatment period with investigational product in test group will be 28 days from the day of first dose. It is however necessary that all patients in either test or control groups be allowed to take concomitant SOC as per the prescribed schedule for entire duration of the study, as applicable.

During entire duration of participation in the study, all patients in both test and/or control groups will take SOC as advised per individual treatment plan and will be asked to monitor signs & symptoms of disease, status of clinical recovery and adverse events, if any.

**CONFIDENTIAL**

Page 11 of 74

 <p>INSIGNIA CLINICAL SERVICES PVT. LTD. DELHI CRO</p>	 <p>TRIAL SITE</p>	 <p><b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25522</p> <p>PRINCIPAL INVESTIGATOR</p>
---------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------


During the both phases of study, clinical evaluations shall be performed as per the below mentioned schedule:

- Screening Period (Day -2 to Day 0)
- Randomization (Day 1\*)
- Treatment Period (Day 1 to Day 28)
- End of Treatment ("Next day of last treatment dose" Or Day 29)
- Follow-up Period [Day 42  $\pm$  2, i.e. 14  $\pm$  2 days (2 weeks) from EOT\*\* or "Death" whichever is earlier]

\*Day 1 to be considered from the day when the first dose of study medication as per treatment plan is administered to the patient.

\*\* Based on the treating physician's opinion, patient's clinical status & outcome of disease treatment, hospital discharge time points may vary for specific patient. Discharge from hospital will depend on clinical status of patient and signs & symptoms of the disease, according to standard clinical practices. Patients who demonstrate improvement in disease status and do not show signs of respiratory distress, breathlessness and hypoxia (SpO<sub>2</sub> > 93% on room air) and not requiring auxiliary oxygen may qualify for discharge based on clinical judgement of the investigator. Hospital discharge will be independent of the treatment schedule for investigational product.

The study flow-chart for the proposed study is as below:



CONFIDENTIAL

Page 12 of 74

<p>INSIGNIA CLINICAL SERVICES PVT. LTD. DELHI CRO</p>	<p>TRIAL SITE</p>	<p>Dr. Shivani Bansal M.D. (Medicine) Professor Medical College And Hospital Saharanpur (U.P.) MCI Reg. No. 1022</p> <p>PRINCIPAL INVESTIGATOR</p>
---------------------------------------------------------------	-------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------

At screening, all subjects will undergo following study assessments:



- Demographics.
- Personal history.
- Complete medical and surgical history.
- Vital signs (heart rate, blood pressure, body temperature, respiratory rate, oxygen saturation).
- Physical examination.
- Concomitant medications.
- Laboratory Investigations to be done at Screening shall include:
  - CBC (including RBC, Hematocrit (HCT, packed cell volume, PCV), Hemoglobin, Platelet, Mean platelet volume, Differential & Absolute Leukocyte Count)
  - Biochemistry (LFT, RFT, CRP, D-Dimer, Sr. Ferritin)
  - Urinalysis (physical, microscopic & chemical examination)
  - Inflammatory markers [hs-cTnI, NT-ProBNP, Neutrophil-Lymphocyte (NL) ratio, IL-6, TNF- $\alpha$ ]
- Urine pregnancy test (only for females of child bearing potential).
- ECG (12-lead)
- Chest X-Ray / CT-Scan (based on PI Discretion if required to assess pneumonia)
- 2D-Echocardiography
- A positive nasopharyngeal / oropharyngeal swab test for COVID-19 nucleic acid test to be done using RT-PCR technique (if not performed already within 72 hours prior to screening).
- Any additional tests / screening procedures which are not part of above study assessments, however, may be required as per standard clinical practice for management of COVID-19 patients or in line with national COVID-19 management protocol are allowed for study participants, however, details of all such investigations should be captured in respective patient CRF.

After screening, all patients who will qualify for participation in the study as per inclusion / exclusion criteria will be randomized in a 1:1 ratio in either of the two study groups.

*Note: If screening and randomization are on same day, then assessments of screening*

**CONFIDENTIAL**

Page 13 of 74

 <p>INSIGNIA CLINICAL SERVICES PVT. LTD. DELHI CRO</p>	 <p>TRIAL SITE</p>	<p><i>Murari Bani</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Medical College And Hospital Ghaziabad (U.P.) MCI-25322</p> <p>PRINCIPAL INVESTIGATOR</p>
---------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Page 24 of 42



will be considered for baseline. All laboratory investigations and X-Ray performed within 72 hours prior to study enrolment can be considered for baseline values).

During randomization (Day 1), all eligible enrolled patients in test group will receive Colchicine loading dose (1mg followed by 0.5mg after 9 hours) on Day 1 & 0.5mg BID from Day 2 up to Day 28 plus Standard of Care (SOC) whereas patients in control group shall receive only Standard of Care (SOC).

During the hospitalization and for entire duration of the study, patients will be monitored to assess clinical signs and symptoms of the disease, laboratory tests values (biochemical & hematology) and adverse events as required per standard clinical practice.

SOC to be given will be decided by the investigator based on the clinical condition of the patients and should be in line with per the Clinical Management Protocol for COVID-19 patients prescribed by Government of India. Details of SOC and supportive care will be recorded for each patient in their respective Case Report Form (CRF) on daily basis for the entire duration of hospitalization. Upon discharge, patients will be given diary cards to record the time of intake of study medications which may be prescribed to them for usage during remain duration of study.

To ensure consistency in line of treatment being administered for all patients who will participate in the study, different institutions/study sites/investigator's participating will be advised / encouraged to refer the updated / latest Clinical Management Protocol for COVID-19 prescribed Government of India while choosing SOC for patients.

Clinical assessments during the study shall be performed as per following schedule:

**Treatment Phase (Day 1 to Day 28):**

- Vital signs, physical examination, adverse events, concomitant medication and clinical signs & symptoms of disease (body temperature, respiratory rate, oxygen saturation, respiratory examination) of the subject will be monitored on the daily basis during hospitalization.
- Routine laboratory investigations as per national COVID-19 management protocol are allowed during the study.
- Nasopharyngeal / Oropharyngeal swab for COVID-19 nucleic acid test (RT-PCR)

CONFIDENTIAL

Page 14 of 74

		<p><i>Dr. Shivani Bansal</i> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad MCI-25922</p>
	TRIAL SITE	PRINCIPAL INVESTIGATOR

to be repeated at Discharge (in cases of -ve report not achieved already).

As per Investigator's opinion, if there is need to change the line of treatment for any patient due to safety issues, such patient shall be withdrawn from the study and managed as per investigator's clinical judgement. In case there is a 2-point deterioration in clinical status of the patient during the treatment, such patients will be immediately withdrawn from the study and shall be treated as per investigator's judgement and shall be considered as treatment failures. In cases of early withdrawal due to any reasons, all possible attempts shall be made by the investigator to complete laboratory investigations, clinical safety and efficacy assessments specified for EOT time point.

Discharge from hospital may occur anytime depending on investigator judgement and clinical recovery status of individual patient according to standard clinical practice. Upon discharge from hospital, patients will be advised to monitor the overall health and status of clinical recovery and adverse events, if any. In case of Discharge before ECT, patients will continue treatment & mandatory investigations as per the prescribed schedule, however, investigational product will not be administered beyond Day 28 to patients who will participate in test group.



**Follow-up Phase (Day 29 to Day 42 ± 2 days):**

Follow Phase will begin from EOT, i.e. Day 29 and will be independent of hospital discharge. Follow-up Phase shall continue for next 14 ± 2 days for each patient during which each patient required to visit study site at the end of study and earlier in case of deterioration in signs & symptoms of disease and / or adverse events (if any). During follow-up visit following study related clinical investigations / assessments may be performed based on clinical judgement of the investigator:

- Vital signs, physical examination, adverse events, concomitant medication and clinical signs & symptoms of disease (body temperature, respiratory rate, oxygen saturation, respiratory examination) of the subject will be monitored on the daily till discharge.
- ECG (12-lead) to be repeated at follow-up visit.
- Routine laboratory investigations which are required as per routine clinical practice.

**CONFIDENTIAL**

Page 15 of 74

		<p><i>Murari Sen</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad, U.P. MCI-25927</p>
	<b>TRIAL SITE</b>	<b>PRINCIPAL INVESTIGATOR</b>



- If at any time during the follow-up period, the investigator performs any laboratory test / clinical investigation as per his/her clinical judgment the date & reasons for such testing should be promptly recorded in the patient CRF
- Adverse events (serious, non-serious, expected, not expected, related, not related) will be monitored throughout the complete study period. All serious adverse events will be reported within 24 hours of occurrence to DCGI, Ethics Committee and Sponsor (vijay.dhondge@laxai.com and pvg@insigniacs.com).

The primary outcome measure for this study will be:

- *Time to clinical improvement of 2-points on WHO 5-point ordinal scale [Time frame: 28 days from randomization]*

Secondary outcome measures for this study will include:

- *Improvement in cardiac & biochemical inflammatory markers [hs-cTnT], D-dimer, NT-ProBNP, CRP, Neutrophil-Lymphocyte (N/L) ratio, Sr. Ferritin, IL-6, TNF-α]*
- *Time to discharge from hospital*
- *Rate of viral clearance*
- *Patients requiring auxiliary oxygen therapy (non-invasive/invasive) & time on auxiliary oxygen therapy.*



Other outcome measures for this study will be:

- *All-cause mortality.*
- *Adverse events (Serious, Expected Unexpected, Related Non-Related).*

Safety and tolerability to study medication will be evaluated based on laboratory tests (hematology and biochemistry), ECG (12-lead), routine clinical examinations, and the incidence, severity and type of AEs reported by the patient over the course of treatment and entire study duration. All AEs (Serious/Non-Serious, Expected/Not expected, Related/Not Related) reported during the study will be coded using the Medical Dictionary for Regulatory Activities (MedDRA updated with COVID-19 terms) and grouped by treatment.

CONFIDENTIAL

Page 16 of 74

		<p><i>Muvani</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Sri Aurobindo Medical College And Hospital Sambalpur, Odisha (U.P.) MCH-2002</p>
<p>DECRO</p>	<p>TRIAL SITE</p>	<p>PRINCIPAL INVESTIGATOR</p>

Clinical efficacy and safety data will be collected everyday till discharge from hospital & during the follow-up phase as per safety & efficacy assessment schedule.

**DIAGNOSIS, TARGET POPULATION AND KEY INCLUSION CRITERIA:**

Male and female subjects between 40 to 65 years (both inclusive) with clinically confirmed and documented diagnosis of moderate coronavirus disease (COVID-19) confirmed by positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens and presenting clinical features of dyspnea and/or hypoxia, fever, cough, including SpO<sub>2</sub> < 94% (range 90-94%) on room air, Respiratory Rate > 24 and < 30 breaths per minute.

All qualified subjects should have at least one of the high-risk criteria, i.e. obesity (BMI ≥ 30 kg/m<sup>2</sup>), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure > 90 mm Hg & systolic blood pressure ≥150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease OR should demonstrate signs of cardiac injury due to Elevated troponin level at the time of screening / study entry.

All patients who present above symptoms and are able to provide voluntary informed consent by self and/or legally accepted representative (LAR) will be screened for participation in the study and will be enrolled for treatment and randomized in either treatment groups (Test vs. Control) in a 1:1 ratio.



Other inclusion and exclusion criteria for the study shall be as follows:

**Inclusion Criteria:**

1. Male & Female patients with age ranging from 40 to 65 years (both inclusive) & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized or practicing a reliable method of birth control during the duration of study)
2. Clinically stable condition for at least 6 months before enrollment.
3. Confirmed diagnosis of at least moderate COVID-19 symptoms demonstrated by:
  - a. Positivity in RT-PCR 2019-nCov test on respiratory tract (nasopharyngeal / oropharyngeal) specimens.

**CONFIDENTIAL**

Page 17 of 74

		<p><i>Shivani Bani</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad MCI-25922</p>
<p><b>CRO</b></p>	<p><b>TRIAL SITE</b></p>	<p><b>PRINCIPAL INVESTIGATOR</b></p>



- b. Presence of clinical features of dyspnea and/or hypoxia, fever, cough, including SpO<sub>2</sub> < 94% (range 90-94%) on room air, Respiratory Rate > 24 and < 30 breaths per minute.
4. Significant COVID-19 symptoms, and judged by the treating doctor to be at high risk of progression to severe category due to presence of any of the following:
- Having at least one of the high-risk criteria, i.e., obesity (BMI  $\geq$  30 kg/m<sup>2</sup>), diabetes mellitus, uncontrolled hypertension (diastolic blood pressure  $\geq$  90 mm Hg systolic blood pressure  $\geq$  150 mm Hg), known respiratory disease (including asthma or chronic obstructive pulmonary disease), known heart failure, known coronary disease;
  - Demonstrating signs of cardiac injury due to Elevated troponin level.
5. Patients who require hospitalization for control of disease at the time of study entry.
6. Within 7 days from symptom onset or within 72 hours of laboratory diagnosis of SARS-CoV2.
7. Able to take oral tablets and agreeing not to participate in any other study for duration of participation in this study.
8. Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent then the same should be obtained from legally acceptable representative (LAR).

**Exclusion Criteria**

- History of present illness: (will be based on treating physician's opinion)
  - Neurological and neuro-developmental disorders.
  - Congenital heart disease
  - Severe heart disease or a history of clinically significant arrhythmias which may affect participants' safety (According to the ECG or medical history) Corrected QT interval of 450 milliseconds or higher (according to the Bazett formula) on a 12-lead surface ECG / Abnormal ECG (to eliminate concerns that a potential interaction between colchicine and hydroxychloroquine could lead to excess QT prolongation)

CONFIDENTIAL

Page 18 of 74

		<p><i>Juvani B</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922</p>
	<b>TRIAL SITE</b>	<b>PRINCIPAL INVESTIGATOR</b>

Page 29 of 42



2. Requirement of oxygen supplementation = SI nasal cannula at the time of enrollment.
3. Treating physician's clinical judgement that the patient will require mechanical respiratory support within 24 hours.
4. Patient currently in Septic shock or with hemodynamic instability requiring vasopressors.
5. History of anesthesia.
6. A subject undergoing hemodialysis.
7. Severe gastrointestinal failure, severe gastrointestinal disorders, or stomach ulcer.
8. Patient is currently taking colchicine for other indications (gout or Familial Mediterranean Fever).
9. Patient with inflammatory bowel disease (Crohn's disease or ulcerative colitis), chronic diarrhea or malabsorption.
10. Severe Hepatic Insufficiency (ALT or AST > 5 times ULN) or Renal Failure (eGFR using the MDRD equation for all subjects < 30 mL/min).
11. Patient received Remdesivir, Sarilumab, Tocilizumab/Lopinavir / Ritonavir or other immunomodulator given for COVID-19 treatment prior to study entry.
12. Patient is on (and cannot discontinue) a strong CYP3A4 inhibitor (e.g. clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nefinavir, ritonavir, saquinavir, telithromycin, atazanavir), a moderate CYP3A4 inhibitor (e.g. diltiazem, verapamil, fluconazole, ampranavir, omeprazole, fosamprenavir) or a P-gp inhibitor (e.g. cyclosporine, ranolazine).
13. Patients who may require IL-6 inhibitors as per clinical judgment of the investigator for management of inflammation at the time of study entry.

CONFIDENTIAL

Page 15 of 74

CRO	TRIAL SITE	PRINCIPAL INVESTIGATOR

14. Pregnant or lactating women; women of a childbearing age with a positive pregnancy test

**INVESTIGATIONAL MEDICINAL PRODUCT (IMP):**

**Test Group:** Colchicine loading dose (1mg followed by 0.5mg after 3 hours) on Day 1 & 0.5mg BID from Day 1 up to Day 28 + SOC

**Control Group:** Standard of Care (SOC)

**Notes:**

- SOC will be administered as per Principal Investigator discretion in line with national COVID-19 clinical management protocol. Standard of Care (SOC) may include licensed antivirals, oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, anti-inflammatory and antiemetic drugs.
- In cases where there is significant increase in oxygen requirement and/or inflammatory markers are increasing, even after 48 hours of admission into the study, investigator is allowed to use either 6 mg of dexamethasone (IV or Oral) OR 40 mg of prednisone OR 32 mg of methylprednisolone for management of inflammation.
- Details of all such concomitant medications, usage will be captured and specific patient CRF for subset analysis at the end of study.

**DISPENSING OF IMP:**

IMP will be handled by a pharmacist or designated personnel at the site.

Patients who are randomized in the study will be instructed to take the study drug as per the protocol. Patients will be informed during the consent process that if they are selected in test group they will receive Colchicine for a period of maximum 28 days upon randomization and will be followed up for additional 14 days (2 weeks) for signs &

**CONFIDENTIAL**

Page 20 of 74

 <p>INSIGNIA CLINICAL SERVICES PVT. LTD. DELHI</p>	 <p>SANTOSH MEDICAL COLLEGE HOSPITAL GHAZIABAD</p>	<p><i>Shivani Bansal</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad MCI-25922</p>
CRO	TRIAL SITE	PRINCIPAL INVESTIGATOR

symptoms of clinical recovery.

The test product will be supplied by the Sponsor for dispensing to the patient during the study treatment phase. The Investigator should confirm the receipt of the study drugs in writing, including follow-up supplies. The investigator / designated personnel will be responsible for dispensing / re-dispensing of study medication and collection of used / empty packs as per patient allocation & randomization schedule. Only patients enrolled in the test group will receive the IMP.

Sponsor representative/designee will ensure at their interim visits that all unused cartons / packs are intact and not opened. Investigator/designee will file opened treatment allocation carton/pack in subject file as documented evidence and accordingly dispense during the study period. Designated study team member at site will have to dispense the treatment to the subject and prior to dispensing the treatment will have to record the randomization number appearing on the treatment allocation envelope and the visit code prior to dispensing it.

The storage and handling instructions for Colchicine oral tablets will be mentioned on the label/carton. Store at Room Temperature. Keep out of the reach and sight of children. Do not use after the expiry date. Investigator/Pharmacist will be advised to store the study drugs in a cool place, protected from heat, freeze and direct sunlight. Reconciliation between the amount of medication supplied, dispensed and returned to sponsor must be performed and any discrepancies accounted for should be documented with a reason for the same.

Compliance will be checked by the count of used and unused study drug returned. Study drug accountability log will be maintained by the investigator or the authorized personnel. Any discrepancies should be well documented in the source notes as well as in the case report form.

**DOSE AND MODE OF ADMINISTRATION:**

Test products is for oral use only.

Subjects will be randomized to either of the two treatment groups:

Test Group: Colchicine loading dose (1mg + Standard of Care

**CONFIDENTIAL**

Page 21 of 74

		<p><i>Shwari Bani</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922</p>
CRO	TRIAL SITE	PRINCIPAL INVESTIGATOR



followed by 0.5mg after 3 hours) on  
Day 1 & 0.5mg BD from Day 2 up to  
Day 28

Control Group: Standard of Care

**CLINICAL ENDPOINTS:**

**EVALUATION OF SAFETY:**

An adverse event is defined as any untoward medical occurrence (sign, symptom or laboratory finding), regardless of severity and whether or not attributed to the investigational product.

All adverse events, whether observed by an Investigator or Study Coordinator or reported by the subject, whether related to study drug or not related to study drug, shall be documented on the CRF and subject records, together with details, i.e. date of onset, the duration and intensity of each episode, the action taken, the relationship to the investigational product and the degree of severity, the seriousness and the outcome.

Safety and tolerability to treatment were evaluated according to routine laboratory tests (haematology and biochemistry), 12-lead ECGs, clinical examinations, and the incidence, severity and type of AEs reported by the patients over the course of treatment.

All AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA updated with COVID-19 terms) and grouped by treatment. The number and percentage of AEs, SAEs, AEs leading to discontinuation, and AEs related to study drug will be summarized by system organ class, preferred term and treatment group. The number and percentage of AEs by severity will also be summarized. All AEs will be displayed in listings. No inferential analyses are planned.

Summary of vital signs, laboratory parameter values at relevant time points as well as change from baseline will be presented. Summary of physical examination findings will be presented by visit. Summary of concomitant medications will be presented.

Safety evaluations in the study will be performed using Safety Analysis Set (SAF). The Safety Analysis Set (SAF) consists of all subjects who took at least 1 dose of study

**CONFIDENTIAL**

Page 22 of 74

 <p>INSIGNIA CLINICAL SERVICES PVT LTD. DELHI CRO</p>	 <p>Ghazipur Medical College Hospital Ghaziabad (U.P.) TRIAL SITE</p>	<p><i>Muvani Basu</i> <b>Dr. Shiyani Bansal</b> M.D. (Medicine) Professor Ghazipur Medical College And Hospital Ghaziabad (U.P.) MCI-25512 PRINCIPAL INVESTIGATOR</p>
--------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

medication, and will be used for safety analysis.

A descriptive analysis comparing the rate, intensity and severity of adverse events in both the treatment groups will be performed

**EVALUATION OF EFFICACY:**

The primary outcome measure for this study will be:

- *Time to clinical improvement of 2-points on WHO 5-point ordinal scale [Time frame: 28 days from randomization]*

Secondary outcome measures for this study will include:

- *Improvement in cardiac & biochemical inflammatory markers [hs-cTn(I), D-dimer, NT-ProBNP, CRP, Neutrophil-Lymphocyte(N/L)ratio, Sr. Ferritin, IL-6, TNF-α]*
- *Time to discharge from hospital*
- *Rate of viral clearance*
- *Patients requiring auxiliary oxygen therapy (non-invasive/invasive) & time on auxiliary oxygen therapy.*
- *All-cause mortality.*

The efficacy evaluations will be performed using the following analysis sets for this study:

- **Full Analysis Set (FAS)** :The Full Analysis set will consist of all subjects who were randomized, received at least 1 dose of investigational product and had at least 1 post baseline measurement. This will be the primary analysis set for efficacy analyses.
- **Modified Intent-to-treat population (mITT)**: The ITT population will consist of all enrolled subjects who met inclusion/exclusion criteria and are on study medication and have at least one post baseline efficacy assessment.

**CONFIDENTIAL**

Page 23 of 74

		
CRO	TRIAL SITE	PRINCIPAL INVESTIGATOR



- **Per protocol population (PP):** The Per-Protocol set will be a subset of subjects in the FAS set who complete the study without any important protocol deviations. The criteria to determine protocol deviations will be defined in the SAP. The PP set will be a secondary analysis set for efficacy analyses.

This will constitute of all the enrolled subjects who were compliant with the assigned study treatment and completed evaluation as per protocol with no protocol deviations that would affect the evaluation or interpretation of the primary efficacy endpoint. Protocol compliance will be evaluated by questioning the subjects, reviewing subject diaries for missed doses etc. Subjects will be considered protocol compliant if he/she used at least 75% but no more than 125% of study drug doses, based on the subject study medication records.

**STATISTICAL METHODS:**

Validated CFR compliant statistical software will be used for analysis in this study. A statistical analysis plan (SAP) will be prepared separately from this protocol which gives descriptions of the statistical methods, models, hypothesis, and analysis populations to be analyzed. The SAP will serve as a companion to the protocol and will serve as the de facto documentation of the proposed statistical evaluations.

**SAMPLE SIZE ESTIMATION:**

The proposed study is being conducted to evaluate the efficacy of Colchicine when given alongside Standard of Care (SOC) Vs. SOC for the treatment of coronavirus disease (COVID-19). The primary endpoint for the study was time to improvement/ response. Thus, the point of clinical improvement or response was treated as an event.

Based on the existing literature data on the current standard of care versus a historical standard of care, the hazard ratio for time to recovery was found to be 1.8. The sample size was calculated with level of significance for two-sided alpha assumed at 5% and power of 80%.

A total sample size of 62 was obtained. Patients will be randomized to the treatment and the standard of care group in a 1:1 ratio with 42 participants in each group. Assuming a dropout rate of around 35%, the total sample size will be 84. Therefore, for this study a total of eighty-four (84) patients may be enrolled (42 patients in each Arm 1 and Arm2) to achieve a sample size of 62 (31 per group) completed patients for this pilot study.

CONFIDENTIAL

Page 24 of 74

 <p>DELHI CRO *</p>	 <p>TRIAL SITE</p>	 <p><b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor College And Hospital Ghaziabad (U.P.) MCI-25922</p> <p>PRINCIPAL INVESTIGATOR</p>
------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**EXHIBIT-B**  
**PART I- BUDGET & PAYMENT SCHEDULE**

**Protocol Title: A prospective, pilot, clinical trial to evaluate the efficacy and safety of COLchicine for improvement of clinical outcomes during COronaVirus (COVID-19) disease treatment in high-risk INdian patients. [Acronym: COLCOVIN Study]**

**Protocol Number: ICS/LAX/2021-001**

**Estimated Per Subject Fee** [including all fixed costs, institutional overheads (as applicable) & other Compensation below]:

- PI Clinical Investigation Charges (Screening, Treatment till Discharge, EOT & Follow-up Visit) = INR 20,000/- Per Completed Subject at the Trial Site\*
- Cardiologist Clinical Investigation Charges (Screening, Discharge & EOT) = INR 3,000/- Per Completed Subject at the Trial Site\*
- Hospital Charges (Bed + Oxygen) = INR 36,000/- Per Completed Subject at Trial Site\*
- Mandatory Study Investigations (details as per Table 1) = INR 10,000/- Per Completed Subject at the Trial Site\*

**Table 1:**

S.No.	Investigation	Repetition Frequency as per protocol
1.	ECG	<ul style="list-style-type: none"> <li>• All days during hospitalization till Discharge.</li> <li>• End of Treatment Visit (EOT)</li> <li>• Follow-up Visit</li> </ul>
2.	2D-ECHO	Screening, Discharge & End of Treatment
3.	RT-PCR	Screening, Discharge & End of Treatment
4.	Chest X-Ray	Screening, Discharge & End of Treatment

- Optional Lab. Investigation Charges as per PI direction (rates prescribed in Table 2):

**Table 2:**

Investigation	Cost	Investigation	Cost	Investigation	Cost
CBC (including absolute and differential blood count)	180/-	D-Dimer	685/-	NT-proBNP	1500/-
Liver Function Test	450/=	Sr. Ferritin	340/-	IL-6	1350/-
Renal Function Test	486/-	Urine Analysis	100/-	TNF- $\alpha$	2200/-
C-Reactive Protein	210/-	Urine Pregnancy Test	100/-	hs-cTn(I)	1012/-

 <b>CRO *</b>	 <b>TRIAL SITE</b>	 <b>PRINCIPAL INVESTIGATOR</b>
-----------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------



**Subject Stipends:** The subject stipend is intended to offset the Study subject's costs associated with travel expenses and meals, where appropriate, incurred as a result of Study participation, and shall be reflected in the informed Consent Form, as will be provided to the Study subject.

**Screen Failure Payments:** No screen failure payment will be provided either to investigators or to study site a result of participation in the present study.

**Payment Terms:**

- a) This Exhibit-B is for completed records for valid subjects. A valid subject is defined as a subject who meets eligibility requirements to enroll in the Study and does not have significant Protocol violations that would exclude his/her Data from analysis. Sponsor/CRO anticipates closure of enrollment upon randomization of a total of 84 valid subjects across all the sites participating in the study. In the event 84 total valid subjects are enrolled, further recruitment will be suspended. No payment will be made for any subject excluded from analysis because of Protocol violations within the Study personnel's control.
- b) Trial Site acknowledges this is a multicenter Study designed to evaluate a set number of Study subjects. When enrollment of the target number of Study subjects in the Study is complete, those sites will be notified and instructed not to continue enrolling Study subjects.
- c) Sponsor/CRO will provide, through a third party vendor, thermometer equipment (as required) valued at up to Rs. 4,000 for use as called for in the Protocol upon termination of the Study at Trial Site, the equipment will be returned in accordance with Sponsor/CRO's or designee's instructions.
- d) **Equipment Calibration:** Trial Site shall be responsible for ensuring Trial Site-owned equipment utilized by Trial Site in accordance with this Agreement is serviced and/or calibrated as per manufacturer's recommendation and/or more frequently as required by Sponsor/CRO. Records verifying the equipment calibration and maintenance shall be provided to Sponsor/CRO upon request for calibrations which are performed solely at the request of Sponsor/CRO, and that are not part of the recommended scheduled maintenance suggested by manufacturer, Sponsor/CRO will reimburse Trial Site for the actual cost without mark-up for each calibration processing of payment will begin upon receipt of invoice and supporting documentation in accordance with paragraph e) below.
- e) To be eligible for payments, the procedures must be performed in full compliance with the Protocol and this Agreement, and data submitted must be complete, correct and entered into the CRF in accordance with Sponsor/CRO's instructions. Payments will be made, at a minimum, on a fortnightly basis, once the corrected invoices are received. These payments will include milestone payments, as well as all invoiced and approved costs from the prior payment cycle. Ongoing reconciliations will be performed during the course of the study. Any erroneous payments discovered will be applied to any pending or future payments due. No payments will be made until all erroneous payments have been offset. If no pending or

		<p>Murari Bar  <b>Dr. Shivani Bansal</b>          M.D. (Medicine)          Professor          Ghaziabad College And Hospital          Ghaziabad (U.P.)  <b>PRINCIPAL INVESTIGATOR</b>          Santosh Medical College          MCI-2552</p>
	<b>TRIAL SITE</b>	<b>PRINCIPAL INVESTIGATOR</b>

future payments exist, Trial Site will promptly refund overpayment according to Sponsor/CRO's instructions.



Original invoices pertaining to this study should be submitted for reimbursement to the following address:

TO  
 Insignia Clinical Services Pvt. Ltd.  
 Unit No. 512,  
 5th Floor, Best Sky Tower,  
 Netaji Subhash Place, Pitampura,  
 New Delhi-110034.

A copy of the invoice, together with the supporting documentation should be emailed to [cral@insigniacs.com](mailto:cral@insigniacs.com) and failure to do so, might delay the payment process

Please note that invoices must contain the following information, or they will be returned, delaying payment:

- Trial Site name
  - Principal Investigator name
  - Protocol number
  - invoice number and date
  - Date & description of services provided Supporting documentation (i.e. third-party invoices, receipts)
  - Any claims for reimbursement of adverse events must be submitted in a separate invoice
  - Site Purchase Order (PO) number
  - ICS GST Number – 07AADCI0529A1Z7
  - PAN (permanent account number)
  - Site (micro, small and medium enterprises) MSME number (If applicable) Site GST number (if applicable)
  - HSN/SAC (Harmonized System of Nomenclature/ Service Account Code)
- f) Costs from, and reimbursement for, activities and items not specifically referenced above, including, but not limited to staff costs, laboratory fees, x-rays, scales and questionnaires (quality of life, etc.), data coordinator fees, travel fees, and subject reimbursement other than any subject stipends specifically identified above, are incorporated into the per-subject payment above. No additional reimbursement for these costs is otherwise provided.
- g) For the avoidance of doubt, the Principal Investigator and/or the Trial Site are responsible for providing any and all compensation benefits and/or insurance to the investigational staff. It is also understood and expressly acknowledged that the investigator and the investigational staff are not eligible to participate in, nor are they eligible for coverage under any of the

 <p><b>CRO</b></p>	 <p><b>TRIAL SITE</b></p>	<p><i>Anurag Bhatnagar</i>  <b>Dr. Shivani Bansal</b>          M.D. (Medicine)          Professor          Santosh Medical College And Hospital          Ghaziabad (U.P.)          MCI-25002</p> <p><b>PRINCIPAL INVESTIGATOR</b></p>
-------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------






Sponsor/CRO's benefit plans, programs, employment policies, procedures or workers compensation insurance.

- h) The Parties agree this Exhibit-B is part of the Agreement and clarifies the payment schedule associated with this Agreement. Payments shall be made in accordance with the provisions set forth in this Exhibit-B, with the last payment being made after the site completes all of its obligations under the Agreement and any exhibits thereto. The Principal Investigator acknowledges and agrees his or her judgment with respect to his or her advice to and care of each subject is not affected by the compensation the site receives hereunder. The parties agree the payee designated below is the proper payee for this Agreement and payments under this Agreement will be made only to the following payee.

<b>Payee Name:</b> (This should be a business name and should match the business name used to file for your tax EIN or other tax ID number)	SANTOSH TRUST
<b>Tax ID number:</b> (Tax ID number must exactly match the payee Name indicated above)	PAN No: AAIT56921N GST No:
<b>Contact Information:</b> (Name , Phone No., & e-mail address)	Name:
	Phone No:
	E-mail:
<b>Payee Address:</b>	No.1, Ambedkar Road, Ghaziabad - 201001 (U.P.)

Trial Site will have 30 days from the last subject out (LSO) date of the Study to resolve the payment discrepancies, which have arisen during the course of study.

 <b>CRO</b>	 <b>TRIAL SITE</b>	 <b>PRINCIPAL INVESTIGATOR</b> Dr. Shivani Bansal M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922
---------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



**PART-2 TAXES**

1. Notwithstanding anything contained in the Agreement, the Trial Site agrees that it is eligible to receive part of the consideration being the Goods and Services Tax(GST) charged in respect of the supply only after the details of such supply are uploaded by the Trial Site in the Form GSTR-1 (or such other form as may be notified in lieu thereof from time to time), which is subsequently reflected in Form GSTR-ZA (or such other form as may be notified in lieu thereof from time to time), made available electronically to the Sponsor/CRO, and are considered as matched with the corresponding details furnished by the Sponsor/CRO in its returns in terms of the relevant provisions of the GST Laws.
2. The Trial Site agrees to indemnify the Sponsor/CRO and keep it indemnified from and against reasonable tax liabilities that may accrue or be demanded by a Taxing Authority, in respect of or in connection with the execution of scope of work or payments made due to the Trial Site, arising under the said Agreement or anything done pursuant to the same. Any such compensation towards liabilities by the Trial Site to the Sponsor/CRO will be made within ninety (90) days of the liabilities accruing / demanded raised by Tax Authorities on the Sponsor/CRO either by way of issuance of demand or show cause notice or order or decree.
3. The Trial Site undertakes to be compliant with the anti-profiteering provision under Section 171 of the Central Goods and Services Tax Act, 2017.
4. **Other terms:**
  - a. The consideration payable under this Agreement shall be exclusive of applicable Goods and Services Tax (GST) including but not limited to CGST and SGST /UTGST or IGST, and or applicable cess, as the case may be.
  - b. The Trial Site shall periodically pay its tax liabilities in compliance with the GST Laws in connection with the goods/ services supplied under this Agreement such that the Sponsor/CRO is entitled to claim such credit of input tax with respect to the good/services supplied under this Agreement as permitted under the GST Laws.
  - c. The Trial Site hereby undertakes that it will make timely payments of all taxes, duties, levies imposed by Government (including but not limited to GST), be responsible for filing of all necessary tax returns and undertake all necessary compliances in accordance with applicable statutory requirements under the relevant statute in relation to sum received from the Sponsor/CRO.
  - d. The Trial Site hereby undertakes that it will issue the tax invoices within the statutory time limits as prescribed under the GST laws and in the manner and with

 CRO	 TRIAL SITE	 PRINCIPAL INVESTIGATOR
--------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------

all the prescribed particulars as are required to be specified as per the GST Laws.

- e. The Trial Site hereby undertakes that the address / location of the CRO to which the invoice will be issued by the Trial Site will be as per the address mentioned in the Purchase Order (PO) issued by the CRO. Separately, prior to issue of an invoice, the Trial Site shall intimate the CRO about the address / location of the CRO to which the invoice will be issued and a prior approval from the CRO in this respect will be taken by the Trial Site.
- f. The Trial Site undertakes that a debit note/ supplementary invoice/credit note with appropriate references to the original invoice will be issued only in such circumstances as agreed between the parties.
- g. Post supply of goods / services under this Agreement, the Trial Site shall cooperate with the CRO and provide any information that may be reasonably requested by the CRO in connection with claiming such credit of input tax under the GST Laws such as tax invoice or debit note issued by the Trial Site or such other taxpaying document(s) as may be required as proof of payment of applicable GST by the Trial Site.
- h. Where, transactions in respect of which the CRO has claimed input tax credit are notified as unmatched vis-à-vis the corresponding disclosures made by the Trial Site in his periodic returns, the Trial Site would extend necessary assistance including inter alia carrying out revision/ rectification of its returns, to enable the CRO to retain such claimed credits.
- i. The Trial Site undertakes that it has secured required GST Registration(s), which is/are in full force and effect and no action or claim is pending nor threatened to revoke or terminate such registration(s) or declare such registration(s) as invalid.

 CRO	 TRIAL SITE	<i>Muvai Bani</i> <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (UP) MCI-25922 PRINCIPAL INVESTIGATOR
--------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Page 41 of 42

EXHIBIT-C

(WITHOUT PREJUDICE)

STATEMENT ISSUED BY TRIAL SITE

1. That the **Dr. Shivani Bansal** is one of the employee of the Trial Site and has signed an Agreement or equivalent document to this effect.
2. The PI is obligated to assign to the Trial Site all inventions and discoveries made in the course of their Consultancy arrangement, explicitly mentioned in the Agreement signed by both the Parties.
3. Trial Site approves and agrees Principal Investigator to be the investigator for the study and responsible to the conduct of the study.

**For Santosh Medical College Hospital**

**Dr. Alpana Agrawal**  
(Medical Superintendent)

Signature Alpana Date and Stamp 20/5/2021



**Dr. Shivani Bansal**  
(Principal Investigator)

Signature Shivani Bansal Date and Stamp 20/5/2021

 CRO	 Medical Superintendent Ghaziabad 01001 TRIAL SITE	 <b>Dr. Shivani Bansal</b> M.D. (Medicine) Professor Santosh Medical College And Hospital Ghaziabad (U.P.) MCI-25922 PRINCIPAL INVESTIGATOR
--------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------





**TO WHOM IT MAY CONCERN**

This is to certify that we Insignia Clinical Services Pvt. Ltd. hold MOU dated 19 Oct. 2020 with Santosh Deemed to be University, Ghaziabad for conduct of human clinical trials at their facility, i.e, Santosh Medical College & Hospital, Ghaziabad.

In accordance with the aforesaid MOU, we are performing clinical trials of different therapeutic indications at Santosh Medical College & Hospital, Ghaziabad. The honorarium for clinical trial payments for the above studies are being made to research account of Santosh Deemed to be University, Ghaziabad as per the invoices / clinical trial agreements.

S.No	Protocol No.	Study Title	Principal Investigator	Site	Final Invoice Amount in lakhs	Final Invoice Amount (PI Grant)	1 <sup>st</sup> Payment Milestone		2 <sup>nd</sup> Payment Milestone		3 <sup>rd</sup> Payment Milestone	
							Site	PI	Site	PI	Site	PI
1	ICS/SYN /2021-001	A phase iii, multicentric, randomized, double blind, parallel group, comparative, clinical study to evaluate the efficacy and safety of bilastine tablets 40 mg for the treatemnt of chronic spontaneous urticaria.	Dr. V K Garg	Santosh Deemed to be University	1.469		Complete payment has been released for both PI (50% of the patient consultation) and Site (Santosh Medical College, Santosh Deemed to be University)					
2	ICS/LAX /2020-006	"A multicentric, phase ii, randomized, open label clinical study to evaluate efficacy, safety and tolerability	Dr. Ashok Kumar	Santosh Deemed to be University	2.4525	41,250	66,217 (30%) 2 May 2022	11,138 (30%) 2 May 2022	30% after completion of CRF and	30% after completion of CRF and	40% after Closeout	40% after Closeout

		of niclosamide for the treatment of hospitalized corona virus disease (covid-19) patients							resolutio n of queries	resolutio n of queries		
3	ICS/LAX /2021- 001	A prospective, pilot, clinical trial to evaluate the efficacy and safety of colchicine for improvement of clinical outcomes during coronavirus (covid-19) disease treatment in high-risk indian patients”.	Dr. Shivani Bansal	Santosh Deemed to be University	4.09157	70,000	1,10,472 06 Jun 2022	18,900 06 jun 2022	30% after completi on of CRF and resolutio n of queries	30% after completi on of CRF and resolutio n of queries	40% after Closeout	40% after Closeout
4	ICS/LAB /2021- 004	An observational, Prescriber based, Multicentric, Post Marketing surveillance study (PMS) to generate safety & efficacy data of fixed dose combination (FDC) of codeine phosphate 10mg & Chlorphenramine Maleate 4mg per 5 ml Oral Syrup for management of Symptoms of Dry Cough in Adult Patients	Dr. Ashok Kumar	Santosh Deemed to be University	2.782	250,000	1,25,190 (50%) 19 April 2022	112500 (50%) 29 April 2022	50 % on closeout	50% on closeout	NA	NA
5	BITEL/ WBL/P3/ 2021	A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative, Active-Controlled, Phase III Clinical Trial to evaluate the Efficacy	Dr. Ashok Kumar	Santosh Deemed to be University	2.16	805,330	2,50,000 19 Mar 2023	1,36,000 19 Mar 2023	50 % on closeout	50% on closeout	NA	NA



	and Safety of Fixed-Dose Combination of Bisoprolol 5 mg and Telmisartan 40 mg tablet versus Fixed-Dose Combination of Metoprolol Succinate ER 50 mg and Telmisartan 40mg in subjects with mild to moderate hypertension.											
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--	--	--	--	--	--	--	--	--	--

**Thank You**

**Kartik Sahni**  
 Digitally signed by **Kartik Sahni**  
 Date: 2023.04.17 15:04:32 +05'30'

**Associate Director**

Corp.Off : 512 , Best Sky Tower , Netaji Subhash Palace , Pitampura - 110034 ☎ 011 - 49049115 , 09868679414 E-mail : [info@insigniacs.com](mailto:info@insigniacs.com)  
 Regd. Off.: B-19 , Vandana Apartments , Sector - 13 , Rohini , Delhi - 110085 URL : [www.insigniacs.com](http://www.insigniacs.com) [insigniacs@gmail.com](mailto:insigniacs@gmail.com)



Clinical Trial Details (PDF Generation Date :- Tue, 28 Mar 2023 10:26:35 GMT)

<b>CTRI Number</b>	CTRI/2021/10/037217 [Registered on: 08/10/2021] - <b>Trial Registered Prospectively</b>	
<b>Last Modified On</b>	22/04/2022	
<b>Post Graduate Thesis</b>	No	
<b>Type of Trial</b>	PMS	
<b>Type of Study</b>	Drug	
<b>Study Design</b>	Single Arm Study	
<b>Public Title of Study</b>	A post marketing surveillance study to monitor the safety and efficacy of Codeine phosphate and Chlorpheniramine maleate for management of symptoms of dry cough in adult patients.	
<b>Scientific Title of Study</b>	AN OBSERVATIONAL, PRESCRIBER BASED, MULTICENTRIC, POST MARKETING SURVEILLANCE STUDY (PMS) TO GENERATE SAFETY & EFFICACY DATA OF FIXED DOSE COMBINATION (FDC) OF CODEINE PHOSPHATE 10mg & CHLORPHENIRAMINE MALEATE 4mg PER 5ml ORAL SYRUP FOR MANAGEMENT OF SYMPTOMS OF DRY COUGH IN ADULT PATIENTS.	
<b>Secondary IDs if Any</b>	<b>Secondary ID</b>	<b>Identifier</b>
	ICS/LAB/2021-004 Version 2.0 Date 19 OCT 2021	Protocol Number
<b>Details of Principal Investigator or overall Trial Coordinator (multi-center study)</b>	<b>Details of Principal Investigator</b>	
	<b>Name</b>	Dr R M Chhabra
	<b>Designation</b>	Medical Monitor/Trial Coordinator
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd., Room # 512, Clinical Trial Division, Clinical Operations Department , Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India. Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department , Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India. North West DELHI 110034 India
	<b>Phone</b>	011-49049115
	<b>Fax</b>	011-49049115
	<b>Email</b>	Chhabradrrm@gmail.com
	<b>Details Contact Person (Scientific Query)</b>	
	<b>Name</b>	Dr R M Chhabra
<b>Designation</b>	Medical Monitor/Trial Coordinator	
<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.	
<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department , Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India. Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department , Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India. North West DELHI 110034 India	
<b>Phone</b>	011-49049115	
<b>Fax</b>	011-49049115	
<b>Email</b>	Chhabradrrm@gmail.com	



**Details Contact Person (Public Query)**

Details Contact Person (Public Query)	
<b>Name</b>	Dr R M Chhabra
<b>Designation</b>	Medical Monitor/Trial Coordinator
<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.
<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department , Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India. Insignia Clinical Services Pvt. Ltd. Room # 512, Clinical Trial Division, Clinical Operations Department , Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India. North West DELHI 110034 India
<b>Phone</b>	011-49049115
<b>Fax</b>	011-49049115
<b>Email</b>	Chhabradrrm@gmail.com

**Source of Monetary or Material Support**

Source of Monetary or Material Support
> LABORATE Pharmaceuticals India Limited, E-11 Industrial Area Panipat 132103 Haryana

**Primary Sponsor**

Primary Sponsor Details	
<b>Name</b>	LABORATE Pharmaceuticals India Limited
<b>Address</b>	E-11 Industrial Area Panipat 132103 Haryana
<b>Type of Sponsor</b>	Pharmaceutical industry-Indian

**Details of Secondary Sponsor**

Name	Address
LABORATE Pharmaceuticals India Limited	E-11 Industrial Area Panipat 132103 Haryana

**Countries of Recruitment**

List of Countries
India

**Sites of Study**

Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
Dr A Gopal Rao	Government Medical College and Government General Hospital (Old RIMSGGH)	Research Wing 2nd Floor Department of Medicine, Government Medical College and Government General Hospital (Old RIMSGGH), Srikakulam, Andhra Pradesh- 532001 Srikakulam ANDHRA PRADESH	9912320517 muralidhargudla@yahoo.com
Dr Ram Babu	Jaipur Golden Hospital	Room NO. 04, Clinical Trial Division, Medicine Dept., 02, Institutional Area, Sector III, Rohini, Delhi 110085 North West DELHI	011-27907000 011-27907000 JGHDSMO@GMAIL.COM
Dr Pathak Niranjana Pandurang	PCMCs PGI Yashwantrao Chavan Memorial Hospital	2nd Floor General Medicine Department PCMCs PGI Yashwantrao Chavan Memorial Hospital Sant Tukaram Nagar Pimpri Pune 411018	7057582759 drpratiksunservices@gmail.com



		Pune MAHARASHTRA	
Dr Ashok Kumar	Santosh Medical College & Hospital	3rd Floor, Clinical Trial Division, No 1, Ambedkar Road, Ghaziabad 201001 Ghaziabad UTTAR PRADESH	1204666650  smchgzb@gmail.com
<b>Details of Ethics Committee</b>	<b>Name of Committee</b>	<b>Approval Status</b>	<b>Date of Approval</b>
	Institutional Ethics Committee Govt. Medical College Govt. General Hospital	Approved	31/01/2022
	Institutional Ethics Com mittee-Yashwantrao Chavan Memorial Hospital	Approved	05/01/2022
	Society for Academic Scientific Translational Research Advancement Ethics Committee	Approved	25/11/2021
	Society for Academic Scientific Translational Research Advancement Ethics Committee	Approved	25/11/2021
<b>Regulatory Clearance Status from DCGI</b>	<b>Status</b>		<b>Date</b>
	Not Applicable		No Date Specified
<b>Health Condition / Problems Studied</b>	<b>Health Type</b>		<b>Condition</b>
	Patients		Other specified respiratory disorders
<b>Intervention / Comparator Agent</b>	<b>Type</b>	<b>Name</b>	<b>Details</b>
	Intervention	Codeine Phosphate 10mg and Chlorpheniramine Maleate 4mg	Codeine Phosphate 10mg and Chlorpheniramine Maleate 4mg per 5 ml syrup two times daily for 7 days
	Comparator Agent	NOT APPLICABLE	NOT APPLICABLE
<b>Inclusion Criteria</b>	<b>Inclusion Criteria</b>		
	<b>Age From</b>	18.00 Year(s)	
	<b>Age To</b>	65.00 Year(s)	
	<b>Gender</b>	Both	
	<b>Details</b>	1. Male & female (non-pregnant, non-lactating, post-menopausal, surgically sterilized  or practicing a reliable method of birth control during the duration of study)  Subjects with age ranging from 18 to 65 years (both inclusive).  2. Subjects having dry cough (less than 7 days) of any origin and may be with related  symptoms as Throat Pain, throat redness, Throat irritation/itching, (Fever if  present) (absence of bronchial mucus/phlegm production).  3. Not under any antibacterial or antiviral treatment before recruitment.  4. Subjects ready to abstain from using any drug (which will affect the study  outcome) other than Investigational Product for the treatment of the study condition  during the study period (except in cases when patient's condition worsens as per  study physician. In this case, Study physician will decide to prescribe antibiotic, if  required).  5. Ready to abstain from the administration of any herbal or ayurvedic treatment	



	<p>or&lt;br/&gt; gargles directed to ease coughing or throat parameters.&lt;br/&gt; 6. Willing to provide written informed consent&lt;br/&gt; 7. Willing and able to understand and comply with all study requirements</p>	
<b>Exclusion Criteria</b>	<b>Exclusion Criteria</b>	
<b>Details</b>	<ol style="list-style-type: none"> <li>1. Subjects with known allergy or hypersensitivity to Codeine Phosphate or Chlorpheniramine Maleate or any of its components.</li> <li>2. Subjects who had taken any medicated confectionary, throat pastille, spray or any product with demulcent properties, any cough medicines or drugs containing antihistamines within last 24 hours prior to screening.</li> <li>3. Subjects taking medications with known cough promoting side effects (e.g., angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) that in the opinion of the investigator are causing symptoms of cough.</li> <li>4. Subjects with diagnosis of diseases of pneumonia, asthma, sinusitis, allergic rhinitis, as well as heart disease.</li> <li>5. Severe cough requiring hospitalization</li> <li>6. Subjects who had used any local anesthetic within the past 24 hours.</li> <li>7. Subjects who have used a longer acting or slow release analgesic during the previous 24 hours.</li> <li>8. Maintenance therapy with any drug, or history of drug dependency, alcohol abuse, or serious neurological or psychological disease</li> <li>9. Any other condition, which in the opinion of the clinician/investigator, could interfere significantly with the treatment and assessment process</li> <li>10. Use of any investigational therapy within 30 days prior to randomization</li> </ol>	
<b>Method of Generating Random Sequence</b>	Not Applicable	
<b>Method of Concealment</b>	Not Applicable	
<b>Blinding/Masking</b>	Not Applicable	
<b>Primary Outcome</b>	<b>Outcome</b>	<b>Timepoints</b>
	Adverse Events, Serious Adverse Events, Unexpected Adverse Events, Adverse Drug Reactions and Treatment Emergent Adverse Events.	7 Days
<b>Secondary Outcome</b>	<b>Outcome</b>	<b>Timepoints</b>
	Change in the cough severity( daily) and frequency (daily) score assessed during follow-up visit at Day 3 and Day 7 or up to complete recovery (whichever is earlier) compared to the baseline.	Day 3 and Day 7
	Number of awakenings in the night due to cough (24 hours) assessed during follow-up visit	Day 7
	Time taken for complete cough relief (days) assessed during follow-up visit	Day 7
	Change in score of throat pain and throat irritation	Day 7





<b>Target Sample Size</b>	<b>Total Sample Size=200</b> <b>Sample Size from India=200</b> <b>Final Enrollment numbers achieved (Total)=0</b> <b>Final Enrollment numbers achieved (India)=200</b>
<b>Phase of Trial</b>	Post Marketing Surveillance
<b>Date of First Enrollment (India)</b>	15/10/2021
<b>Date of First Enrollment (Global)</b>	No Date Specified
<b>Estimated Duration of Trial</b>	<b>Years=0</b> <b>Months=6</b> <b>Days=0</b>
<b>Recruitment Status of Trial (Global)</b>	Not Applicable
<b>Recruitment Status of Trial (India)</b>	Completed
<b>Publication Details</b>	Not Applicable
<b>Brief Summary</b>	<p>This is a prospective, single arm, multi-center, open-label, prescriber based, observational Post Market Surveillance study in Indian adult subjects who have symptoms of cough associated with upper respiratory allergies or common cold aged 18 years or older. The current study will aim to evaluate the safety and efficacy of fixed dose combination of Codeine Phosphate 10mg &amp; Chlorpheniramine Maleate 4mg per 5ml oral syrup in the actual field conditions for the management of symptoms of cough associated with upper respiratory allergies or common cold.</p> <p>The duration of individual participation will be approximately 7 days (7 days treatment period).</p> <p>Key safety assessments include : Adverse Events (AEs), Serious Adverse Events (SAEs), Unexpected Adverse Events, Adverse Drug Reactions.</p> <p>Key efficacy assessments include : Change in the cough severity (daily) and frequency (daily) score assessed during follow-up visit at Day 3 and Day 7 or up to complete recovery (whichever is earlier) compared to the baseline, Number of awakenings in the night due to cough (24 hours) assessed during follow-up visit, Time taken for complete cough relief (days) assessed during follow-up visit, Change in score of throat pain and throat irritation.</p>





# INDIAN MEDICAL ASSOCIATION

(Registered under Societies Act XX1 of 1860)

GHAZIABAD CHAPTER (2022-23)

IMA BHAWAN-SECTOR-8, Raj Nagar, Ghaziabad, 201001 (U. P.)

Mob. No. 9999081239, 9555650853, Email: ghaziabadima@gmail.com, Web: www.imagzb.com

**PRESIDENT**  
DR. SUNDEEP VARSHNEY  
9810148852  
**PRESIDENT ELECT**  
DR. VANI PURI RAWAT

**VICE PRESIDENT**  
DR. RAJIV GOEL (ENT)  
9810181251  
**JT. SECRETARY**  
DR. PREETY TYAGI

**HONY. SECRETARY**  
DR. GYANENDRA S. MITTAL  
9899100517  
**JT. SECRETARY**  
DR. NEHA PODDAR

**TREASURER**  
DR. BHAVUK MITTAL  
9540191068  
**JT. TREASURER**  
DR. V. K. BATRA

**Patron**  
CMO Ghaziabad  
**IMA HQs/U P State**  
Dr Rajeev Goel (Surg.)  
Dr V B Jindal  
**Ex. Officio**  
Dr R K Garg  
Dr Sanjeev K Jain  
Dr Tanu Aggarwal (Anes.)  
**Advisory Board**  
Dr Naresh Chand  
Dr R K Poddar  
Dr Ashok Agarwal  
Dr Subhash Agarwal  
Dr H L Sharma  
Dr Shalabh Gupta  
Dr D P Singh  
Dr Ashish Agarwal  
**Scientific Team**  
Dr Shashi Arora  
Dr Amitabh Goel  
Dr Ashish Prakash  
Dr Arun Kumar (Pead.)  
Dr Rajiv Garg  
Dr Amit Jain  
Dr Puneet Gupta  
Dr Nikunj Jain  
**Press & Media Incharge**  
Dr Navneet Verma  
**Crisis Management**  
Dr Sushil Tyagi  
Dr Anil Rathi  
Dr Pradeep Goel  
Dr A K Anuragi  
Dr Anil Tomar  
Dr Apoorva Agrawal  
**Web Master**  
Dr Sanjay Jain  
Dr Bharat Rastogi  
**IMA BCT**  
Dr Ajit Dinkar  
Dr Arvind Govil  
**School Awareness & School Health**  
**(Mission Pink Health -1)**  
Dr Neelu Khaneja  
Dr Madhu Poddar  
Dr Reena Gupta  
Dr Aruna Agarwal  
Dr Alpna Kansal  
Dr Archana Sharma  
Dr Prahlad Chawla  
Dr Pramod Sabharwal  
**Cancer Awareness**  
**(Mission Pink Health -2)**  
Dr Madhu Gupta (SN)  
Dr Rashi Agarwal  
Dr Archana Verma  
Dr Reenu Goel  
Dr Neetu Masand  
Dr Sandeep Agarwal

**IMA - HBI**  
Dr Santosh Ch Agarwal  
Dr Sangeeta Garg  
**IMA Excursion**  
Dr Rajeev Aggarwal (Pead.)  
Dr Abhinav Goel  
Dr Vipin Agarwal  
**Sports Team**  
Dr Umesh Madan  
Dr Kuldeep Gogia  
Dr Subhash Goel  
Dr Pallav K Rastogi  
Dr Satish Tyagi  
Dr Ekta  
Dr Ritu Jain  
**Health & Yoga**  
Dr Mukesh Agarwal  
Dr Smita Agrawal  
Dr Shalini Agrawal  
**News & Views**  
Dr Manisha Gupta  
Dr Parul Singhal  
Dr Nalinee Garg  
**IMA Shakti & WDW**  
Dr Seema Varshney  
Dr Rashmi Sharma  
Dr Sarla Mehta  
**Cultural Team**  
Dr Atul Gupta  
Dr Mohan Bandhu Gupta  
Dr H H D Bhardwaj  
Dr Mukta Agarwal  
Dr Vinita Mittal  
Dr Sarita Anand  
Dr Alok Sharma  
**Catering**  
Dr Apoorv Goel  
Dr Harshit Kansal  
**Area Executives**  
Dr Rajeev Tyagi  
Dr Sachin Agarwal (Ex Tre.)  
Dr Dhruv Sharma  
Dr Prachi Pal  
Dr Achal Swami  
Dr Manisha Jain Agarwal  
Dr Shweta Mishra  
Dr Rajesh Kalra  
Dr Rajeev Goel (Path)  
Dr Vikas Sharma  
Dr Sumit Gupta

Date: 6<sup>th</sup> Jan 2022

To,  
Dr Shalabh Gupta  
HOD of General Surgery  
Santosh Medical College and Hospital  
Ghaziabad.

Dear Shalabh Gupta,

We are pleased to inform you that upon thorough review of your project titled as below:

Title	Department	Principal Investigator	Amount
1. Use of Cautery in Surgical Incisions	General Surgery	Dr Shalabh Gupta	1,00,000

Cautery Pencils for skins Incisions worth Rs. 1,00,000/- will be provided to Santosh Medical College & Hospital, Ghaziabad.

Kindly share the final report of the project once it is complete.

Best Regards

*Sundeep*

Dr Sundeep Varshney  
President IMA  
2022-23



Dr. Sundeep Varshney  
M.B.B.S., M.D.  
MCI No. 7843  
L-216, Lalpal Nagar, Sahibabad  
Ghaziabad (U.P.)

TOGETHER WE CAN DO GREAT THINGS  
LONG LIVE IMA GHAZIABAD

Permanent Invitees  
All Past Presidents  
President & Secretary of Sub Specialties



# INDIAN MEDICAL ASSOCIATION

(Registered under Societies Act XX1 of 1860)

GHAZIABAD CHAPTER (2021-22)

IMA BHAWAN-SECTOR-8, Raj Nagar, Ghaziabad, 201001 (U. P.)

Mob. No. 9999081239, 9555650853, Email: ghaziabadima@gmail.com, Web: www.imagzb.com

**PRESIDENT**  
DR. R. K. GARG  
9891515215

**PRESIDENT ELECT**  
DR. SUNDEEP VARSHNEY

**VICE PRESIDENT**  
DR. ABHINAV GOEL  
9810177667

**JT. SECRETARY**  
DR. ALPNA KANSAL

**HONY. SECRETARY**  
DR. SANJEEV KR. JAIN  
9811006993

**JT. SECRETARY**  
DR. PRACHI PAL

**TREASURER**  
DR. TARUN KUMAR  
9810390115

**JT. TREASURER**  
DR. V. K. BATRA

## Patron

CMO Ghaziabad

IMA HQs/U P State

Dr Sharad Kr Agarwal

Dr Rajeev Goel (Surg.)

Dr Rajiv Goel (ENT)

## Ex. Officio

Dr Ashish Kr Agarwal

Dr Vani Puri Rawat

## Advisory Board

Dr Arun Gupta (Ortho)

Dr R K Poddar

Dr Ashok Gupta

Dr Ashok Agarwal

Dr H L Sharma

## Scientific Team

Dr Naresh Chand

Dr Shashi Arora

Dr Vinieta Diwakar

Dr Ashish Prakash

Dr Puneet Gupta

Dr Amitabh Goel

Dr Anurag Singhal

Dr Amit Jain

Dr Nikunj Jain

## Press & Media Incharge

Dr Navneet Verma

## Crisis Management

Dr Sushil Tyagi

Dr Arun Kumar (Pedia)

Dr Anil Rathi

Dr Harish Sharma

Dr A K Anuragi

## Web Master

Dr Sanjay Jain

## IMA BCT

Dr Navin Kumar

Dr Arvind Govil

Dr Atul Jindal

## School & Public Health

Dr Madhu Gupta (SN)

Dr Subhash Agarwal

Dr Prahlad Chawla

Dr Rajiv Garg

Dr Sarika Jain

Dr Neetu Masand

Dr Malvika Gupta

## Social Awareness

Dr Madhu Singhal

Dr Neelu Khaneja

Dr Madhu Poddar

Dr Reena Gupta

Dr Archana Sharma

Dr Aruna Agarwal

Dr Rashi Agarwal

## IMA Shakti

Dr Vinita Mittal

Dr Sarita Anand

## Cultural Team

Dr Atul Gupta

Dr Mohan Bandhu Gupta

Dr HHD Bhardwaj

## Permanent Invitees

## All Past Presidents

## President & Secretary of Sub Specialties

## IMA - HBI

Dr Santosh Ch Agarwal

Dr Shalabh Gupta

Dr V B Jindal

## Go Green

Dr Rakesh Bansal

## IMA Excursion

Dr D P Singh

Dr Alok Sharma

## Sports Team

Dr Kuldeep Gogia

Dr Umesh Madan

Dr Apoorva Agrawal

Dr Ritu Jain

Dr Pallav K Rastogi

Dr Sarika Kesarwani

## New Member

## Coordinator

Dr Sharad Gupta

Dr Apporv Goel

## Health & Yoga

Dr Shalini Agrawal

Dr Smita Agarwal

Dr Seema Varshney

## News & Views

Dr Rajeev Agrawal (Ortho)

Dr Dharendra Singh

Dr Seema Gupta

Dr Parul Singhal

## Catering

Dr Pradeep Goel

Dr Reenu Goel

## Area Executives

Dr Subhash Goel

Dr Mukesh Grover

Dr Rajeev Aggarwal (Pedia)

Dr Rajeev Goel (Path)

Dr Achal Swami

Dr Vikas Sharma

Dr Manisha Jain

Dr Anup Mittal

Dr Shishir Srivastava

Dr Pankaj Gupta

Dr Naveen Agarwal (Skin)

Dr Saurabh Agarwal (Ortho)

Dr Rajeev Tyagi

Dr Gaurav Sirohi

Dr Sachin Agarwal (Ex Tre.)

Dr Dhruv Sharma

Date: 6<sup>th</sup> Dec 2021

To,  
Dr Shalabh Gupta  
Professor and Head  
Department of General Surgery  
Santosh Medical College and Hospital  
Ghaziabad.

Dear Dr Shalabh Gupta,

We are pleased to inform you that upon thorough review of your project titled as below:

Title	Department	Principal Investigator	Amount
1. Role of Uroflowmetry In Urinary outflow Disorders	General Surgery	Dr Shalabh Gupta	1,20,000

Gadgets worth Rs. 1, 20,000/- will be provided to support the above project

Kindly share the final report of the project once it is complete.

Best Regards

Dr R K Garg  
President IMA  
2021-22



TOGETHER WE WILL MAKE A HEALTHY WORLD"  
LONG LIVE IMA GHAZIABAD



Date: 28/07/2021

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Request for research funding

Respected Mam,

We have received a request from your side for a research grant to conduct medical/dental research in various departments. We have received your proposals and revert back after review committee's decision.

<b>S.No.</b>	<b>Title</b>	<b>Name of Principal investigator</b>
1	A Study on Profile of Poisoning Cases in a Tertiary Care Hospital in Ghaziabad	Dr Shilpa Singh
2	Uncoupling proteins in various gene-environment interaction associated with heavy metal exposure and type 2 Diabetes Mellitus in North Indian Population	Dr Juhi Aggarwal, Dr Jyoti Batra

**Rajeev Khanna**  
**(Authorized Signatory)**



Date: 13/01/2022

To,

Dr. Jyoti Batra

Dean Research

Santosh Deemed to be University

Subject: Approval for research funding

Respected Mam,

I am pleased to inform you after thorough discussion with you and your faculty members, I am ready to fund the following research projects worth a sum of INR 60,000.

S.No.	Title	Name of Principal investigator	Amount (INR in Lakhs)	Study duration
1	A Study on Profile of Poisoning Cases in a Tertiary Care Hospital in Ghaziabad	Dr Shilpa Singh	0.30	6 Months
2	Uncoupling proteins in various gene-environment interaction associated with heavy metal exposure and type 2 Diabetes Mellitus in North Indian Population	Dr Juhi Aggarwal, Dr Jyoti Batra	0.30	3 Months

Please share with me the full proposals within 30 days of receiving this letter. Further, please submit a copy of final project report post completion.



Thank you and regards.

**Rajeev Khanna**  
**(Authorized Signatory)**

CC to:

1. Dr Shilpa Singh
2. Dr Juhi Aggarwal, Dr Jyoti Batra

प्रायः लेखा नम्बर /PERMANENT ACCOUNT NUMBER  
AEFPK6006D




नाम /NAME  
RAJEEV KHANNA

पिता का नाम /FATHER'S NAME  
RANBIR KHANNA

जन्म तिथि /DATE OF BIRTH  
20-09-1961

हस्ताक्षर /SIGNATURE



अधुकर नमूना, मेरठ  
COMMISSIONER OF INCOME-TAX, MEERUT



भारतीय विशिष्ट पहचान प्राधिकरण

भारत सरकार

Unique Identification Authority of India


Government of India

नामांकन क्रम / Enrollment No.: 2020/75007/00131

To  
राजीव खन्ना  
Rajeev Khanna  
S/O: Ranbir Khanna  
B-9 Shivaji colony cantt board Fiat  
rajman bazar  
Bela  
laikurti Bazar  
Mawana Meerut  
Uttar Pradesh 250001  
9471422664

19/10/2014

186494859



ML864948593FT



आपका आधार क्रमांक / Your Aadhaar No. :

**5599 9190 4205**

आधार - आम आदमी का अधिकार



भारत सरकार

Government of India



राजीव खन्ना  
Rajeev Khanna  
जन्म तिथि / DOB : 20/09/1961  
पुरुष / Male



**5599 9190 4205**

आधार - आम आदमी का अधिकार



Clinical Trial Details (PDF Generation Date :- Tue, 28 Mar 2023 10:29:03 GMT)

<b>CTRI Number</b>	CTRI/2022/01/039787 [Registered on: 28/01/2022] - <b>Trial Registered Prospectively</b>		
<b>Last Modified On</b>	30/09/2022		
<b>Post Graduate Thesis</b>	No		
<b>Type of Trial</b>	Interventional		
<b>Type of Study</b>	Drug		
<b>Study Design</b>	Randomized, Parallel Group, Active Controlled Trial		
<b>Public Title of Study</b>	A Clinical Trial to evaluate the efficacy and safety of Bisoprolol and Telmisartan Fixed Dose Combination Tablets for management of Hypertension.		
<b>Scientific Title of Study</b>	A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative, Active-Controlled, Phase III Clinical Trial to evaluate the Efficacy and Safety of Fixed-Dose Combination of Bisoprolol 5 mg and Telmisartan 40 mg tablet versus Fixed-Dose Combination of Metoprolol Succinate ER 50 mg and Telmisartan 40mg in subjects with mild to moderate hypertension.		
<b>Secondary IDs if Any</b>	<b>Secondary ID</b>	<b>Identifier</b>	
	BITEL/WBL/P3/2021 version 2.0 date 14.10.2021	Protocol Number	
<b>Details of Principal Investigator or overall Trial Coordinator (multi-center study)</b>	<b>Details of Principal Investigator</b>		
	<b>Name</b>	Dr R M Chhabra	
	<b>Designation</b>	Trial Coordinator	
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.	
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512,Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India North West DELHI 110034 India	
	<b>Phone</b>	011-49049115	
	<b>Fax</b>	011-49049115	
	<b>Email</b>	Chhabradrrm@gmail.com	
	<b>Details Contact Person (Scientific Query)</b>	<b>Details Contact Person (Scientific Query)</b>	
		<b>Name</b>	Dr R M Chhabra
<b>Designation</b>		Trial Coordinator	
<b>Affiliation</b>		Insignia Clinical Services Pvt. Ltd.	
<b>Address</b>		Insignia Clinical Services Pvt. Ltd. Room # 512,Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash Place, Pitampura North West, DELHI 110034, India North West DELHI 110034 India	
<b>Phone</b>		011-49049115	
<b>Fax</b>		011-49049115	
<b>Email</b>		Chhabradrrm@gmail.com	
<b>Details Contact Person (Public Query)</b>	<b>Details Contact Person (Public Query)</b>		
	<b>Name</b>	Dr R M Chhabra	
	<b>Designation</b>	Trial Coordinator	
	<b>Affiliation</b>	Insignia Clinical Services Pvt. Ltd.	
	<b>Address</b>	Insignia Clinical Services Pvt. Ltd. Room # 512,Clinical Trial Division, Clinical Operations Department, Best Sky Tower, Netaji Subhash	





	Place, Pitampura North West, DELHI 110034, India North West DELHI 110034 India
<b>Phone</b>	011-49049115
<b>Fax</b>	011-49049115
<b>Email</b>	Chhabradrrm@gmail.com

**Source of Monetary or Material Support**

Source of Monetary or Material Support	
>	Windlas Biotech Limited 40/1, Mohabewala Industrial Area, Dehradun – 248 110 Uttarakhand, India

**Primary Sponsor**

Primary Sponsor Details	
<b>Name</b>	Windlas Biotech Limited
<b>Address</b>	40/1, Mohabewala Industrial Area, Dehradun – 248 110 Uttarakhand, India
<b>Type of Sponsor</b>	Pharmaceutical industry-Indian

**Details of Secondary Sponsor**

Name	Address
Windlas Biotech Limited	40/1, Mohabewala Industrial Area, Dehradun – 248 110 Uttarakhand, India

**Countries of Recruitment**

List of Countries
India

**Sites of Study**

Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
Dr Sudhir Kumar Bhatnagar	Abhinav Multispeciality Hospital	Room No 01 Department of Cardiology, Abhinav Multispeciality Hospital, Nayanakasha, Kamal Chowk, Nagpur, Maharashtra 440017 Nagpur MAHARASHTRA	9823148978 a_bawangade@yahoo.com
Dr A Gopal Rao	Govt. Medical College and Govt. General Hospital	Dept. of Medicine, Govt. Medical College & Govt. General Hospital(Old RIMSGGH), Srikakulam 532001 Srikakulam ANDHRA PRADESH	9912320517 muralidhargudla@yahoo.com
Dr Giriraja K V	Rajalakshmi Hospital and Research Center	Room No 01, Ground Floor, Department of General Medicine, Rajalakshmi Hospital and Research Center 21/1 Lakshmipura Main Road, Vidyananyapura Post Bangalore KARNATAKA	08023254855 drgirirajkv@gmail.com
Dr Tanmoy Majee	Ruby General Hospital Ltd	Department of Clinical Pharmacology and Research, Ruby General Hospital Ltd, 576 Anandpur EM	03366011800 drtanmoymajee@gmail.com





		Bypass, Kasba, Kolkata Kolkata WEST BENGAL	
Dr Bal Kishan Gupta	S P Medical College and AG Hospitals	Department of Medicine S P Medical College and A G Hospitals Bikaner Rajasthan 334001 Bikaner RAJASTHAN	7615914143  manojbkn108@gmail.com
Dr Laxmi Kant Goyal	S.M.S. Medical College and Attached Hospitals	Ground Floor, Department of Medicine S.M.S. Medical College and Attached Hospitals JLN Marg Jaipur Rajasthan- 302004 Jaipur RAJASTHAN	09462651019  drkkgoyal@gmail.com
Dr Ashok Kumar	Santosh Medical College & Hospital	3rd Floor, Clinical Trial Division, No 1, Ambedkar Road, Ghaziabad 201001 Ghaziabad UTTAR PRADESH Ghaziabad UTTAR PRADESH	1204666650  smchgzb@gmail.com
Dr R M Chhabra	Saroj Super Speciality Hospital	Department of Internal Medicine, Saroj Super Speciality Hospital, Bhagawan Mahavir Marg, Near Madhuban Chowk, Block A, Sector 14, Rohini 110085 New Delhi DELHI	9147903333  drchhabrarm@yahoo.co.in
Dr Suhas N Kalashetti	Shree Samarth Hospital	Room No. 12 Department of Clinical Research Shree Samarth Hospital 227, Karande Chowk Pune, 411011 Pune MAHARASHTRA	02026128345  skalashetti@yahoo.com

**Details of Ethics  
Committee**

Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
Ethics Committee S.M.S. Medical College and Attached Hospitals	Approved	27/04/2022	No
Ethics Committee, SP Medical College	Approved	25/02/2022	No
Institutional Ethics Committee Government Medical College and Government General Hospital	Approved	31/01/2022	No
Institutional Ethics Committee Ruby General Hospital	Approved	28/03/2022	No



Institutional Ethics Committee Shree Samarth Hospital	Approved	16/04/2022	No
Jasleen Hospital Ethics Committee	Approved	21/02/2022	No
Rajalakshmi Hospital Institutional Ethics Committee	Approved	15/03/2022	No
Society for Academic Scientific Translational Research Advancement Ethics Committee	Approved	18/01/2022	Yes
Society for Academic Scientific Translational Research Advancement Ethics Committee	Approved	08/02/2022	Yes

**Regulatory Clearance Status from DCGI**

Status	Date
Approved/Obtained	15/11/2021

**Health Condition / Problems Studied**

Health Type	Condition
Patients	Essential (primary) hypertension

**Intervention / Comparator Agent**

Type	Name	Details
Intervention	Fixed-Dose Combination of Bisoprolol 5 mg and Telmisartan 40 mg tablet	One tablet daily for 84 days
Comparator Agent	Fixed-Dose Combination of Metoprolol Succinate ER 50 mg and Telmisartan 40 mg tablet	One tablet daily for 84 days

**Inclusion Criteria**

Inclusion Criteria	
<b>Age From</b>	18.00 Year(s)
<b>Age To</b>	65.00 Year(s)
<b>Gender</b>	Both
<b>Details</b>	1. Male or female participants with age 18 years to 60 years (both inclusive) at the time of screening 2. Adult subjects who are capable of understanding and giving written informed consent and willing to comply with the study protocol 3. Subjects diagnosed with mild to moderate Essential Hypertension with SBP ranging between 140-159 mmHg and/or DBP ranging between 90-99mmHg 4. Females of non-child bearing potential (surgically sterile or menopausal) OR females of child bearing potential using effective birth control measures and non-pregnant & non-lactating females.

**Exclusion Criteria**

Exclusion Criteria	
<b>Details</b>	1. Subjects previously sensitive to any of the ingredients of the fixed-dose combination under study or beta-blockers or angiotensin receptor blockers, 2. Subjects with clinically significant renal (estimated glomerular filtration rate: 114 mm Hg) 5. Subjects with evidence of any cardiac arrhythmia on ECG 6. Any known cardiac disease/disorder in which any of the study medication is contra-indicated (e.g. severe bradycardia, heart block greater than a first degree or significant first-degree block, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome without pacemaker etc.) 7. Subjects with known significant



	respiratory/liver/kidney/neurological diseases / uncontrolled diabetes, 8. Pregnant and lactating women or the women of child bearing age who are not practising the effective means of contraception, 9. Subjects otherwise judged to be inappropriate for inclusion in the study by the investigator's judgment 10. Subjects who will receive some other drug during the study besides that in the protocol that could alter the pharmacokinetic/ pharmacodynamic profile of the study drug, 11. Subjects with known alcohol or drug abuse 12. Subjects with known history of HIV, Hepatitis B and Hepatitis C										
<b>Method of Generating Random Sequence</b>	Computer generated randomization										
<b>Method of Concealment</b>	Pre-numbered or coded identical Containers										
<b>Blinding/Masking</b>	Participant and Investigator Blinded										
<b>Primary Outcome</b>	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>Percentage of the subjects achieved the target levels of clinical BP among mild to moderate hypertensive subjects (target level: SBP less than 140 mm Hg and DBP less than 90 mm Hg)</td> <td>12 weeks</td> </tr> </tbody> </table>	Outcome	Timepoints	Percentage of the subjects achieved the target levels of clinical BP among mild to moderate hypertensive subjects (target level: SBP less than 140 mm Hg and DBP less than 90 mm Hg)	12 weeks						
Outcome	Timepoints										
Percentage of the subjects achieved the target levels of clinical BP among mild to moderate hypertensive subjects (target level: SBP less than 140 mm Hg and DBP less than 90 mm Hg)	12 weeks										
<b>Secondary Outcome</b>	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>Mean reduction in systolic and diastolic blood pressure measured in sitting position compared to baseline</td> <td>4, 8 and 12 weeks</td> </tr> <tr> <td>Proportion of responders after 12 weeks of dosing (Responder rate defined as the proportion of subjects with a decrease in diastolic BP by at least 10 mmHg).</td> <td>12 weeks</td> </tr> <tr> <td>Reduction in mean heart rate compared to baseline</td> <td>4, 8 and 12 weeks</td> </tr> <tr> <td>Adverse Events assessment, Physical and systemic examination, Vital signs, Lab abnormalities</td> <td>4, 8 and 12 weeks</td> </tr> </tbody> </table>	Outcome	Timepoints	Mean reduction in systolic and diastolic blood pressure measured in sitting position compared to baseline	4, 8 and 12 weeks	Proportion of responders after 12 weeks of dosing (Responder rate defined as the proportion of subjects with a decrease in diastolic BP by at least 10 mmHg).	12 weeks	Reduction in mean heart rate compared to baseline	4, 8 and 12 weeks	Adverse Events assessment, Physical and systemic examination, Vital signs, Lab abnormalities	4, 8 and 12 weeks
Outcome	Timepoints										
Mean reduction in systolic and diastolic blood pressure measured in sitting position compared to baseline	4, 8 and 12 weeks										
Proportion of responders after 12 weeks of dosing (Responder rate defined as the proportion of subjects with a decrease in diastolic BP by at least 10 mmHg).	12 weeks										
Reduction in mean heart rate compared to baseline	4, 8 and 12 weeks										
Adverse Events assessment, Physical and systemic examination, Vital signs, Lab abnormalities	4, 8 and 12 weeks										
<b>Target Sample Size</b>	<b>Total Sample Size=264</b> <b>Sample Size from India=264</b> <b>Final Enrollment numbers achieved (Total)=292</b> <b>Final Enrollment numbers achieved (India)=292</b>										
<b>Phase of Trial</b>	Phase 3										
<b>Date of First Enrollment (India)</b>	29/01/2022										
<b>Date of First Enrollment (Global)</b>	No Date Specified										
<b>Estimated Duration of Trial</b>	<b>Years=0</b> <b>Months=9</b> <b>Days=0</b>										
<b>Recruitment Status of Trial (Global)</b>	Not Applicable										
<b>Recruitment Status of Trial (India)</b>	Completed										
<b>Publication Details</b>	NIL										
<b>Brief Summary</b>	In India, Bisoprolol and Telmisartan are already approved and marketed. Therefore, considering the unmet need for an FDC and based on regulatory requirement M/s. Windlas Biotech Ltd. proposes the present study be conducted to generate data on the Indian population. The study design is a multi-centre study to evaluate efficacy and safety of fixed-dose combination (FDC) of Bisoprolol 5 mg and										



Telmisartan 40 mg tablet in subjects with mild to moderate hypertension. The purpose of the present study is to demonstrate that a fixed-dose combination (FDC) of Bisoprolol 5 mg and Telmisartan 40 mg tablet is efficacious and safe in Indian subjects with regard to the routine clinical setting.

This will be a multicentre, randomized, double-blind, parallel-Group, comparative active-controlled phase III clinical trial to evaluate the efficacy and safety of fixed-Dose Combination of Bisoprolol 5 mg and Telmisartan 40 mg tablet versus a fixed-Dose combination of Metoprolol Succinate ER 50 mg and Telmisartan 40 mg tablets in subjects with mild to moderate hypertension. Initially, subjects will be screened as per predefined eligibility criteria for the study. The ITT population will include approximately a total number of 264 eligible male and female patients of any ethnicity diagnosed with mild to moderate hypertension. Eligible 264 subjects will be either enrolled to receive Fixed-Dose Combination (FDC) of Bisoprolol 5 mg and Telmisartan 40 mg tablet or Fixed-Dose Combination of Metoprolol Succinate ER 50 mg and Telmisartan 40 mg tablets in 1:1 ratio.

**Test**

**Arm: Treatment Arm 1:** Fixed-Dose Combination (FDC) of Bisoprolol 5 mg and Telmisartan 40 mg tablet (n=132)

**Reference Arm: Treatment Arm 2:** Fixed-Dose Combination of Metoprolol Succinate ER 50 mg and Telmisartan 40 mg (n=132)

**Efficacy:**

**Primary endpoint**

- Percentage of the subjects achieved the target levels of clinical BP among mild to moderate hypertensive subjects (target level: SBP < 140 mm Hg and DBP < 90 mm Hg);

**Secondary end point**

- Mean reduction in systolic and diastolic blood pressure measured in sitting position compared to baseline (After 4, 8 and 12 weeks)
- Proportion of responders after 12 weeks of dosing (Responder rate defined as the proportion of subjects with a decrease in diastolic BP by at least 10 mmHg).
- Reduction in mean heart rate compared to baseline (After 4, 8 and 12 weeks)

**Safety (Screening visit to end of study visit)**

- Adverse Events (AE) assessment
- Physical & systemic examination
- Vital signs
- Lab abnormalities



**SANTOSH**  
Deemed to be University